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Abstract  
Plasmid DNA (pDNA) vectors are being developed as preventive or therapeutic 
DNA medicines for the treatment of parasitic, bacterial and viral diseases and 
also for other indications, such as the treatment of devastating inherited 
diseases. This has been reflected in a demand for efficient and cost-effective 
large-scale processes for the production of pharmaceutical-grade pDNA. 
The utilisation of aqueous two-phase systems (ATPS) for the extraction of pDNA 
has several advantages over the conventional chromatographic processes; 
namely, easier scaling-up, operation simplicity, higher capacity, and the 
possibility to combine purification, concentration and clarification into one unit 
operation. However, the main drawback of ATPS is the low selectivity for the 
target pDNA in complex Escherichia coli cell lysates. In this thesis two protein-
based affinity systems were investigated in order to enhance selectivity of the 
ATPS by exploring sequence-specific recognition of target pDNA:  
1) GST-ZnF/pTS: a fusion protein, comprised of Glutathione-S-Transferase 
(GST) and a zinc finger transcription factor (ZnF) that binds to 5´-
GGGGCGGCT-3´ sequence within pTS plasmid.  
2) LacI-His6-GFP/pUC19: a lac repressor protein (LacI) fused to a His6-tag 
and to a Green Fluorescence Protein (GFP) that displays affinity for two 
lac operator sequences (lacO1/lacO3) within pUC19 plasmid.  
Initially, polyethylene glycol (PEG) - dextran (DEX) systems were selected for the 
favourable partitioning of the pDNA impurities to one of the phases, i.e. 
dextran. In this way the affinity ligand would steer the pDNA to a phase with 
less impurities, so increasing its purity and the selectivity of these systems. The 
PEG 600 – DEX 40 system was selected with all major pDNA impurities 
accumulated predominantly in the bottom DEX phase (RNA >99 % and protein 
>80 %) with total pDNA recoveries >80 %.  
In order to efficiently steer the affinity ligand into the top phase, the GST-ZnF 
fusion protein was covalently bound to PEG polymer (PEGylation). Initially, four 
 
X 
different PEGylation reagents were optimized for conjugation to the free GST. 
Thiol selective PEGylation reactions were completed after 1h under reducing 
conditions. By contrast, amine selective reagents required much longer reaction 
times (24h) or high PEG equivalents, in order to yield more than 80% 
conjugation. Optimized reactions on free GST were then applied to GST-ZnF 
fusion protein resulting in similar PEGylation yields. The PEG-GST-ZnF ligand 
was then used for the complete isolation of pre-purified pTS plasmid from 
bottom phase to the top phase in PEG 600 – DEX 40 systems. The PEGylated 
ligand accumulated 97.5 % in the top phase, while 96.5 % of the native GST-
ZnF protein and 99.9 % pDNA accumulated on the bottom. Although the proof-
of-concept for a pDNA affinity extraction process was demonstrated, no further 
assays were carried out using bacterial cell lysates due to the tight protein–DNA 
binding which make the elution of the pDNA impractical.  
An alternative approach to attach PEG to the affinity ligand was tested with an 
immobilized metal–ion affinity PEG (PEG-IDA-Cu2+) which binds to the his-tag 
accessible on the surface of LacI-His6-GFP protein. The affinity extraction of 
pUC19 plasmid from a bacterial cell lysate in PEG 600 – DEX 40 ATPS 
containing 0.273 nmol of LacI fusion protein and 0.14 % (w/w) functionalised 
PEG, resulted in more than 72 % of the plasmid DNA partition to the top phase, 
without RNA or genomic DNA impurities. Although pDNA elution from LacI 
binding complex proved to be difficult, the method described removed more 
than 75 % of the protein yielding ~27 % of pCU19 pDNA. This represents 
about 7.4 µg of pDNA extracted per mL of desalted lysate which is about 9 fold 
improvement to what was previously obtained using LacI-His6-GFP immobilized 
into a chromatographic column. 
To conclude, it is envisaged in this thesis that the knowledge obtained using 
pDNA affinity ligands would contribute for the development of a highly 
selective plasmid DNA manufacturing process fulfilling the stringent 
specifications and demands for gene therapy or DNA vaccines applications.  
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Resumo 
Vectores de DNA plasmídeo (pDNA) estão a ser desenvolvidos para a 
prevenção e tratamento de doenças do foro viral, bacteriano e parasitário, bem 
como, para o tratamento de doenças crónicas hereditárias. Nesse sentido, existe 
a necessidade crescente de processos eficientes e económicos de produção 
industrial de pDNA com qualidade farmacêutica.  
A utilização de sistemas de duas-fases aquosas (SDFA) para a purificação de 
pDNA tem várias vantagens comparativamente aos processos cromatográficos 
convencionais, nomeadamente a facilidade de aumento de escala, maior 
capacidade e a possibilidade de combinar numa única operação os processos 
de purificação, concentração e clarificação. No entanto, a maior desvantagem 
dos SDFA deve-se à sua baixa selectividade para os vectores pDNA em lisados 
celulares de Escherichia coli. Nesta tese, foram investigados dois sistemas de 
afinidade com o objectivo de aumentar a selectividade dos SDFA utilizando 
ligandos proteicos com especificidade de ligação ao pDNA:  
1) GST-ZnF/pTS: proteína fusão, composta pela proteína Glutationa-S-
Transferase (GST) e um factor de transcrição dedo do zinco (ZnF), que se 
liga à sequência 5´-GGGGCGGCT-3´ do plasmídeo designado por pTS.  
2) LacI-His6-GFP/pUC19: proteína fusão, constituída pela proteína 
repressora do operão lac (LacI) fundida com 6  resíduos de aminoácidos 
de histidina e com a proteína verde fluorescente (GFP), que se liga a 
duas sequências lac operão  (lacO1/lacO3) do plasmídeo pUC19.   
Inicialmente, SDFA com polietilenoglicol (PEG) e dextrano (DEX) foram 
seleccionados de acordo com a acumulação preferencial na fase de DEX (ou 
fase inferior) dos contaminantes principais do pDNA presentes nos lisados. 
Deste modo, os ligandos de afinidade permitem extrair o pDNA para a fase com 
menos contaminantes - fase de PEG - aumentando assim o grau de purificação e 
selectividade dos SDFA. O sistema PEG 600 – DEX 40 foi seleccionado para o 
efeito, obtendo-se a acumulação do RNA (>99 %) e das proteínas (>80 %) na 
fase inferior e com  recuperação superior a 80 % do pDNA.  
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Para facilitar a partição do ligando para a fase superior, a proteína GST-ZnF foi 
ligada covalentemente ao polímero PEG (PEGuilação). Inicialmente, 4 reacções 
de conjugação foram optimizadas usando a proteína GST livre. A PEGuilação 
dos grupos tiol foi total ao fim de 1 h em condições redutoras. Conjugações 
superiores a 80 % com os grupos amina foram obtidas ao fim de 24 h ou 
usando uma maior razão reagente/ligando. As reacções optimizadas foram de 
seguida aplicadas à proteína fusão GST-ZnF, resultando em rendimentos 
semelhantes. O ligando PEG-GST-ZnF foi posteriormente usado para transferir 
totalmente o plasmídeo pTS da fase inferior para a fase superior em sistemas 
PEG 600 – DEX 40. O ligando PEGuilado acumulou-se 97,5 % na fase superior, 
enquanto que a proteína GST-ZnF nativa e o plasmídeo pTS, acumularam-se 
96,5 % e 99,9 % na fase de DEX, respectivamente. Embora o “proof-of-
concept” para um processo de extracção de pDNA por afinidade tenha sido 
estabelecido, o processo não foi testado com lisados bacterianos dado que a 
ligação GST-ZnF/pDNA é extremamente forte e a sua eluição impraticável.  
Foi ainda desenvolvido um processo alternativo para ligar PEG ao ligando, 
usando PEG funcionalizado com iões metálicos (PEG-IDA-Cu2+) com afinidade 
para as histidinas à superfície da proteína LacI-His6-GFP. A extracção do 
plasmídeo pUC19 de lisados celulares em SDFA foi realizada com a presença 
de 0,273 nmol do ligando LacI-His6-GFP e 0,14 % (w/w) de PEG 
funcionalizado. Cerca de 72 % do pUC19 acumulou-se na fase superior, sem a 
co-purificação de RNA ou DNA genómico. Embora a eluição do pDNA se 
tenha provado difícil, a metodologia desenvolvida permitiu remover 75 % da 
proteína total e obter um rendimento final de 27 % de pUC19 (7,4 µg pUC19 
por mL lisado). Estes resultados correspondem a uma capacidade 9 vezes 
superior ao método cromatográfico descrito na literatura com o mesmo ligando.  
Em suma, este trabalho resultou no aumento de conhecimento na utilização de 
ligandos de afinidade em SDFA que poderá contribuir para o futuro 
desenvolvimento de processos industriais com alta especificidade para o pDNA, 
satisfazendo as especificações e procura de pDNA para terapia genética e 
vacinas de DNA.  
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Objectives and Thesis Layout 
The major aim of this project was to investigate and discuss whether protein-
based affinity ligands could be exploited for the large-scale purification of 
plasmid DNA in aqueous two-phase Systems (ATPS). The affinity extraction of 
pDNA in ATPS has generated interest, since it has high potential to improve the 
low selectivity of these systems combined with high pDNA capacities, faster 
processing times, and potentially more cost-effective compared to the traditional 
chromatographic methods. In the quest to accomplish the general objective, this 
thesis is organized in 5 individual chapters each aiming to fulfill a specific goal: 
Chapter 1 presents a general introduction that reviews the central biochemical 
challenges on plasmid DNA production and overview the current advantages 
and disadvantages of the existent pDNA purification methods.  
The Chapter 2 focus on the selection of suitable ATPS for the affinity extraction 
of pDNA by studying the partitioning of total DNA, total protein and total RNA 
from a bacterial cell alkaline lysate in PEG – dextran systems.  
In Chapter 3 results are presented on the optimization of protein PEGylation 
reactions and on the utilisation of covalent PEGylated and non-PEGylated GST-
ZnF affinity ligand for the affinity partitioning of pDNA bearing the zinc finger 
recognition site (pTS). Subchapter 3.1 focus on the optimization of four different 
PEGylation reactions for either amine or cysteine PEG conjugation on the free 
GST-tag protein. The Subchapter 3.2 presents the affinity partitioning of pTS 
plasmid using the modified and native GST-ZnF fusion ligand in the previously 
selected systems. 
The Chapter 4 focus on the utilization of the sequence specific DNA binding 
protein, LacI-His6-GFP, and a metal affinity PEG-IDA-Cu(II) as a dual affinity 
mechanism for the pUC19 plasmid extraction from a bacterial cell lysate in 
ATPS systems. 
Finally, Chapter 5 is devoted to an integrative discussion focused on the main 
contributions of the present work to the understanding of affinity purification of 
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plasmid DNA in aqueous two-phase systems. Brief suggestions for future 
directions to complement our research are presented, together with a few 
general concluding remarks. 
 
 
 Chapter 1 
General Introduction and Literature Review 
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1.1 Why Purify plasmid DNA 
1.1.1 Gene Therapy and DNA Vaccines 
The dawn of the modern biotechnological era can be traced back to the 
discovery of the DNA structure by James Watson and Francis Crick in 1953 [1]. 
However it was the discovery of basic tools of recombinant DNA, including the 
DNA ligases and restriction enzymes, that led Paul Berg and colleagues, to the 
creation of the first recombinant DNA in 1972 [2]. In 1973, Herbert Boyer and 
Stanley Cohen created the first recombinant DNA organism [3], a genetic 
engineering breakthrough with implications in the development of whole new 
therapies approaches for the treatment of a widespread type of diseases in the 
following decades.  
 
Gene therapy is one of the fields that in recent years has attracted a lot of 
interest, which is expected to grow more promptly in the future as the whole 
human genome has been sequenced and is now being annotated for potential 
therapeutic targets [4; 5]. The high potential of this therapy strategy is owed to 
the possibility to cure by the introduction of nucleic acids into human cells in 
order to restore, enhance or cancel a specific element on the genetic repertoire. 
Unlike other traditional treatments, gene therapy aims to remove the cause of a 
disease and not to correct the biochemical imbalance, or getting rid/attenuate 
the disease symptoms as in the traditional treatments [5].  
Traditionally, patients with particular genetic disorder are treated by the 
administration of therapeutic drug, e.g. proteins, that have to be taken 
frequently in order to tackle the disease. This is because proteins in the blood 
stream are degraded or eliminated with time and the therapeutic effect is limited 
to a short period. Gene therapy may circumvent these problems because the 
gene encoding the therapeutic protein is stably placed inside the cell and thus 
may result in longer-term expression of the therapeutic proteins [5]. 
Commonly, the nuclei acid used is the double-stranded DNA (dsDNA) 
encoding a specific protein but other nuclei acids such as the single stranded 
1. General Introduction and Literature Review 
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DNA (ssDNA) or antisense of RNA, have also been described [6]. Antisense 
RNA binds to a target sequence in the host cell and inhibits the expression of a 
specific gene by blocking either gene expression or its promoters.  
Alternatively, these transgenes can encode a target antigen that will elicit both 
humoral and cellular immune system’s response to the specific antigen. This 
process is designated by DNA vaccination [7]. The genetic transfer vector uses 
the host cell protein machinery to produce the antigen protein that will 
eventually emerge on the cell surface as Major Histocompatibility Complex 
(MHC) molecules, thereby inducing an immune response to the antigen [7; 8].  
One of the critical challenges in gene therapy and DNA vaccines is the 
efficiently and safety delivery of the nucleic acids into the target cells. Viral and 
non-viral delivery vectors have been developed for this purpose [9]. The use of 
viral vectors (e.g. retrovirus, adenovirus) have been questioned due to safety and 
regulatory concerns because of their toxicity and strong immune response after 
repeated administration [6]. In addition, the possibility to activate oncogenes or 
suppress tumor-suppressor genes have raised apprehension in the application of 
this vectors [9]. In fact, the viral vectors are responsible for some of biggest gene 
therapy setbacks as deaths on clinical trials have been reported [10]. 
The development of non-viral vectors has thus emerged as a safer alternative to 
viral vectors and led to the study of naked plasmid deoxyribonucleic acid 
(pDNA) or encapsulated/complexed pDNA as vector for transferring 
prophylactic and/or therapeutic genes. It is generally simpler to develop 
compared to the viral counterparts, and has the advantage of being free from 
most of safety concerns associated to the virus [11].  
However, the main disadvantage of non-viral vectors has been the insufficient 
level of production of protein/antigen by the host cell, thus triggering generally 
weak immune response. In addition, short duration of the expression has also 
been described [12]. At the present, virus vectors are the most efficient gene 
delivery systems and, regardless of the safety concerns, they are still dominant 
and widely applied in clinical trials. More than 66 % clinical trials worldwide 
1. General Introduction and Literature Review 
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are currently being performed using attenuated virus, such as the adenovirus, 
retrovirus or vaccinia virus; whereas naked / plasmid DNA represents only 17.9 
% (246 ongoing clinical trials) [13]. 
Despite the low transfection efficiencies, plasmids do not seem to activate anti-
DNA antibody secreting B lymphocytes, thus they are usually recognized as 
having better safety profiles and improved stability compared to the viral vectors 
[8]. Researchers are hoping to overcome the non-viral vectors disadvantages by 
co-expressing enhancing agents within the cells and by mimicking live virus 
infections [14].  
Other area of concern is the potential integration of the pDNA into the host cell 
genome. Although, the integration into the host genome has not been observed 
after 18 weeks of pDNA administration, concerns of this possibility remains a 
main issue [15]. There are stringent regulatory controls in order to prevent these 
problems to happen and thus a pDNA product has to comply with high levels of 
safety, quality and efficacy in order to be licensed [6; 16]. Nevertheless, it is 
believed that all the hazards of the pDNA side effects will be overcome in a 
near future. The potential for the improvement of current disease treatments or 
vaccination are the most promising attributes of the pDNA-based therapeutics, 
which eventually will transform the future healthcare. 
 
1.1.2 Current demands for plasmids 
In gene therapy, the therapeutic effects of plasmids are due to the DNA 
sequence that they carry, which, generally, encodes a protein that will induce 
the desirable therapeutic effect. The first successful direct transfection of animal 
cells with plasmid DNA in vivo was reported in 1990 by Wolff et al. [17] in a 
mouse. Since that time, the gene therapy field has developed very fast and now, 
there are already widespread gene-based indications for human use, which are 
currently in clinical trial phase. As last updated in March 2009, the foremost 
clinical trials worldwide addressed by gene therapy (n= 1,537) are for cancer 
diseases (64.6 %), cardiovascular (8.9 %), monogenetic (8.1 %) and infectious 
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diseases (7.9 %) such as HIV, malaria, and tuberculosis [13]. Naked / plasmid 
DNA represents about 18 % of the total trials and this represent clearly a rising 
demand, as figures in 2000, were only about 4 %. [18] 
The increasing usage of pDNA vectors in gene therapy/DNA vaccination trials 
results in an urgent need for development of large-scale and cost-effective 
manufacturing process of pDNA in order to meet those demands. Since pDNA 
has commonly low transfection efficiencies, it is also expected that larger doses 
of the DNA-based product are needed, or repeated administrations of the pDNA 
will be necessary in order to achieve successfully gene transfer [6; 12]. An 
average dose size will differ between therapies and each disease is likely to 
have specific needs. It is expected that typical doses size may vary between 0.1-
5 mg of pDNA, but full treatments may require larger quantities of plasmid DNA 
[19]. Thus, great amounts of pDNA have to be produced in order to be 
sufficient to supply for world requirements [6; 20].    
Some companies are already preparing and launching new facilities for the 
large-scale pDNA production. Aldevron LLC, for example, is a USA biotech 
company, which opened a facility in 2007 to manufacture kilogram amounts of 
pDNA. They claim to be sufficient for the production of up to 2,000,000 DNA 
vaccine doses assuming that a dose contains 500 µg of pDNA [18]. This clearly 
shows that really large amounts of the therapeutic vector may be required and 
this poses several challenges for the biochemical engineers. In addition, when 
the DNA vaccines prove to be efficient, safer and efficient alternative to the 
traditional vaccination methods, the demand for these pDNA vectors will 
increase dramatically. 
DNA vaccines will have an important role in the fight against virus pandemics 
outbreaks as the influenza virus outbreak (H1N1) we are currently suffering 
[21]. Compared to conventional therapeutic methods, DNA vaccines can be 
cheaper to produce, more stable at ambient temperature and safer to 
administrate [22]. Moreover, DNA vaccines can be produced as short as in two 
weeks, contrasting to 8-9 months of the actual methods [21]. This represents 
1. General Introduction and Literature Review 
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clearly a huge advantage since a much rapid-response to an epidemic outbreak 
can be achieved. Kieny et al. [23] have calculated that for the prevention of 
epidemics, like the H1N1 virus, it will require the vaccination of 60 % of the 
world population (6.8 billion, as last revised 2008 [24]) and it has been 
estimated that existing production methods are able to supply only 350 million 
doses per year [18].  
In Portugal, the government recently placed an initial order of 6 million doses of 
the H1N1 influenza virus vaccines (costing !45 Million) for the initial 
vaccination of about 30 % of the Portuguese population [25]. Orders of this 
magnitude have been placed all over the world in order to stop a potential 
spread of the virus between populations. In fact, several countries have placed 
orders higher that their entire populations, in the case repetitive doses are 
needed; Canada [26], United Kingdom [27], Israel [28] are amongst them. 
Ultimately, the replacing of the current vaccines by the DNA vaccines will 
make these a leading “drug” in the new generation of blockbuster therapeutics, 
since the demand for these vectors will be huge.   
 
1.1.3 Current gene-based products / market size 
The first gene therapy product is currently being commercialised only in China 
since 2004 with the trade name GendicineTM (Sibione GeneTech) for the 
treatment of head and neck squamous cell cancer [29]. The second licensed 
gene-based product has been also approved only for China market in 2006, 
under trade name of OncorineTM (Sunway Biotech), for the treatment of the same 
cancer. Cerepro® from the Anglo-Finnish company Ark Therapeutics Group 
PLC, will be probably the first gene-based product to be commercialized 
outside china, as European Medical Agency (EMEA) is currently reviewing it for 
marketing authorisation in European Union [29]. All the three products 
described above are virus-based drugs for human use. 
Nonetheless, as March 2009, there are currently 246 ongoing gene therapy 
trials worldwide that utilize plasmid DNA, of which 2 are already in clinical 
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trial phase III [13; 30]. Thus, it is expected these products to reach the market in 
2-5 years if it gets approval for commercialization.  
However, four pDNA-based therapeutics have been already licensed in the 
veterinary environment. The world’s first licensed DNA vaccine was attributed 
in 2005 for the immunization of horses against West Nile Virus (Ft Dodge 
Animal Health). Later it was also approved a pDNA vaccine for necrosis virus 
immunization in salmon (Novartis), for the melanoma cancer treatment in dogs 
(Merial) and for the growth hormone therapy in Pigs (VGX Animal Health). As 
the pDNA effectiveness in animals is been demonstrated and well established, 
soon it is also expected the same successes for such pDNA applications in 
humans [7; 30].  
The market size for gene therapy/DNA vaccines in humans is difficult to 
estimate, as the only two gene-based products were approved to the Chinese 
market and the true potential of the DNA-based drugs are still under evaluation. 
Nonetheless, the exponential increase in the number of patents issued in the 
area of DNA vaccines indicates that DNA-based drugs have generated a huge 
interest of many, demonstrating that pDNA could be a promising therapy 
technology in the future. In 1990 there were only 2 patents contained the term 
“DNA vaccine” whereas by time this thesis is written there are 1223 issued 
patents index by the United States Patent and Trademark Office [18; 31].  
The revenue predication to be generated from sales of these products is in the 
order billions of dollars worldwide [6]. However, since the human genome 
seems to encode 20,000-25,000 protein-coding genes [4], and their therapeutic 
value being asserted, the potential value of gene therapy could be as high as 
trillions of dollars globally. Therapeutic plasmid DNA is an example of a new 
generation of high-value low-volume medicines.  
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1.2 Central biochemical engineering issues  
There are three main stages on the manufacturing of plasmid DNA, Figure 1. 
The first stage is the construction of the vector and the transformation to a 
suitable host strain and is designated as upstream processing. The second stage 
is the cultivation / fermentation of pDNA host cells in order to amplify the 
pDNA. The third stage consists of the purification and formulation of plasmid 
DNA vectors and is designed as pDNA downstream processing. All the three 
stages are interconnected; hence each former step may have an impact on the 
efficiency of the following steps. In all these steps there are several critical 
challenges and difficulties, which the biochemical engineers have to address in 
order to produce pharmaceutical grade pDNA.  
This introduction does not set out to cover all these initial aspects of the 
plasmids manufacturing, consequently only a general perspective of some 
important aspects on the upstream processing of pDNA will be given. Reviews 
have been published elsewhere by Williams et al. [30] and by Tejeda-Mansir et 
al. [32] covering some important aspects of the pDNA upstream processing, 
which are not covered here but cannot be neglect for efficient plasmid DNA 
production.   
 
Figure 1 – Overall process for the plasmid DNA manufacturing. Adapted from [6]. 
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1.2.1 Vector selection and design 
The judicious selection of the plasmid vector is determinant for the production 
of high pDNA yields and for pDNA stability (i.e., the tendency of bacteria to 
completely loose the plasmid during cultivation) but also to increase 
transfection efficiencies and safety [30]. A careful design of the backbone vector 
is essential in order to fulfil with all the regulatory license guidelines.  
For efficient gene expression, pDNA must contain the desirable gene but also 
other important elements such as intron(s), eukaryotic promoter, 
polyadenylation sequences and, possibly an operon region. The majority of the 
plasmids vectors currently in used on DNA vaccines trials are derived from 
pBR322 or pUC plasmids, and use high copy derivatives of the pMB1 origin 
(closely related to the ColE1 origin)[14; 30]. The plasmid copy number in each 
host bacterial cell is important for greater yields but also to facilitate its 
downstream processing since the ratio pDNA to gDNA, RNA and cellular 
proteins (pDNA impurities) is increased. However high copy plasmid, such as 
the ones with pUC origin of replication, tend to reduce the growth rate, which 
over a period of time, may result in cells that has lower pDNA content [14; 30]. 
This phenomenon results of lack of active partitioning functions, as plasmids are 
not precisely distributed between cells. Consequently, plasmid-free cells arise as 
the propagation time increases [30].  
In order to increase the number of cells carrying the therapeutic gene, often the 
DNA vector carries a gene that confers resistance to an antibiotic. This gene is 
important for the selective growth of the cells with the vector to dominate. The 
common antibiotic resistance gene is KanR which confers resistance to 
kanamicin antibiotic [33]. Ampicillin resistance gene (Amp) is discouraged 
since some patients may have hyperactivity to β-lactam antibiotics [30]. 
Nevertheless, Amp is commonly used on vectors for non-therapeutic use. To 
ensure safety, regulatory agencies recommend elimination of antibiotic 
resistance markers from therapeutic pDNA vectors. 
Interestingly, the selection via antibiotic resistance does not also necessarily 
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lead to the production of high titer of plasmid DNA in the bacteria due to 
segregation instability during cell division [34]. Thus, several other antibiotic-
free selections for the pDNA production have been developed, such as a RNA 
selective marker (as shown in a model plasmid vector represented in Figure 2), 
amino acid auxotrophy complementation [35], strains lacking the essential gene 
initiation factor 1 [36] or Lac operator [14]. 
A representative example of RNA selective marker was developed by Luke et al. 
[37]. The authors have incorporate and express a 150 bp RNA-OUT antisense 
RNA that represses expression of a chromosomally integrated constitutively 
expressed counter-selectable marker (sacB), allowing plasmid selection on 
sucrose. This approach resulted in pDNA yield as high as 1 g/L.  
Antibiotic-free selection is a safest and most recommended alternative since the 
presence of the gene marker is discouraged due to concerns regarding the 
dissemination of antibiotic resistance genes to patient’s enteric bacteria [30].  
 
 
Figure 2 - Antibiotic free bird flu DNA vaccine vector. Vector specific features such as the 
CMV-HTLV-1 R-U5 derived mRNA leader (UTR) and RNA selective marker are indicated [30].  
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Commonly, DNA vectors have also the human cytomegalovirus/immediate-
early or CMV-chicken-β actin promoters because it provides highest levels of 
gene expression in a variety of cell types and tissues. These promoters usually 
lack any DNA sequences that are not essential for their function, therefore 
minimizing the possible homology with the host [33; 38]. 
Examples of some backbone vectors currently in use in some clinical trials are 
the pVAX1 (Invitrogen), V1JNS (Merck), pCMVKm2 (Chiron) but many others 
vectors, having different features, are also been currently in use [30].  
In summary, the design of pDNA vector is thus of paramount importance for the 
overall success of DNA vaccines production and applications. Varied aspects 
on the plasmid design cannot be given negligence since the impact on the 
following upstream and downstream processing can be significant, as well as, it 
may have an impact on the safety for human administration.  
 
1.2.2 Fermentation  
Plasmids are traditionally propagated in Escherichia coli (E. coli) K12 strains 
such as DH5α, DH1, JM108 [30]. Fermentation strategies combines the 
selection of fermentation conditions with the host organism and construct 
design to maximize both volumetric yield (mg/L) and specific yield (mg/OD600/L) 
of high quality supercoiled form plasmid DNA.  
Plasmid copy number increases as the specific growth rate decreases [38]. Thus,  
the selection of cell growth media and the fermentation mode has to be 
cautiously performed. For example, some studies have found that the pDNA 
content increases by tenfold as the carbon/nitrogen ratio increases from approx. 
0.2 to 2.78 [39]. Higher pDNA yields were also obtained using amino acid 
starvation or with the addition of chloroamphenicol to the growth media. 
Furthermore, the use of a heat shock (shift from 30 to 42 ºC) have also shown to 
increase the plasmid yield, nonetheless, at large scale, heat shock may be 
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difficult to apply [14]. The use of chloroamphenicol may also pose some 
regulatory concerns and thus may not be a suitable option.   
Fed batch cultivation, employing an exponential feed regime, is the most 
efficient mode for controlling specific growth rate (growth rate < µmax) and thus 
enrichment of pDNA in the biomass contrasting with batch mode. Both 
methods have been successfully employed for plasmid production with E. coli 
systems, but the fed-batch mode is the most dominant approach in several 
pDNA production operations [18]. 
The fermentation optimization process has three main heuristics that are always 
desirable to be achieved. The first is the cell culture mass per liter of 
fermentation. Evidently, higher cell density yields higher plasmids per unit 
volume of culture; Secondly, is the plasmid copy number per each cell host, 
which also leads to high specific yields; and third the plasmid quality, i.e., 
supercoiled pDNA content (see Section 1.2.4), to meet the regulatory demands 
for approval.  
Changes in growth conditions including nutrients concentrations, temperature, 
pH, oxygenation and growth phase can affect the pDNA quality, so these 
parameters should be carefully monitored. The production of plasmid DNA at 
high titer depends on the selection of suitable strategies for the control and 
regulation of bacteria growth and nutrient supply, but, as shown above, the 
optimization process starts at the plasmid design stage.  
Currently, a plasmid titer as high as 2.2 g/L is the benchmark [30]. At this 
productivity, 1 kg of plasmid in a 500 L fermentor could be generated. Yet, it 
should be noted again, the titer is not the only important fermentation criterion, 
as maintaining high pDNA quality is also are a major issue. In fact, the major 
problems in the pDNA manufacturing at the present resides mainly on the 
improvement of the bottleneck cell lysis and in the downstream processing of 
pDNA to solve this mismatch [19]. 
Representative examples of patents using fed-batch fermentation processes are 
issue to Merck [40] and to Boehringer Ingelheim using the E. coli JM108 
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strain [41]. 
1.2.3 pDNA Impurities  
One of the major concerns on the production of clinical grade pDNA is the 
assurance that the gene-based products have stringent impurities clearance. The 
high standard removal of all these impurities is essential for product approval as 
therapeutic drug, which represents one of the major concerns on the scaling-up 
production of plasmids. The regulatory agencies limits the impurities contents in 
each DNA formulation as summarized in Table 1.  
 
Table 1 – Impurities specifications and content in bacterial cell lysates. Adapted from [42] 
Final Product 
Content of bacterial cell 
lysates Issue in focus 
Range of 
acceptance 
Determined by 
55 % Proteins Protein <3 µg/mg pDNA BCA test 
3 % host gDNA gDNA <2 µg/mg pDNA TaqMan-PCR 
3 % LPS Endotoxins <10 E.U./mg pDNA LAL test 
>3 % Plasmid 
scDNA over oc 
form 
>97 % CGE 
21 % RNA* RNA <0.2 µg/mg pDNA Analytical HPLC 
15 % Others  
 * 53 % 23S rRNA; 27 % 16S rRNA; 2 % 5S rRNA; 14 % tRNA; 4 % mRNA 
 
The required pDNA product specifications shown above impose several 
problems on the downstream processing of pDNA, resulted by the relative low 
amounts of the target pDNA molecule in the E. coli bacterial cell lysates. 
Plasmid DNA accounts for less than 3 % of total content of a typical cell lysate, 
which increases the difficulty of its extraction. In addition, the pDNA is 
structurally related with other impurities such as RNA and with the genomic 
DNA. Both these impurities are in higher concentrations in the lysate and share 
some physicochemical properties with pDNA, such as, size and charge.  
Non-fragmented gDNA is a large molecule, which has a molecular weight of 
2700 MDa, whereas pDNA may vary between 2-20 MDa, which is significantly 
smaller [43]. However, inefficient alkaline lysis and the shear effects during 
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preparation of the lysate may fragment the gDNA into smaller portions with 
similar sizes and charge densities to pDNA, making the removal of genomic 
DNA particularly challenging. It is being observed that the size of pDNA and 
gDNA are on the major constraint in the physical operations due to their 
susceptibility to fluid mechanical forces. This represents one of the most critical 
bottlenecks in the large scale purification of plasmid DNA in all the spectrum of 
pDNA downstream processing techniques available [43]. 
A non-nucleic acid impurity consists mainly of endotoxins and proteins. 
Bacterial endotoxins are negatively charged (net charge) lipopolysaccharide 
elements of the outer membrane of gram-negative bacteria. When cells are 
broken down during the cell lysis, endotoxin globules of widely varying sizes 
can appear. In humans, endotoxins can cause responses ranging form slight 
effects of septicaemia to severe effects such as intravascular coagulation [44]. 
Thus, the removal of endotoxins from a DNA formulation is also crucial but 
since it also exhibits similar sizes to plasmids (and charge) they are considered 
difficult to remove.  
Endotoxins have affinity to almost every material and/or solvent used in the 
purification process, and it has been observed that endotoxins concentration 
decreases rapidly when a chain of purification systems is employed. Thus, at the 
end of multi-stage purification process the endotoxins are usually in sufficiently 
reduced concentrations to meet the regulatory demands without the need for 
specific endotoxin-removal operation [45; 46]. Nonetheless, affinity matrices 
such as polymyxin B [47], thiophilic aromatic chromatography [48] and HIC (in 
some extent) [49]  have been optimized for endotoxin removal.  
On the other hand, proteins impurities as low as 1ng per dose has been known 
to give rise to adverse reactions in humans, although the immunogenic response 
is highly dependent on specific proteins and recipients [50]. Therefore, the 
efficient protein removal during a pDNA extraction process is also required by 
the regulatory agencies, which impose a maximum limit of 3 µg/mg pDNA. As 
seen in Table 2, proteins are physiochemical less similar with pDNA molecules, 
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and generally, the efficient protein removal does not impose a lot of hurdles on 
the plasmid downstream processing, since selective conditions for pDNA can 
be found more easily.   
Table 2 – Comparison of the physico-chemical properties of proteins and 
plasmids. Adapted from [51].  
Biomolecule 
Characteristics 
Protein Plasmid DNA 
Building blocks amino acids nucleotides 
Molecular mass (kDa) 103 - 105 106 - 107a) 
Stokes radius < 5 nm 100 > 300 nm 
Charge depending on pI/pH negative 
Diffusion coefficient medium-high low 
Viscosity low high 
Shear force sensitivity low high 
a) The larger size of the plasmids strongly influences all other properties. 
 
1.2.4 Physico-chemical properties of plasmid DNA  
In addition to the efficient removal of pDNA impurities, the plasmid DNA 
formulations have to be in high quality form, i.e. 97 % of the plasmid DNA 
should be in the supercoiled form (Figure 3) and the content should be 95 % 
(w/w) of total nucleic acid [6; 42]. 
Plasmids are circular DNA molecules and there are found in bacteria 
independent of the chromosomal DNA. The pDNA can exist in three tertiary 
structures: supercoiled, open circled and linear. As seen in Figure 3, the plasmid 
structure denoted as supercoiled is a circular double-strand DNA structure 
where the DNA helix has been wound up. FDA states that pDNA may be less 
effective in the open circular or linear form and thus requires almost all pDNA 
content in the supercoiled form for its clinical approval. However, there is not 
yet a consensus opinion whether the therapeutic effectiveness in gene therapy is 
affected by the detailed topological structures, as efficient transfections have 
been already described using these tertiary forms of pDNA [14].  
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Figure 3 – Plasmid DNA supercoiling. Adapted from [52]   
 
The open circular and linear forms result from enzymatic or shear-induced 
breakage of the sugar phosphate backbone and represents also a critical and 
difficult purification challenge since they are also treated as an impurity, but 
share identical nature to the supercoiled DNA [38]. 
Another hurdle in the pDNA downstream processing is the pDNA vector size, 
which may vary from 2-50 kbp dependent on the length of the therapeutic gene 
and/or the length of the promoters or other gene elements integrated in the 
construct. The extraction of large plasmids from cells without being damaged is 
a significant challenge for the biochemical engineers and usually does not 
perform well as smaller plasmids [43]. Commonly, this is a generic effect and 
not sequence specific. The increase viscosity and the shear sensitivity of the 
larger plasmids are the major concerns, but also the difficulty to separate the 
pDNA from other larger similar molecules such as gDNA. For these reasons, 
small vectors are usually preferred since they are easier to purify but also 
because small pDNA vectors penetrates the target cells more efficiently and also 
shows increased expression rates in contrast with larger vectors [53]. In 
addition, smaller pDNA has higher copy number, hence better product yields 
can be obtained [14]. 
In summary, from the design of plasmid to the bacterial cell fermentation 
followed by the pDNA extraction, there are several and distinct challenges 
which a biochemical engineer have to address and overcome in order to obtain 
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clinical grade plasmid DNA. Several approaches have been developed from the 
initial stage of pDNA production to the formulation/polishing step. In the next 
Section 1.3, the most relevant approaches to overcome the downstream 
processing challenges will be presented.  
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1.3 How to purify plasmid DNA  
Several commercial kits and protocols are now available for the purification of 
plasmids at the laboratory scale from different manufactures (Quiagen®, 
Promega®, Invitrogen®, etc). However, none of them are suitable for large-scale 
production of plasmids due to the utilization of materials unsuitable for human 
use (e.g. alcohol, RNase A, chloroform) and/or are, technically difficult to scale 
up or economically not profitable [6]. As a result, there is an ongoing search for 
the design of a pDNA purification process, which address the utilization of safer 
materials and solvents, scalability, robustness, and efficiently removal of all 
contaminants/impurities.  
In Figure 4 there are represented several alternative and innovative pDNA 
extractions strategies that have been proposed and applied from the initial 
stages of the pDNA downstream processing to the final polishing step. The 
advantages and disadvantages of each technique will be outlined in this 
Section, as well as principles behind each one.  
 
 
Figure 4 - Typical plasmid production alternatives. Commonly used operations for each phase 
of the process maybe combined to make variety of processing routes. 
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1.3.1 Cell recovery, lysis and removal of solids   
Cell recovery processes and the cell lysis stage marks the initial steps of the 
downstream processing of plasmid DNA. After cell culture fermentation the 
pDNA-contained cells are recovered usually by centrifugation or by filtration in 
order to concentrate out from the growth media. Bacterial cells walls are then 
disrupted for the pDNA release to the supernatant in order to be captured in the 
following purification steps. Cell disruption fall into two main categories: 
mechanical and chemical disruption [16]. 
The mechanical disruption (e.g. sonication, bead milling, heat, etc) is usually an 
excluded option since the mechanical stress may potential damage the genomic 
DNA resulting in varied DNA fragments with the same size of the pDNA, 
complicating the plasmid isolation from these lysate impurities as discussed 
above [43]. 
Alternatively, a chemical lysis process has been widely adopted as a variation of 
the alkaline lysis originally described by Birnboim et al. [54]. Briefly, cells are 
resuspended in a neutral buffer, to which is added an alkaline 0.2 M NaOH 
solution containing 1 % (w/v) SDS. This step solubilises the cells walls releasing 
its contents to the supernatant. Within the pH range of 12.0-12.5 the pDNA 
does not fully denatures and remains in solution, whereas within this pH range 
both gDNA and proteins irreversibly denatured. This is a critical step since 
higher pH buffers will also irreversibly denature pDNA and may also affect the 
supercoiled form content of pDNA. The lysate shows marked non-newtonian 
properties, exhibiting a rheological behaviour that makes flow and handling of 
the material very difficult [43]. Such pH extremes may occur in a mechanical 
stirred lysis reactor, given the high concentration of NaOH and SDS. At large 
scale, mixing cannot be very efficient and consequently the lysate homogeneity 
in the vessel may be compromised and affect the pDNA quality and purification 
efficiency. The third step is used to lower the pH of the lysate mixture to 5.5 by 
addition of ice-cold sodium acetate solution. The change on the pH causes the 
flocculation of the gDNA and the precipitation of protein-SDS complexes and 
some RNA [14; 43].  
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The separation of the precipitated and flocculated material in the pDNA 
containing supernatant is usually achieved at large scale by low-shear filtration. 
Whereas, at the laboratory and preparative scale, centrifugation on fixed-angle 
rotors are the most common operations [55]. At large scale, the continuous feed 
flow centrifugation has been also described due to high capacity, but the liquid 
entering the centrifuge can cause shearing effects compromising the efficient 
removal of debris [56; 57]. After the removal of the debris, most gDNA and 
proteins are also removed, even so, the pDNA content still represents less than 
3 % of the total lysate contents (see Table 1).  
Some times a clarification and concentration step is performed after this first 
step. The clarification is mainly designed to remove remained proteins in the 
supernatant and usually is performed by using chaotropic salts, such as, lithium 
chloride and ammonium acetate [58; 59]. Plasmid DNA can be concentrated 
using poly(ethylene glycol) (PEG) in order to concentrate for the next 
purification steps but also to remove some host nucleic acids. This step has also 
an advantage of enabling the buffer exchange preparing the pDNA lysate for the 
sequent steps [14]. Alternative precipitation methods are discussed in more 
detail in the Section 1.3.3 – non-chromatographic purification processes. 
The patent landscape in this initial lysate preparation steps includes various 
methods and devices to perform the alkaline lyses at large scale. A notable 
patent is issued to Boehringer Ingelheim, which discloses a method and device 
for continuous flow lysis that utilizes glass bead columns to act as lysis and 
clarification reactors [60]. A high salt precipitation of impurities is described in 
the patent WO2004060277 [61] to remove some of the RNA and much of the 
endotoxins.  
 
1.3.2 Chromatography purification of pDNA 
Chromatography is a well-characterized and well-established method for 
protein purification in the pharmaceutical industry and considered the method 
with the highest resolution and reproducibility [62]. It is therefore one of 
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techniques that has been widely explored in plasmid DNA purification systems. 
Several physicochemical features of either the target pDNA, or its impurities, 
can be exploited via selective interactions with the solid chromatographic 
supports. Properties such as size, charge, hydrophobicity, conformation and 
accessibility of molecular groups have been studied. An extensive review of the 
currently available chromatography matrices for the separation of plasmid DNA 
has been given by Diogo et al. [63] 
 
1.3.2.1 Anion-exchange chromatography 
Anion-exchange chromatography (AEXC) is the most used method for the 
primary capture of plasmid DNA with more then 81 % of the patents within 
DNA purification methods [64]. AEXC explores the electrostatics interactions 
between the negatively charged plasmid and the stationary phase bearing 
positively charged groups such as quaternary amines [65].  
The main limitation of this technique is the co-purification of anionic polymers 
of similar structure and charge with pDNA, such as gDNA, endotoxins and 
some RNA [65; 66]. Therefore, additional purification steps are necessary, 
increasing the operational costs. Another disadvantages of AEX chromatography 
are the relative low capacity for the pDNA, and its elution in high salts buffers.  
Nonetheless, some AEXC supports has been shown to be selective to the 
supercoiled form of pDNA (which have higher charge density), eluting later the 
open circular forms (which have lower charge density) [57]. This is one of the 
major advantages of this technique. The efficient removal of RNA (although 
usually with the pre-treatment of the lysate with RNase), oligonucleotides and 
some proteins are the others main advantages of this chromatographic method 
[63]. Anion-exchange stationary phases are used in most of lab kits used for the 
pDNA purification, such as the commercial available from Qiagen or Promega.  
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1.3.2.2 Size exclusion chromatography  
Size exclusion chromatography (SEC) explores the different hydrodynamic size 
of plasmid and its impurities rather than the adsorption process in order to 
purify the target molecule. To achieve good separation between two species, it 
is required that the two molecules differ in size by 2-fold otherwise co-elution of 
the two species is obtained hence the resolution is limited [67]. Although good 
removal of impurities, such as RNA and proteins, has being observed, the 
separation between the pDNA and the gDNA proved to be more difficult since 
both nuclei acids eluted near the void volume [67], or efficient separation was 
dependent of the concentration of the two species in the lysate [68].  
Thus, the main disadvantages of this approach are the co-elution of impurities 
with similar size to the pDNA; the limited scale-up to a manufacturing scale; 
and the high dilution factors that may result [63]. Therefore, SEC is applied 
more often at later stages of the pDNA purification process for the polishing step 
and to accommodate the pDNA on the formulation buffers.  
 
1.3.2.3 Hydrophobic Interaction Chromatography  
Hydrophobic interaction chromatography (HIC) has also been used to purify 
plasmid DNA [49; 69; 70]. HIC makes use of the more hydrophobic nature of 
single stranded nucleic acids impurities (RNA, denatured gDNA and denatured 
pDNA) and endotoxins to retard the flow of these impurities through a 
chromatography column with a hydrophobic support (e.g. phenyl, octyl), 
consequently that supercoiled DNA is eluted in the flow through [63]. HIC 
needs high salt concentration to promote binding, thus it can be more 
conveniently used after anion exchange chromatography, or when the plasmid 
pool has a high salt content.  
Despite the low plasmid binding capacities of HIC resins, yields as high as 95 % 
have been reported with minimal solvent requirement [71]. The main limitation 
of the technique is that it requires high salt concentrations (e.g. 1.5-2.5 M 
ammonium sulfate) and pDNA is eluted in high salt buffer. Additionally, pDNA 
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has to be pre-precipitated from the lysate using isopropanol (with limited 
utilisation at large-scale) followed by its solubilisation in high salt concentration 
buffer prior to loading into the column, increasing the operation time and costs 
[63; 70]. Several patents have been issued using HIC for pDNA purification [72; 
73; 74]. 
 
1.3.2.4 Affinity chromatography  
The affinity capture of plasmid DNA based on their biological function or 
individual chemical structure has been developed recently and is gaining more 
interest in academia. Nonetheless, there is not yet an extensively literature 
available. At the present time there have been developed mainly three relevant 
approaches for the high affinity recovery of pDNA: Triple-helix, DNA binding 
proteins and amino acid interactions [75].  
Triple-helix affinity (THAC) is based on the sequence specific interaction of a 
pyrimidine oligonucleotide with pDNA [76; 77]. The binding occurs via the 
major DNA groove and through the formation of Hoogsteen hydrogen bonds. 
The binding kinetics is generally slow (may need >1 h) and requires acidic pH 
in order to the binding complex be stable. Despite the discrimination of 
different plasmids based on their sequence in one step, the recovery yields are 
typically low (best yield ~50 % [77]) and it is necessary long chromatography 
runs due to the slow kinetics of triple-helix formation. However, a good 
elimination of the gDNA, RNA has been achieved. 
The first demonstration of the usage of DNA binding proteins as affinity ligands 
on a pDNA chromatographic purification was performed by Woodgate et al. 
[78]. In this study the bifunctional Zinc Finger DNA-binding protein fused to 
glutathione S-transferase Zinc-finger (GST-ZnF) was used for the direct isolation 
from crude lysate of pDNA bearing the Zinc Finger recognition site. Using this 
approach it was possible to distinguish plasmids that contained the Zinc Finger 
recognition sequence from other plasmids [78]. Nonetheless, very low yield was 
obtained (10 %) and the authors did not demonstrate the pDNA elution from the 
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binding complex.  
A similar strategy was developed within the same research group exploiting a 
different heterofunctional protein, LacI-His6-GFP, that binds to the lac operon in 
a sequence specific manner [79; 80]. This technique allowed the isolation of a 
plasmid DNA bearing the lac operon directly from crude cell lysates free of 
gDNA, RNA, proteins and open circular pDNA. The major limitation of this 
chromatography process is the lack of capacity and difficulty to scale-up.  
The two pDNA affinity proteins described above are the central affinity ligands 
used in aqueous two-phase systems presented in this thesis. More detailed 
specifications and mechanism of interaction will be further discussed in the 
following chapters.  
Finally, amino acid–DNA affinity chromatography has been explored by using 
histidine [81] or arginine [82] amino acid ligands [75]. Usually referred as 
pseudobio affinity ligands, both these amino acids have been immobilized into 
a chromatography support and discriminate between supercoiled and open 
circular pDNA forms in one operation step. The elimination of gDNA and 
endotoxins were performed within the acceptable levels and no proteins or 
RNA was detected in the elution sample. However, these ligands have shown to 
have relative low yields and the interaction between pDNA and amino acid is 
dependent on the base composition, which may compromise future purification 
process with different plasmid [75].  
 
1.3.2.4 Monoliths 
Technological alternative to porous particles, monoliths, are currently gaining 
increase significance in the pDNA purification processes. Monoliths are single 
piece of macroporous (10-4000 nm or larger) solid material with high mass 
transfer rates, which make them more suited for larger molecules such as pDNA 
than traditional bead chromatography [83]. This new novel type of 
chromatographic stationary phase, has thus improved capacity (can reach up to 
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10 mg/mL) over the traditional chromatography supports (tenths of milligrams 
plasmid per milliliter) resulting in higher pDNA recovery yields [84]. 
Furthermore the optimal separation of large molecules can be achieved with 
short and fast runs without sacrificing resolution. Polymethacrylate based short 
monolithic columns distributed under the trade name “Convective Interaction 
Media (CIM)” (BIA Separations, patent [85]) is the most common type of 
monolith column being used. Several studies reporting the use of this material 
for pDNA purification have been published [84; 86; 87].  
The difficulty in preparing high-volume monolithic columns with uniform pore 
structure, owing to the exothermic nature of the polymerization, is probably the 
major drawback of this technique. This could be circumvented by preparing 
individual units and merging them to form one large monolith with uniform 
properties, which will behave as a single radial-flow tube [62].   
 
1.3.3 Non-chromatography processes 
Alternatively, non-chromatography processes have been developed for the 
pDNA purification in order to circumvent some of the pDNA chromatography 
disadvantages. Although high resolution can generally be achieved using a 
chromatographic technique, the capacity for pDNA is usually low, resulting in 
relative low pDNA yields. This is usually attributed to the fact that 
chromatographic supports have been originally designed with small pore sizes 
for proteins purifications and not for much larger molecules such as plasmids 
[63; 78]. It has been observed that in these chromatographic supports the 
plasmid adsorb only at the beads´ outer surface and thus, not all the potential 
binding sites are used to bind to pDNA [51]. As a result, whereas the capacity is 
usually in the order of 200 mg of protein per mL of matrix, it is only about few 
hundreds micrograms for plasmid DNA [51]. 
Although new supports are being developed with high binding capacities, such 
as the monoliths, chromatography process are also difficult to scale-up and at 
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larger scales, the resolution can be lost due to diffusion problems with large 
volumes feeds [62]. Chromatography based process are also acknowledged to 
be more a expensive technique in terms of global operation costs (columns, 
pumps, process controller, high volume of buffers, absorbents, etc) 
comparatively to a non-chromatographic approach [88].  
Chromatography-free processes are thus very attractive approach since it could 
circumvent the disadvantages of the chromatographic technique, therefore it has 
a high potential to improve the overall pDNA purification processes. The costs 
of the downstream processing of a biotech product is a major contributor to the 
overall process economics (estimated as high as 80 % [89]), hence an important 
attention is given to this stage. There is great potential for substantial savings to 
be made in the downstream processing by improvements of existing methods. 
Eliminating the need of chromatography steps will dramatically reduce these 
costs. 
In this Section it is not intended to cover the aqueous two-phase systems 
(ATPSs) extraction of plasmid DNA although it is probably the must explored 
non-chromatographic method for the purification of therapeutic pDNA. Detail 
description of the technique and the current the state-of-the-art on the pDNA 
purification from bacterial cell lysates are given on the Section 1.4 and 1.5. 
 
1.3.3.1 Precipitation  
Precipitation techniques are a convenient and common way to separate DNA 
from soluble contaminants such as RNA and some proteins at the lab scale. 
Plasmid can be precipitated selectively by the addition of isopropanol [58], 
poly(ethylene glycol) [16; 61], spermidine [90], cetyltrimethylammonium 
bromide, CTAB [91; 92]. Curiously, CTAB was used in one of the first industrial 
application of a non-chromatographic process for the purification of plasmid 
DNA [93]. Using CTAB at 20 g/L an overall recovery of 83 % of pDNA was 
obtained. 
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Although good removal of pDNA main impurities can be achieved, the 
precipitation approach is not easily scaled-up since plasmid may need to be 
centrifuged out and the resulting pellet resuspended for further processing. 
Additionally, some solvents are not recommended for large-scale manufacturing 
since some of them are not safe for human health or may need special facilities 
such as spark-proof ones.  
Alternatively, some precipitation methods have been developed for the selective 
precipitation of pDNA impurities while pDNA remains in solution. For example, 
RNA can be precipitated out by antichaotropic salts, such as ammonium acetate 
[94], ammonium sulfate [95], lithium chloride [96] but the use of high 
concentrations of these salts is environmentally and economically problematic 
at large scale.  
Of notable interest are the recently developed plasmid affinity precipitation 
reagents such the thermoresponsive elastin-like proteins (ELPs) [97; 98]. ELPs 
are conjugated with a DNA-binding protein resulting in a thermally reversible 
affinity precipitation system, specific for plasmids that incorporate the 
corresponding DNA-binding sequence. 
 
1.3.3.2 Membrane  
Adsorptive membranes are another non-chromatographic technique used to 
reduce the concentration of plasmid impurities and an alternative option for the 
desalting and condition/formulation step. The main advantages of this technique 
are the increased loading capabilities of some of these membranes (∼10 mg/mL 
of membrane) and the potential to maintain high efficiencies with large 
molecules at high flow-rates [99; 100]. Nonetheless, the relatively high cost of 
the membranes prevents their use at large scale [101].  
Different approaches have been developed for pDNA purification. Tangential 
flow filtration (TFF) and nitrocellulose-integrated process have been optimized 
for the pDNA purification with pDNA recoveries virtually of 100 % and with 
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significant removal of RNA, proteins, endotoxin and gDNA [102]. Charged-
based membranes have also been developed (just like in anion-exchange 
chromatography) for rapid and high capacity (~10 mg/mL) purification of pDNA 
[100; 101]. However, contaminant RNA could not be removed completely 
without the use of RNAse. The poor purification factor is probably the main 
drawback of this technique, which requires the pre-treatment of the feed stream 
to remove excess of RNA, either by using RNAse or extended alkaline lysis 
(1day) [103].  
Representative examples of patents claiming the use of TFF for a pDNA 
purification process are issued to Butler et al. [104] and for Pall, for an anion 
exchange membrane, Pall MustangTM [105]. 
 
1.3.4 Integration / multistage operations 
Since some of the techniques described above cannot achieve high pDNA 
purity/quality pDNA in one single operation, usually several combinations of 
different techniques are explored in order to obtain the required standard 
product specifications. Prazeres et al. [65] designed several overall process 
flowsheets representing the current panorama in downstream processing. In all 
them multiple stage downstream processing was assumed for efficient overall 
processes.  
Several examples of combined operations have been also reported elsewhere, 
such as the combination of AEXC, triple Helix and Hydrophobic interaction 
chromatography that was developed by Centelion (Gencell) yielding pDNA 
within the product standards [19].  
Urthaler et al. [51] have demonstrated an automated continuous system of HIC, 
AEXC and SEC, delivering high pure pDNA homogeneities (98 %) of the 
supercoiled form in any desirable final buffer.  
Cobra Bionufacturing Plc (UK) uses three chromatographic stages, starting with 
a anion exchange, followed by size exclusion and mixed mode 
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chromatography, which uses the commercial adsorbent, Poly-FloTM that binds to 
endotoxins during the purification [64].  
Such combinations of multi-chromatography techniques are very common, 
however, they are not cost effective for commercial scale purification [19]. 
Alternatively, the combination of chromatographic and non-chromatographic 
techniques in the same overall purification process is frequently developed. 
However, it is unusual for an overall process to eliminate the use of packed-bed 
chromatography totally and at least one chromatographic process is commonly 
necessary for the final polishing step [65].  
For example, it has been performed the integration of non-chromatographic 
process such as the utilization of PEG precipitating agents to enhance AEXC 
[106]. The authors claim the use of PEG-8000 (at concentration of 1 %) prior to 
AEX chromatography with recoveries increased from about 20 % to 80 %.  
Frequently companies have issued patents for only individual stages of the 
downstream processing of pDNA which have to be integrated with third-parties 
systems for complete downstream processing operation or for the upstream 
processing stage. GE Healthcare, for example, has developed the PlasmidSelect 
Xtra downstream purification package [107], which combines different 
proprietary technologies: the high fermentation process from Nature technology 
Corporation, and a proprietary thiophilic aromatic chromatographic media [19; 
108]. S-aryl ligands represents a selective tool to remove unwanted forms of 
plasmid DNA, thus it is highly selective for the supercoiled pDNA. The 
supercoiled concentration of the affinity column reached 96 % from 45 % in the 
original feed [14]. Other companies, such as Boehringer Ingelheim and Merck 
have combinations process platforms that couple high yield fermentation, cell 
lysis and purification patents portfolios allowing them to perform pDNA 
production operation almost with own licensed technologies [19].   
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1.4 Aqueous Two-Phase Systems 
Aqueous two-phase systems (ATPSs) are probably the most well explored non-
chromatography process for the purification of plasmid DNA. In this Section it 
will be described in more detail the ATPS technique and the principal factors 
involved on the biomolecule partitioning in these systems. The current state-of-
art on the utilisation of ATPS for the pDNA is also presented.  
 
1.4.1 Advantages / Disadvantages of ATPSs 
Aqueous two-phase systems are known for more than 100 years, but it was the 
pioneering work of the Swedish biochemist, Per-Ake Albertson started in 1956 
that have demonstrated its application for biological material separation and 
extraction [109]. Since that time, enormous advances and new systems have 
been introduced and extensively studied for the recovery of cells, viruses, 
proteins (e.g. enzymes, antibodies), amino acids and nucleic acids [110]. Unlike 
proteins, that have been studied in ATPS for a long time, plasmid DNA 
purification using ATPS had only recently attracted more attention. Few related 
references have appeared in the literature before the year 2000 (only the work 
of Cole 1991 [111]and Ohlsson 1978 [112] has been reported), and most of the 
advances in this area have developed since that time. 
In ATPS, the bulk of the two phases are mainly constituted by water (80–95 %), 
and most polymers have a stabilizing effect to the biological products. This 
provides a biocompatible and “friendly” environment for the bioproduct [88; 
109]. In addition, the ATPS allow the integration in one step of several 
downstream processing steps, such as clarification, concentration and 
purification, with fast separations times (due to low viscosity of the phases) and 
technical simplicity [113; 114]. Furthermore, the scaling-up of this technique is 
easy and reliable and most of the traditionally equipment used in chemical 
industry for liquid-liquid extractions can be easily adapted for the ATPS 
extraction of biological products [110]. The interfacial tension is very low in 
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these systems, creating a high interfacial contact area of the phases, and thus it 
shows a good mass transfer between phases [115].  
However, despite the advantages described above, ATPS are not extensively 
used in industrial/commercial processes. Such situation may be attributed to 
several factors including: the difficulty to predict the partition behaviour of a 
given biomolecule; the cost of the phase forming polymers; the utilization of 
environmental aggressive salts (e.g. phosphates); and the lack of knowledge of 
the technique [116]. In addition, the selectivity of ATPS is usually low and 
further steps are commonly needed to remove remaining product impurities. 
Although successful exploitation of the ATPS has been reported, the potential 
usage of ATPS as main purification process in the future requires that these 
disadvantages be overcome.   
ATPSs are generally regarded as a cheaper alternative to all the 
chromatographic approaches for the purification of plasmid DNA [88]. 
However, a detailed cost comparison between currently established techniques 
and ATPS-based process is currently lacking. Nonetheless, as intermediate 
recovery unit operation, ATPS have been found to be less cost effective than 
other non-chromatographic techniques [117]. ATPS composed with PEG 
600/ammonium sulfate (AS) has been simulated for the overall operation costs 
and resulted that ATPS is 2.5-fold more expensive comparatively with 
isopropanol/ammonium sulfate precipitation and tangential flow filtration. 
Nonetheless, this study, shows that pDNA yields "90 % were always obtained 
in all three techniques but ATPS delivered the highest HPLC purity (59 %), 
followed by precipitation method (48 %) and TFF (18 %) [117].  
With the objective to lower the ATPS operations costs, cheaper and crude phase 
forming polymers have been considered with similar product purification 
efficiencies [110]. For example, efforts have also being put into replacement of 
the fractionated dextran (DEX) (proximally US$500/Kg [118]) by less expensive 
polymers, such as crude dextran, starches and maltodextrins as the bottom-
phase component, which greatly reduces the processing cost [110; 119]. 
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Alternatively, the phase forming components can be recycled, which may 
minimize these limitations and, at the same time, be less environmental harmful 
[113]. The disposal of some salts, such as phosphates, in wastewater lines are 
known to be toxic for the environment and its not recommended to be 
discarded without previously treatment [117]. The components recycling will 
attenuate this problems and lower the operation costs at the same time.  
The poor selectivity of these systems has been addressed by using affinity 
ligands for the target product [120; 121]. Usually the ligand is covalently 
bounded to one of the phase forming polymers (usually PEG) enhancing the 
partitioning of the target product to the phase with less contaminants.  
Several protein-based affinity ligands (Protein A [122] , antibodies [123]), or 
small molecule-ligands (NADH  [124], ATP [125] and fatty acids  [126] have 
been grafted to PEG and used in this way. The utilization of affinity ligands for 
the pDNA purification will be address in more detail in Section 1.5.  
 
1.4.2 Phase diagrams   
Aqueous two-phase systems are formed spontaneously upon mixing two 
aqueous solutions of structural different components above a threshold 
concentration [109]. In contrast to what may be expected, phase separation is a 
relative very common phenomenon. However, the mechanism of phase forming 
is not yet fully understood and sometimes apparently miscible solutions results 
in two-phase systems. For example, polymers very closely related and highly 
hydrophilic may show phase separation when mixed, such as dextran sulfate 
and dextran polymers [110].  
It is recognized that the two principal factors to determine the result of mixing of 
two polymers are 1) the gain in entropy and 2) the interaction between the 
molecules [109; 127]. The prevalence of one these factors will determine the 
result of mixing: two phase separation or homogeneous solution.  
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A typical phase diagram is represented in Figure 5. Phase diagrams defines the 
potential working area for a particular ATPS and it is characteristic for a specific 
mixture of two polymers or polymer-salt systems under a set of conditions, such 
as buffer concentration, temperature, and pH. The two-phase region is defined 
by the binodal curve represented in Figure 5. Systems with the composition 
above the binodal will form two-phase system, whereas a system with the 
concentration of the phase components below the binodal will form a one-
phase solution.  
Turbidometric titration is a commonly used method for determination of the 
binodal since when the two phase components are mixed, the mixture become 
turbid only when immiscibility occurs and thus turbidometry can be measured 
[109]. Briefly, a series of systems of known total composition are prepared in 
order to make two-phase systems. Upon dilution, the mixture will eventually 
turn “clear” when one phase is formed. The system composition, at the point of 
transition, is calculated and defines the binodal curve.  
 
Figure 5 – Phase diagram showing the binodal curve for systems composed with two phase-
forming components. Tie-lines are represented and three selected ATPS, from the same tie-
line, with different volume ratio (VR) are schematically drawn.  
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There are several information that can be extracted from the diagram: 1) the 
minimum concentration of the phase forming polymers or salts for two-phase 
separation; 2) concentration of phase components in the bottom and top phase; 
and 3) phase volumes ratio.  
Suppose a point A (Figure 5) represents the total composition of a system, 
percentage of the top and bottom phase component per total system weight. 
The composition of the bottom and top phase of that particular system are the 
coordinates of the tie-line intersection (nodes) with the binodal curve. In Figure 
5, the A´ is the composition of the two components in the top phase, whereas 
the A´´, is the phase composition of the bottom phase. Any other system with 
the total composition lying in the same tie-line, will give rise to an ATPS with 
the same top and bottom phase composition, but with different volumes of the 
two phases as schematically represented in the Figure 5. If the composition is 
expressed in weight per weight (w/w) percent, the weight ratio of bottom phase / 
top phase is equal to the ratio between lines AA´ and AA´´. Hence from the 
diagram:  
! 
VTopdTop
VBottomdBottom
=
AA"
AA""             (1) 
where, 
! 
V  is the volume of top and bottom phase; and 
! 
d  the densities of 
polymer or salt phases. Since the densities of the top and bottom are not very 
different (~1.0-1.1) the ratio of the segments AA´ and AA´ is proximally the 
volume ratio in that system.  
 
1.4.3 Tie-Line Length 
Tie-lines are determined by calculating the polymer or salt composition on both 
the top and bottom phases for each system studied. For example, PEG 
concentration (a commonly phase-forming polymer) is usually determined by 
refractometry using a calibration curve constructed with PEG standards of 
known concentration. The dextran (DEX) concentration, other traditionally used 
phase-forming polymer, is quantified by polarimetry using calibration curves 
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obtained for dextran solutions of known concentration. Salts are usually 
quantified by conductivity measurements [109; 128]. Tie-Line lengths (TLL) 
characterise the compositional differences between the two phases and in a 
system with a component 1 (C1) and a component 2 (C2) re calculated using 
the following formula (2): 
! 
TLL = (" C1[ ])2 + (" C2[ ])2         (2) 
where 
! 
" C1[ ] = C1[ ]top # C1[ ]bottom   ;    
! 
" C2[ ] = C2[ ]top # C2[ ]bottom     (3) 
All aqueous two-phase systems compositions are expressed in % (w/w). The 
point where the 
! 
TLL = 0 is called the critical point and lies on the binodal 
curve. This is a theoretical system where the composition and volume of both 
phases are equal. In theory, in this point a particle will partition equally to both 
phases since the composition of the two phases are similar. The critical point 
can be determined by drawing a line connecting the middle points of each tie-
line (A, B, C in Figure 5) and extrapolated it to the binodal. The critical point is 
the intersection of this line with the binodal.  
 
1.4.4 Partitioning in Aqueous Two-Phase Systems 
The basis of biomolecule separation in a two-phase system is the selective 
distribution of substances between the two phases. It is this phenomenon of 
partition that is exploited in ATPS extractions operations, since it provides a 
method whereby the desired solute can be removed from a solution, and 
separated from other undesirable impurities.  
The distribution of substances between each phase is governed by a number of 
parameters related with the properties of the phase system and the substance, 
and also by the interaction between the two through hydrogen bonds, van der 
waals, electrostatic, and hydrophobic interactions [109; 115]. The biomolecule 
partitioning is also influenced by conformation effects, steric hindrance and size 
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of the biomolecule, increasing the difficulty to predict its partitioning behavior 
in ATPS. Since there are many forces governing the partition, the separation 
modeling of a biomolecule in ATPS poses an extremely complex problem 
because of its dependence on the above array of factors. 
The partitioning of a molecule, x, is normally defined as the partition 
coefficient, 
! 
K , which is the ratio of the concentration of the molecule in the top 
phase 
! 
x[ ]top  to that in the bottom phase 
! 
x[ ]bottom :  
! 
Kx =
x[ ]top
x[ ]bottom
          (4) 
The contributions of these factors to the observed partition coefficient can be 
summed up in logarithmic terms, as follows: 
! 
lnKx = lnK0 + lnKelec + lnKhydrop + lnKsize        (5) 
wherein 
! 
lnKelec , denotes the electrostatic effects; 
! 
lnKhydrop, a hydrophobic term; 
! 
lnKsize, a term for biomolecule and polymer size; while 
! 
lnK0 represents other 
factors.  
All the properties are not equally important and this depends on the system 
used. For example, hydrophobicity was shown to be more important in 
polymer-salt systems than in polymer-polymer systems [129]. On the other 
hand, the physicochemical properties of the phases depends on the conjugation 
of other factors, such type and the molecular weight of polymer, pH, salt 
composition, molecular weight, and temperature; adding to the complexity 
mechanism of partition [115].  
It should be noted that the complexity of these systems is even greater because 
these factors are not completely independent of each other. Consequently, due 
to the lack of partitioning models, most of the times the partitioning of a 
biomolecule has to be determined experimentally and this is probably one of 
the reasons why this technique has not yet been widely adopted [116]. 
However, this also means that the partitioning of a compound is rather unique 
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and the modification of some parameters may increase the selectivity of that 
compound to the phase where fewer impurities accumulate [130]. Nonetheless, 
the selection of suitable ATPS could be a rather laborious process in order to 
find the appropriate/desirable conditions. The utilisation of robotic high 
throughput screening approach would be an advantage at this stage, since it is 
possible to test several factors in a short time, such as, system composition, pH, 
polymers molecular weight, ionic strength and all other added compounds 
[131]. 
Currently, there is not yet a holistic model describing the selection of key system 
parameters for the purification of any target biomolecule. The elucidation of the 
molecular mechanistic understanding of solute partitioning is currently one of 
the major areas of research. Despite advances that have been made, additional 
knowledge is needed to fully understand the partitioning mechanisms [116].  
  
1.4.5 Aqueous Two-phase Systems for pDNA purification  
The recovery of pDNA by ATPS often makes use of the polymer PEG, and a 
second polymer- or a salt- enriched bottom phase. Potassium phosphate, 
ammonium sulphate and sodium citrate had been used as phase-forming salt 
with comparable results [70; 114; 132]. In most of the studies published using 
the PEG/salt systems, high recovery of pDNA is obtained to the salt phase with 
the elimination of most RNA, proteins and endotoxins to the polymer phase. 
Better results are usually obtained using a PEG-salt system with low molecular 
weight PEG. However, the system composition must be carefully chosen as 
significant differences between the top and bottom phase compositions, 
corresponding to high tie-line values, result in plasmid precipitation at the 
interface, with the concomitant yield reduction [70].  
The PEG molecular weight in PEG/(NH4)2SO4 systems seems to have greater 
effect on the pDNA partition. Results showed that pDNA could be directed 
towards the top phase (PEG-rich phase) (MW<400) or to the bottom phase (salt-
rich phase) (MW>400) [70; 132]. In PEG 600/salt systems the pDNA partitions 
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totally to the bottom phase (yield 88.4 %) whereas the protein from bacterial 
cell lysate remained in the top phase [70].  
Rahimpour et al. [133] reported 99 % pDNA recovery in systems composed 
with PEG400/citrate at pH 6.9. Under these conditions the RNA removal was 
only about 68 %. A recent study reported that while ammonium sulphate 
systems give higher purity (~100 %) compared to the citrate systems, a lower 
recovery yield is obtained [134]. A compromise between these two parameters 
could be found using a mixture of the two salts. A mixture of 25 % (w/w) 
ammonium sulfate and 75 % (w/w) sodium citrate resulted in plasmid recovery 
of 91.1 % and purity (17.2 %). In this study it was demonstrated that ammonium 
sulfate could be partially replace with citrate buffers without compromising 
performance [134]. However, purification improvements are still needed in 
order to increase the pDNA purity.  
From an environmental point of view, the utilisation of citrate is preferable to 
sulfate or phosphate systems, because its biodegradable and non-toxic [117; 
133]. On the other hand, the extraction of pDNA to the ammonium sulfate 
phase is advantageous since the salt phase could be applied directly to HIC 
chromatography for removal of remained impurities [70]. 
Polymer/polymer systems are usually regarded as a more expensive alternative 
than polymer/salts systems [88]. However these systems can avoid some of 
problems associated with the polymer/salt systems, such as the interference of 
the salts on the utilization of ligands for the affinity partitioning of plasmid DNA 
[128]. In addition, there is less variation of the pDNA partition and its impurities 
from system-to-system in polymer-polymer systems as compared to the 
polymer-salts as demonstrated in this thesis.  
Thermoseparating phase components  such as the 50 % ethylene oxide – 50 % 
propylene oxide copolymer (EOPO) have been used with dextran to form two-
phase polymer systems [135].  In EOPO-dextran systems almost 100 % of 
pDNA accumulated in the EOPO rich phase, which can be removed and heated 
to 55 ºC to form a second aqueous phase to eluted the pDNA. With this 
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approach the removal of RNA is not so efficient, although 80 % reduction of 
this contaminant has been achieved [135]. Another drawback of this approach 
is that the lysate has to be previously desalted in order to precisely control the 
salt composition of the systems, which determines the partitioning of nucleic 
acids. In contrast, in salt-polymer systems the phase components could be 
directly added to the lysate [114]. 
Some of the aforementioned studies applied other purification steps to recover 
the pDNA from the salt phase of ATPS and to remove remained impurities. 
ATPS integration with HIC chromatography [70], membranes [136] or with 
more than two unit operations have been reported for this purpose [137].  
Kepka et al. [137] integrated aqueous two-phase systems with membrane 
filtration and lid bead chromatography, a procedure that has also been 
described in patent WO2004020629 [138]. The process started with a volume 
reduction and lysate buffer exchanged using hollow fibber membrane system. 
The concentrated samples were then applied to EOPO-dextran system to 
remove most of the proteins and RNA. Finally, the eluted pDNA from the top 
phase was polish using lid bead chromatography. This new type of 
chromatography uses positively charged inner cores (for the binding of 
remained RNA) and inert surface layer. A good removal of all impurities was 
accomplished but the overall process pDNA yield was about 69 %.  
Frerix el al. [139] have used membranes as polishing step after a PEG-Salt ATPS 
extraction (avoiding totally a chromatographic step) to select the supercoiled 
form of pDNA (35 mg / 95 %) free from remaining nucleic acid impurities, such 
as open circular pDNA (<3 %) and gDNA (<1 %). This process has been also 
described in a patent issued in 2006, US2006286080 [140].  
Another type of process integration is the combination of downstream 
separation operations into single separation step by adding an affinity 
component to the system in order to increase selectivity of ATPS. In fact, this 
was our approach for the development of efficient pDNA purification process.   
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1.5 Affinity purification of plasmid DNA in ATPS 
1.5.1 Affinity-based separations in ATPS  
The results obtained so far using ATPS for the pDNA purification are promising 
since most of impurities could be removed in a single step. However, the ATPS 
methods hitherto have been used mainly as primary recovery/enrichment step 
after cell lysis and further purifications steps are required in order to obtain 
clinical grade pDNA. The main limitation of using ATPS as main downstream 
operation is due to its low selectivity for the target pDNA. The utilisation of 
affinity ligands on aqueous two-phase systems extractions is thus an attractive 
approach since it will improve the poor selectivity of these systems and, at the 
same time, it will exploit the technical advantages of using ATPS for large-scale 
operations (see Section 1.4.1). 
The affinity approach is based on the specificity and biorecognition properties 
of the ligands for the target pDNA. Affinity ligands has the potential for the 
efficient capture of pDNA from a crude feedstock with large and structurally 
related impurities, such as, high molecular weight RNA, endotoxin and shear 
genomic DNA [75]. 
Affinity-based separations have been extensively applied for proteins extractions 
in chromatography [141; 142; 143] and in aqueous two-phase systems [144; 
145; 146], but only one recent study from our group, explored the utilisation of 
a non-specific ligand in aqueous two-phase systems for the plasmids extractions 
from a bacterial cell lysates [128]. 
Duarte et al. [128] have used the cationic polymer poly(ethyleimine) (PEI) as 
non-specific ligand for the purification of pDNA from crude cell lysates in a 
two-step ATPS process. The authors report to 100 % pDNA recoveries in a form 
of DNA/PEI polyplexes with only minor protein impurities. An initial system 
with the composition of PEG 600 – ammonium sulfate was used to remove most 
of the impurities to the top phase. The bottom phase was collected and mixed in 
a second system composed by PEG 3350 – DEX 110 and 0.2 % of PEI. The 
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purification of pDNA as polyplex form would be an advantage since after some 
polishing steps the polyplex would be ready for human administration. 
Nonetheless, safety concerns may rise in the future using this purification 
approach since it may be difficult to control the ratio pDNA/PEI in each 
operation resulting in product heterogeneity. In this study, the authors did not 
demonstrate the DNA elution from the polyplexes and it is not clear yet if the 
pDNA could be eluted and used as non-complex form. Additionally, the 
PEI/DNA interactions are mainly electrostatic, thus there is a potential risk for 
non-specificity binding of the cationic polymer to other negative charged 
molecules, such as RNA and gDNA, which will present some safety concerns. 
However, it is notable that in this study that no RNA was co-purified in system 
composed with 0.2 - 0.5M ammonium sulfate [128].  
The utilisation of pDNA sequence specific ligands is consequently a logical 
approach, but yet they have not been explored in the two-phase systems so far. 
In this work, two protein-based ligands were used as basis for the designing a 
pDNA affinity purification process (Figure 6).  
 
Figure 6 – Schematic representation of the two protein-based affinity ligands used in this work. 
A) GST-ZnF fusion protein; B) LacI-His6-GFP  
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One of the ligands used is a Zinc Finger protein (ZnF) fused to the glutathione-S-
transferanse (GST) protein resulting in the fusion protein named GST-ZnF [78]; 
the other protein ligand is a lac repressor protein, LacI, fused to both a His6 tag 
and to a green fluorescence protein (GFP) tag resulting in the heterofunction 
protein named LacI-His6-GFP [79]. These two proteins have already been 
proved to be efficient ligands when immobilized on to a chromatographic 
support for pDNA purification (Section 1.3.2.4). However, the pDNA capacity 
of the chromatographic process was shown to be suboptimal for large-scale 
pDNA production [78; 79].  
The utilisation of these ligands in ATPS should thus increase the previously 
found low yield as the interaction takes place in an homogeneous phase and 
there is no steric hindrance caused by the binding to the resin. Moreover, loss of 
products due to non-specific adsorption to the solid support should also be 
avoided.  
The main drawbacks of protein-based ligands are related to the fact that ligands 
come from a biological source and they may require previous purification and 
can be costly to produce. In addition they maybe contaminated with other 
impurities, which could complicate the downstream processing of pDNA. The 
utilisation of the crude cell lysates of these ligands, instead of using the pure 
protein ligands, could significantly reduce the high costs associated to the 
ligands. Nonetheless, this could increase the purification challenge since 
impurities will also increase in the two-phase systems.  
The stability of the protein ligands is another issue of concern, as proteins are 
usually not very stable at room temperature for long times. Even so, it has been 
already shown that these ligands could be lyophilized, stored at room 
temperature and re-hydrated when required [80]. Alternatively, synthetic 
ligands can potentially be a more suitable alternative in the future, as they are 
more stable than the biological counterparts, easier to scale-up and they are 
more durable [147]. Synthetic ligands may prove to be more cost-effective, but 
they may lack the bioselectivity of the sequence-specific DNA protein ligands.  
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1.5.2 Systems selection for affinity partition  
The successful and efficient utilisation of affinity ligands in ATPSs requires the 
selection of a two-phase system where the ligand/pDNA complex can partition 
into the phase with less impurities. Thus, a suitable ATPS would be one that all 
pDNA impurities accumulates mainly in one phase in order to be possible to 
extract the pDNA to the “clean” phase, therefore increasing pDNA purity.  
It has been reported that in some polymer-polymer systems, particularly PEG-
dextran, it is easier to select conditions where the majority of pDNA impurities 
can accumulate in one particular phase. ATPSs have been described in which 
97.5 % of denatured genomic DNA [112]; the majority of the total proteins 
[109], nearly 100 % RNA and ~100 % pDNA from bacterial cell lysate 
accumulate in the bottom dextran rich phase [128]. We thus hypothesised that 
the PEG-dextran would be potential suitable systems for first extractions systems 
since pDNA could be extracted from its main impurities by means of affinity 
ligands, which would accumulate in the opposite top phase (PEG-rich phase).  
However, the further utilisation of affinity ligands requires a complete 
understanding of the partition of the bacterial cell lysate’s components on this 
polymer-polymer systems and the evaluation of the influence of parameters 
such as polymers molecular weight and concentration might have on the 
partitioning of these components. There are few examples reporting to the 
partition of DNA bacterial cell lysate in PEG-dextran systems in the literature 
[112; 128], and a systematic study of the partitioning of plasmid DNA from a 
bacterial lysate in PEG-dextran had not been made yet.  
For the utilisation of affinity ligands in ATPS the polymer-polymer systems are 
preferred over polymer–salt systems since a high salt concentration may impair 
the interaction between the protein ligands and pDNA and thus should be avoid 
as first operation systems [128].  
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1.5.3 Affinity ligands relevant for this work 
1.5.3.1 Zinc finger protein  
Zinc finger proteins are one of the best-known class of DNA-binding proteins 
that binds sequence specifically to the DNA recognition site [148; 149]. A 
recent model proposes that these proteins bind initially non-specifically by 
electrostatic interaction and then run along the DNA strand until they find the 
recognition site where they strongly attached [150]. In this work we made use of 
ZnF protein which the sequence specificity has been previously described by 
Desjarlais et al. [151]. The authors have determined that the ZnF bind to the 
target sequence (5´-GGGGCGGCT-3´) with a KD of 2nM and the affinity could 
drop substantially (to KD of 1µM) if two bases were modified on the target 
sequence. Woodgate et al. [78] have also demonstrated that the zinc finger 
protein (10.7 kDa) fused to a glutathione-S-transferase, GST-ZnF (38.3 kDa), 
could distinguish plasmid that contained the target DNA sequences (pTS 
plasmid) from other plasmids, pUC19, that shares natively 7 bp of the 9bp. In 
the above study, the pTS plasmid was constructed by inserting a synthetic 
oligonucleotide cassette containing the recognition sequence into the smaI site 
of pUC19 plasmid.  
The same bifunctional affinity protein, GST-ZnF (hydrodynamic radii of less 
than 10 nm) will be accessed here for pDNA extraction in ATPS systems. The 
GST moiety will not be removed from the GST-ZnF protein since it has been 
shown that the GST does not interfere with the ZnF binding properties [78; 
152]. The GST-tag protein is used for the purification of the fusion protein by 
selectively absorption onto a glutathione affinity matrix allowing its purification 
from the expression host.  
The main problem associate with the GST-ZnF fusion protein is related to the 
strong binding to the target DNA, consequently the elution from the protein-
DNA complex was impractical [78]. Consequently, this ligand cannot 
effectively be used in an efficient pDNA purification process since the presence 
of the bounded protein would be restricted by the regulatory agencies. Hence, 
in this thesis the GST-ZnF fusion protein is used to demonstrate the proof-of-
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concept of a specific affinity strategy for pDNA purification in aqueous two-
phase systems.   
1.5.3.2 Lac repressor protein  
The repression of lac operon is achieved by halting the binding of the RNA 
polymerase in a pre-transcriptional complex with the promoter by the first lac 
operator (lacO1) being bound to the lac repressor [153]. Native LacI protein is a 
tetrameric protein (two dimer units) that binds to the first lac operator, lacO1, 
and with lower affinity to the lacO2, or lacO3 operators sequences [154; 155]. 
The binding to a second operator was found to make no significant contribution 
to the repression, however, stabilizes the protein/DNA complex and aids to the 
formation of the repression loop [79]. However, unsurprisingly, the interaction 
between the plasmid containing the lacO1 and lacO3, such as pUC19, is 
stronger when two rather than one operator, lacO1, is present (KD of 12 pM and 
1nM, respectively) [156]. 
The LacI-His6-GFP protein has the molecular weight of 274 kDa [79] and 3 
domains. The GFP domain enables the specific detection of the fusion protein 
by fluorescence in a mixture of other proteins; the His6 tag enables the binding 
to the immobilized metal affinity matrix; and the LacI domain binds sequence 
specifically to the LacO3/ LacO1 operator on the  “native” pUC19 plasmids (~1.8 
MDa).  
Recently, LacI-His6-GFP DNA binding protein was immobilized into an 
immobilized metal-ion chromatography column and explored for the affinity 
capture of pDNA directly from crude cell lysates (see Section 1.3.2.4). The 
resulted pDNA eluate was virtually free from all main pDNA impurities in 
highly pure pDNA free from contamination of gDNA, denatured pDNA, RNA 
and proteins.  
1.5.4 Ligand PEGylation  
It was hypothesised that partitioning of the DNA ligand to the PEG-rich phase 
could be accomplished by either (1) tailoring the two-phase PEG-dextran system 
such that the affinity protein preferentially accumulates in the PEG phase, or (2) 
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PEGylating the ligand to cause preferential partitioning into the PEG phase. The 
latter approach was investigated by two different methods. The first method was 
investigated using the GST-ZnF protein where the PEGylation was achieved by 
covalent binding of the PEG polymer into the affinity protein by reacting it with 
different activated PEGs targeted for either amine or cysteins groups within the 
protein. The second PEGylation method hypothesised was composed of 
immobilized metal–ion affinity PEG which binds to the poly(histidines) that are 
accessible on the surface of LacI-His6-GFP protein.  
In both methods it is expected enhancement of partitioning of the affinity 
protein / pDNA complex to the PEG-rich top phase, where less pDNA 
impurities accumulate. The DNA binding affinity ligands are dependent on the 
presence of recognition sequence (less then 120 bp), so the success of the 
systems does not depends on the size or charge of the DNA (as in PEI systems). 
This would enable the specifically capture of pDNA in one step without gDNA, 
RNA and proteins, thus eliminating the need of further purification or polishing 
steps.  
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2.1 Abstract 
 
Aqueous Two-Phase Systems (ATPSs) used for affinity partitioning of plasmid 
DNA (pDNA) require that most contaminants accumulate in one phase, together 
with the pDNA, while the affinity ligand and its complex with pDNA should 
accumulate in the other phase. In this way the affinity ligand steers the pDNA to 
a phase with less contaminants, so increasing its purity. In this work the 
partition of total protein, DNA and RNA from an alkaline bacterial cell lysate in 
ATPSs composed of poly(ethylene glycol) (PEG) / Dextran (DEX) was examined 
to identify appropriate systems for pDNA purification. In systems composed by 
PEG 600 – DEX 40 all major pDNA contaminants accumulated predominantly 
in the DEX rich phase (protein >80 % and RNA >99 %). These systems are 
suitable for utilization of DNA affinity ligands based on PEGylated affinity 
proteins, as well as non-protein ligands that accumulate preferentially in the 
PEG phase. Total pDNA recoveries in these systems was >80 %, indicating that 
pDNA precipitation at the interface is low and thus showing them to be 
appropriate for pDNA affinity purification. 
. 
 
 
 
 
 
Keywords: Aqueous two-phase; Affinity ligands; Poly(ethylene glycol); Dextran; 
Plasmid purification, Contaminants partitioning 
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2.2 Introduction 
Some of the most promising advances in molecular medicine have been 
reported in the field of gene therapy and DNA vaccines. Non-viral vectors, such 
as plasmid DNA gene delivery systems, are been considered for this purpose 
with great acceptance [1; 2]. However the widespread application of this 
methodology will require adequate methods to produce and purify plasmids at 
large scale. Although several chromatographic methods had been proposed for 
plasmid DNA (pDNA) downstream processing [3; 4], aqueous two-phase 
systems (ATPSs) represent an attractive alternative.  
ATPSs can be scaled-up easily and integrate clarification, concentration and 
purification in a single operation. Additionally, phase equilibrium is usually 
achieved in a short time, enabling fast separations that can be performed in 
continuous mode at low cost [5; 6]. Despite these advantages, ATPSs are not 
widely adopted in industry, which may be because the prediction of partition 
behaviour is difficult and suitable systems for a given application are usually 
found by trial and error. Also, selectivity of ATPSs is usually low and further 
steps are commonly needed to remove remaining impurities [7; 8; 9].  
The use of affinity ligands to enhance the partitioning of a target molecule to a 
particular phase minimises these two problems by increasing selectivity and 
makes partition behaviour more predictable [10; 11]. However, such studies 
have been mainly restricted to the purification of proteins. So far as we know, 
only our group had reported the utilisation of affinity ligands to enhance 
plasmid DNA isolation in ATPSs [12; 13].  
Efficient utilisation of DNA affinity ligands requires that most contaminants 
accumulate in one phase, while the affinity ligand and ligand-pDNA complex 
should accumulate in the opposite phase. In this way the affinity ligand steers 
the partitioning of pDNA to a contaminant-free phase, so increasing its purity. 
The selection of appropriate systems to conduct the affinity partition is thus of 
paramount importance for the success of the process. In our previous studies 
polymer-polymer systems namely poly(ethylene glycol)(PEG)-dextran were 
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used. They were preferred to polymer-salt systems since their high salt 
concentration may impair the affinity binding between the ligand and target 
pDNA. The composition of each system was selected from preliminary data 
obtained in our laboratory.  
However the further utilization of affinity ligands requires a complete 
understanding of the partition of the contaminants on the systems and the 
influence that parameters like polymers molecular weight and concentration 
might have. Although there is some data about the partition of DNA in literature 
[5; 14] a systematic study with plasmid DNA from a bacterial lysate in PEG-
dextran has not been made yet.  
The goal of this work was to study the partitioning of total DNA (DNAT), total 
protein (ProteinT) and total RNA (RNAT) from a bacterial cell alkaline lysate in 
PEG – dextran systems with different polymer molecular weights. Combinations 
of PEG MW ranging from 600 to 10,000 Da and dextran MW from 40 to 500 
kDa were used. For each combination of the phase forming polymers three 
systems were assessed with different polymer concentrations.  
From the results obtained we propose two ATPSs for the efficient utilisation and 
exploitation of PEGylated and non-PEGylated pDNA affinity ligands in pDNA 
downstream processing.  
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2.3 Materials and Methods 
2.3.1 Chemicals (Materials)  
Poly(ethylene glycol) of molecular weight 600 Da (PEG 600), 1,000 Da (PEG 
1000), 3,350 Da (PEG 3350) and 10,000 Da (PEG 10000) was purchased from 
Sigma (St. Louis, MO, USA). Dextran of molecular weight 40 kDa (DEX 40), 100 
kDa (DEX 100) and 500 kDa (DEX 500) was purchased from GE Healthcare 
(Chalfont St Giles, UK). LB broth media was purchased from Sigma.  
2.3.2 Cell Culture  
Escherichia coli DH5-! strain, harbouring the pUC19 plasmid was cultivated 
with solid LB agar media (50 µg/mL Ampicillin) overnight at 37 ºC. One single 
colony was then used for the inoculation of 10 mL liquid LB media and growth 
was conducted for 8 h at 37 ºC.  50 µl of this culture was then used to inoculate 
200 mL of similar media and growth was conducted overnight at 37 ºC with 
rotary shaking at 250 rpm.  
2.3.3 Preparation of the alkaline lysate   
An overnight cell culture was harvested by centrifugation at 6000 g for 15 min 
at 4 ºC and the pellet was resuspended in 8 mL of solution S1 (50 mM glucose, 
25 mM Tris-HCl, 10 mM EDTA, pH 8.0). Alkaline lysis was performed by 
adding 8 mL of solution S2 (200mM NaOH, 1% (w/v) sodium dodecyl sulfate 
(SDS)) with gentle mixing. The mixture was incubated at room temperature for 
10 min. The lysate was then neutralised by adding 8 mL of an ice cold solution 
S3 (3 M potassium acetate, 11.5% (v/v) glacial acetic acid) and kept on ice for 
15 min. The white precipitate containing cell debris, protein and genomic DNA 
(gDNA) was removed by centrifugation at 15,000 g for 30 min. The supernatant 
was transferred to a clean tube and a further centrifugation at the same speed for 
15 min was used to further clarify the supernatant. The clarified lysate was 
filtered using a 0.22 µm syringe filter and stored at -20 ºC. 
2.3.4 ATPS – Tie Line Determination   
Tie-lines were determined by calculating the polymer composition of both the 
top and bottom phases for each ATPS studied. To each system was added a 20 
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% (w/w) blank solution of the resulting mixture of solutions S1, S2 and S3, as 
described above for the bacterial cell lysate preparation. The PEG concentration 
in both phases was determined by refractometry using a calibration curve 
constructed with PEG standards of known concentration. The dextran 
concentration was quantified by polarimetry using calibration curves obtained 
for dextran solutions of known concentration.  
Tie-Line lengths (TLL) characterise the compositional differences between the 
two phases and were calculated using the following formula (1):  
! 
TLL = (" PEG[ ])2 + (" DEX[ ])2        (1) 
where 
! 
" PEG[ ] = PEG[ ]top # PEG[ ]bottom   ;    
! 
" DEX[ ] = DEX[ ]top # DEX[ ]bottom   (2) 
All aqueous two-phase systems compositions are expressed in % (w/w). 
2.3.5 ATPS – Preparation 
PEG – dextran ATPSs were prepared by weighing appropriate amounts of stock 
solutions of the phase forming polymers of different molecular weights in 2 mL 
graduated tubes. A 20 % (w/w) lysate was then added (0.3 g) and the total 
weight was adjusted to 1.5 g with ultra pure water. The systems were then 
mixed and centrifuged (2000 g, 2 min) to collect the phases for further analysis. 
Phase turbidity was avoided by equilibrating the systems at 35 ºC prior to 
collection of each phase sample. All analyses were conducted at room 
temperature on the same day that the partitioning systems were prepared. Blank 
systems were prepared in a similar way but replacing the lysate by 20 % (w/w) 
of the resulting mixing solution of solutions S1, S2 and S3. 
2.3.6 Analytical Methods 
2.3.6.1 DNA quantification  
Total DNA quantification was performed using a Picogreen assay (Invitrogen, 
Carlsbad, CA, USA) in a 96 well plate reader. Blanks for each system were 
prepared and a series of calibration curves using standard concentrations of 
purified pUC19 plasmid in the blank top or bottom phase of each system was 
used. To each blank ATPS the lysate was substituted by the mixture of solutions 
2. Selection of Aqueous Two-phase Systems for Affinity Purification of Plasmid DNA 
 68 
S1, S2 and S3 with exactly the same final composition as used during the 
alkaline lysis.  
2.3.6.2 RNA quantification  
The amount of RNA in each phase was quantified using a nucleic acid-binding 
reagent, Ribogreen (Invitrogen). Calibration curves were prepared in a similar 
way to the DNA assay but using pure RNA (from Ribogreen Kit). The 
contribution of fluorescence arising from DNA binding to Ribogreen was 
eliminated according to the manufacturer´s manual.  Briefly, DNA was digested 
by incubating the samples for more then 90 min at 37 ºC with RNAse free 
DNAse (Sigma, 5 units per microgram DNA presumed in the sample) in 0.11 
volume of 10X DNAse digestion buffer (200mM Tris-HCl, pH 7.5, containing 
100 mM MgCl2 and 20 mM CaCl2). Each sample was diluted 120 times to 
diminish the effects of salts and polymers present. Fluorescence was measured 
at 500 nm excitation wavelength and 525 nm emission wavelength in the 
fluorescence spectrometer.  
2.3.6.3 Protein Quantification  
Quantitative determination of the protein content in each phase was performed 
by Bradford assay using BSA as a standard. The interference of PEG and DEX 
was overcome by diluting the samples ten-fold and making a series of 
calibration curves using the diluted phase under analysis as solvent for the BSA 
standards.  
2.3.7 Analysis Parameters  
The partition coefficient (Kx) is the ratio of the concentration in each phase, 
defined as:  
! 
Kx =
x[ ]top
x[ ]bottom
         (3) 
Where 
! 
x[ ]  is the concentration of the each component 
! 
x  in the respective 
phase.  
Total Recovery (RT) of DNA is defined as the ratio of DNA (mass) in the top 
phase plus the bottom phase to the mass of the DNA added, DNAi :  
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! 
RT =
DNA[ ]top "Vtop + DNA[ ]bottom "Vbottom
DNAi
"100     (4) 
Where 
! 
V  is the phase volume. Phase recovery (PR) of each component x in 
each phase (i) from the total recovered component was calculated as:  
! 
PR = x[ ]i "Vixtop + xbottom
        (5)  
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2.4. Results and Discussion 
2.4.1 Aqueous two-phase systems 
The partitioning of total DNA, RNA and protein (DNAT, RNAT and ProteinT) 
from an alkaline bacterial cell lysate (20 % w/w) harbouring the pUC19 plasmid 
was studied in ATPSs composed by different molecular weight combinations of 
PEG and dextran (Fig. 1 inset). PEG molecular weights ranging from 600 to 
10,000 Da and Dextran from 40 to 500 kDa were used. For each combination 
of the phase forming polymers three systems were assessed with different tie-
line lengths (Fig. 1). These systems were named short TLL, medium TLL and 
long TLL systems according to the relative size of the tie-line. The TLL in any 
given system is determined by the total polymer concentration in each phase 
and is a measure of the relative difference between the phases composition (see 
equation 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Example of phase diagram showing the three systems with increased TLL (A- short 
TLL system, B – medium TLL system and C – long TLL system) selected per each combination of 
different MW polymers used. The binodal represented is for the system composed by PEG 3350 – 
DEX 40. Inset table shows the combinations of the molecular weights (MW) selected of the phase 
forming polymers for each ATPS. 
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As TLL decreases and approaches zero (at the critical point) the polymer 
composition in each phase differentiates less from the opposite phase and 
partition coefficients (K) approach one. Consequently, in this study systems with 
TLL > 8 % (w/w) (Table 1) were chosen to distinguish from systems where K ! 1. 
This allows the selection of ATPSs where biomolecules accumulate 
preferentially in one of the phases.  
 
2.4.2 Partition studies 
Fig. 2 shows the variation of the partition coefficient logarithm (log K) of DNAT, 
RNAT and ProteinT as a function of TLL for the different PEG/dextran 
compositions. In the 36 systems analysed the log K values for total DNA and 
RNA were always lower then zero independently of the molecular weight of the 
phase forming polymers and the TLL of the system. This means that both DNA 
and RNA accumulated in the bottom phase. Similarly the total protein from 
these bacterial cell lysates accumulated predominantly in the bottom phase of 
the ATPSs, but its partition coefficient was always higher then the partition 
coefficient of DNA or RNA in the same system. The logarithm of the total 
protein partition coefficient varied from -0.52 to 0.33 within all the systems 
whereas for DNA this parameter ranged from -1.9 and -1.1 and for RNA 
between total accumulation in the bottom phase and -1.1.  
Proteins preferentially accumulated in the bottom phase of most systems with 
the only exception being for the ones composed of PEG 1000 – DEX 500, where 
log KProtein was 1.6, 1.8, and 2.2 for short, medium and long TLL length’s 
systems, respectively. Similar systems made up of PEG 1000, but in which DEX 
500 was replaced by DEX 40 or by the DEX 100, did not show log KProtein values 
above 1 and thus the total protein no longer accumulated in the top phase if 
lower molecular weight dextrans were used. This distinctiveness of DEX 500 
systems is usually attributed to the excluded volume effect (as MW of the phase 
forming polymers increases, less protein accumulates in the same phase due to 
exclusion) and has been observed for several proteins [15; 16].  
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Figure 2 - Partitioning coefficient (K) of total Protein, total DNA, and total RNA in systems 
composed by poly (ethylene glycol) - dextran with different molecular weights. A) Systems 
composed by PEG 600 – DEX (500; 100, 40); B) PEG 1000 – DEX (500; 100, 40) systems; C) PEG 
3350 – DEX (500; 100, 40) systems; D) PEG 10000 – DEX (500; 100, 40) systems. 
 
 
The same effect was not readily observed for DNA and RNA partitioning and 
this could be due to their electrostatic charge and size. Although there are a 
limited number of studies of the partitioning of nucleic acids in 
polymer/polymer ATPSs, the available data shows that partition behaviour is 
extremely sensitive to ionic composition.  In the initial work by Albertsson [5] it 
was shown that the partitioning of DNA in PEG 6000 - DEX 500 systems with 
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10 mM sodium phosphate buffer at pH 6.8 was extremely dependent on the 
addition of small amounts of salts. For instance the addition of 5 mM NaCl 
decreased the partition coefficient of DNA from 10 to 2 whilst with 10 mM 
NaCl the partition coefficient fell to 0.2.  Similar effects were observed with 
other salts, such as RbCl and CsCl. Other have similarly reported that in DEX 
500/breox systems, a shift in plasmid DNA partitioning and accumulation from 
the top to the bottom phase was observed upon increasing the concentration of 
sodium phosphate from 50 mM to 100 mM [17].   
In the present study the precise concentration of salts is unknown as the lysate 
solution resulted from the mixture of solutions S1, S2 and S3 (see Materials and 
Methods) and some precipitation occurred. However, given the high 
concentration of potassium acetate and acetic acid in solution S3 it is expected 
that the final acetate concentration would have been in excess of 200 mM. 
Potassium ion concentration would have been of a similar magnitude and this 
high salt concentration may justify the observed partition behaviour.  
Total DNA accumulated preferentially in the bottom phase (> 91.3 %) in all the 
ATPSs studied, as shown in Table 1. No genomic DNA was detected by agarose 
gel analysis in either the top or bottom phases of these systems (Fig. 3) 
indicating that gDNA had been removed during the alkaline cell lysis process. 
The RNA accumulated more unevenly in all systems with the highest partition 
coefficient of log KRNA = -1.03 obtained for the PEG 3350 – DEX 40 system. This 
signifies that more than 92 % of the recovered RNA accumulated in the dextran 
phase.  
In systems composed of PEG 1000 – DEX 500 the RNA was found to 
accumulate exclusively in the bottom phase and thus complete removal of this 
contaminant in pDNA downstream processing could be achieved in one 
extraction step. 
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System Composition Bottom Phase Recovery % 
ATPS 
(nº) PEG MW 
(Da) 
DEX MW 
(x103 Da) 
PEG 
(WT, %) 
DEX 
(WT, %) 
TLL 
(%, w/w) 
 
Phase ratio 
(Ø) Protein DNA RNA 
1 600 17.5 16.0 25.80 1.07 75.53 ± 3.29 93.80 ± 8.36 99.60 ± 3.09 
2 600 18.5 19.0 38.99 0.86 80.78 ± 2.08 94.12 ± 8.78 99.75 ± 1.79 
3 600 19.0 21.0 44.82 0.75 79.60 ± 4.57 94.43 ± 3.04 99.77 ± 1.14 
4 1000 13.6 14.0 27.43 1.00 64.92 ± 0.77 93.52 ± 8.24 99.69 ± 3.87 
5 1000 14.3 16.0 32.58 1.07 64.77 ± 1.10 92.77 ± 6.98 99.73 ± 2.88 
6 1000 16.0 19.0 39.44 1.16 64.10 ± 0.78 92.25 ± 1.18 99.90 ± 2.81 
7 3350 7.0 11.0 16.73 0.87 76.22 ± 4.74 96.48 ± 7.60 92.46 ± 8.25 
8 3350 7.5 12.0 22.35 1.08 70.84 ± 9.53 95.42 ± 5.29 97.86 ± 8.42 
9 3350 8.0 13.5 27.16 1.00 71.31 ± 1.09 95.44 ± 3.94 98.72 ± 1.42 
10 10000 4.0 8.5 11.85 0.78 80.37 ± 3.34 95.84 ± 6.84 94.77 ± 2.40 
11 10000 4.6 10.0 17.67 0.75 79.74 ± 3.84 96.77 ± 2.94 97.11 ± 2.32 
12 10000 
40 
 
5.5 11.0 21.31 0.75 79.97 ± 2.28 96.95 ± 3.01 97.81 ± 0.86 
13 600 17.6 13.7 14.69 0.81 68.94 ± 4.92 97.30 ± 2.72 99.21 ± 3.82 
14 600 15.9 16.2 25.26 0.85 65.18 ± 2.31 97.43 ± 2.41 99.84 ± 1.82 
15 600 16.2 17.4 30.94 0.85 62.81 ± 1.79 97.30 ± 3.98 99.86 ± 1.13 
16 1000 12.2 14.4 18.27 1.10 58.44 ± 6.98 98.72 ± 0.87 99.15 ± 1.05 
17 1000 12.5 16.3 25.45 0.86 64.17 ± 4.54 98.69 ± 3.07 99.58 ± 2.02 
18 1000 13.0 17.7 31.17 0.87 66.02 ± 4.02 98.68 ± 5.39 99.74 ± 4.06 
19 3350 6.1 10.6 11.24 0.66 76.05 ± 4.53 97.46 ± 0.98 96.74 ± 1.70 
20 3350 6.4 11.7 16.66 0.75 70.48 ± 4.67 97.95 ± 5.55 98.72 ± 0.70 
21 3350 6.6 12.7 20.57 0.86 74.19 ± 8.34 97.83 ± 6.97 99.64 ± 0.78 
22 10000 3.9 8.07 8.21 0.73 69.75 ± 4.25 96.03 ± 2.14 94.48 ± 0.95 
23 10000 3.1 8.82 12.39 0.75 65.93 ± 4.90 96.96 ± 5.54 96.33 ± 1.02 
24 10000 
100 
 
3.6 9.61 14.91 0.93 62.10 ± 1.62 97.54 ± 1.65 97.59 ± 2.01 
25 600 16.0 9.0 14.54 1.14 57.92 ± 3.71 94.85 ± 7.57 98.41 ± 1.77 
26 600 16.5 11.0 21.70 0.75 51.95 ± 4.73 94.38 ± 5.45 98.13 ± 0.40 
27 600 16.8 12.5 25.75 1.00 50.19 ± 6.78 93.42 ± 5.18 98.42 ± 3.43 
28 1000 12.5 11.0 21.38 0.86 40.51 ± 7.54 94.34 ± 5.14 99.99 ± 0.41 
29 1000 13.0 13.0 27.78 1.00 36.07 ± 0.98 93.27 ± 2.14 100.18 ± 1.99 
30 1000 13.5 15.5 33.04 1.00 31.45 ± 3.39 91.28 ± 6.37 100.17 ± 1.24 
31 3350 6.0 7.0 12.30 0.55 72.78 ± 5.08 94.90 ± 1.10 97.00 ± 0.16 
32 3350 6.5 10.5 21.67 0.86 61.01 ± 1.46 94.87 ± 1.98 99.18 ± 1.25 
33 3350 7.0 12.0 25.93 0.75 63.62 ± 8.35 94.66 ± 3.77 99.56 ± 1.77 
34 10000 3.6 6.0 12.89 0.93 69.59 ± 1.20 92.37 ± 2.39 95.74 ± 0.87 
35 10000 4.2 9.0 18.55 0.75 73.74 ± 3.40 94.52 ± 4.89 99.03 ± 1.92 
36 10000 
500 
 
5.0 11.0 23.59 0.75 74.99 ± 3.60 93.45 ± 6.50 99.77 ± 4.55 
Table 1 - Systems composition and bottom phase recovery for total Protein, total DNA and total RNA in all ATPS analysed 
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Figure 3 - Agarose gel analysis of the top phase (TP) and Bottom phase (BP) samples of the three 
systems studied (Short TLL, Medium TLL and Long TLL) for the PEG 10000 – DEX 40 systems. 
Open Circular plasmid DNA (ocDNA); Supercoiled plasmid DNA (scDNA) and genomic DNA 
(gDNA). 
 
The increase of TLL in each system had little effect on the protein and pDNA 
partition coefficients in all of the systems studied (Fig. 2). In contrast, the RNA 
partition coefficient decreased with increasing TLL (see also agarose gel, Fig. 3). 
This effect is more evident when high MW PEGs were used. Nevertheless, the 
percentage of RNA remaining in the top phase was always below 8 % of the 
total RNA recovered.   
Total pDNA recoveries in these polymer – polymer ATPSs were usually above 
80 % (Fig. 4), being greater for short TLL systems.  Nearly 100 % recovery was 
achieved using the PEG 3350 – DEX 100 system. Systems composed of low MW 
PEG and DEX 40 displayed low pDNA recoveries (some systems below 80 %) 
and the same trend was seen in long TLL systems composed of DEX 500. It is 
likely that this effect is due to increased interfacial tension between the two 
phases as the TLL increased, promoting the precipitation of pDNA at the 
interface. A similar trend has been observed for systems composed by 
PEG/ammonium sulphate but to a greater extent than observed here, reflecting 
the higher interfacial tension in polymer/salt systems than in polymer/polymer 
systems [8].  
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Figure 4  - Total DNA recovery for all the ATPSs systems screened. A) Systems composed with 
the DEX 500 – PEG (600; 1000; 3350; 10000); B) Systems composed with the DEX 100 – PEG 
(600; 1000; 3350; 10000); C) Systems composed with the DEX 400 – PEG (600; 1000; 3350; 
10000). 
 
2.4.3 ATPS selection for pDNA affinity isolation  
From the results of this study we divided the ATPSs into two categories (A and 
B) that differ mainly in the partitioning of total protein from the bacterial cell 
lysate. In Category A systems, protein accumulated mainly in the bottom 
dextran phase together with the pDNA and RNA. By contrast, in category B 
systems protein accumulated in the PEG rich phase, whilst pDNA and RNA 
accumulated in the bottom phase.  
The systems composed by PEG 1000 – DEX 500 were the only ones to fit into 
category B and all the other ATPSs could be included in category A. 
Nevertheless systems composed of DEX 500 showed a high accumulation of 
proteins in the top phase due to the exclusion effect, as discussed above. For 
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instance in the systems composed of PEG 600 – DEX 500, only 50.2 % of total 
protein accumulated in the bottom phase so the protein was almost equally 
distributed between the two phases.  
The system composed by 18.5 % (w/w) PEG 600 – 19.0 % (w/w) DEX 40 was 
the one to best fit into category A since it offered the highest protein 
accumulation in the bottom phase (> 80 %) and it also had 94 % of the DNA 
and 99 % of RNA in the bottom phase, as shown in Table 1.  
Both categories A and B could be used in affinity purification processes, 
although employing different strategies. In category A systems a one-step 
elimination of most  pDNA contaminants is achieved. Nevertheless, chemical 
modification of the DNA affinity ligand (e.g. PEGylation) might prove to be 
necessary since is likely that non-modified protein based ligands will 
accumulate in the bottom phase of these systems as do lysate proteins. Systems 
within category B may allow the use of protein-based ligands without previous 
chemical modification, since they might accumulate in the PEG phase, thus 
reducing operating costs and time compared to systems where the PEGylation is 
necessary. However, a further extraction may have to be done in order to 
remove any lysate proteins that are accumulated into the same phase where the 
protein ligand accumulates. 
Although prediction of the partitioning of a particular ligand is difficult, and has 
to be confirmed experimentally, we have shown recently that the DNA affinity 
binding protein, zinc finger–GST (Glutathione-S-Transferase) partitions as 
envisaged here for systems A and B [13]. The non-PEGylated protein was 
observed to accumulate in the top phase of systems composed by PEG 1000 – 
DEX 500 in contrast with systems composed by PEG 600 – DEX 40, where the 
protein accumulated mainly in the bottom phase. When using the PEG 600 – 
DEX 40 systems we also showed that the zinc finger–GST partitioning could be 
greatly enhanced by PEGylation. In other preliminary studies with another DNA 
affinity binding protein (LacI) we have observed the same partitioning trend in 
each category (data not published).  
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Table 2 summarises the advantages and drawbacks of using either category A or 
B systems for the utilization of pDNA affinity ligands in ATPSs. Both category A 
and B systems achieved good removal of RNA (almost 100 %) in the first 
extraction. The second extraction used for the removal of remaining impurities 
could be also used for pDNA elution from the ligand and for the recovery of the 
affinity ligand. For this step a PEG-salt system is preferred, as a high salt 
concentration would aid the separation of pDNA from the protein ligand since 
the interactions between the two are usually electrostatic.  
Table 2 - Advantages and drawbacks of using systems A or B for the DNA affinity purification 
in ATPS 
a) Alternatively, system PEG 3350 – DEX 100 could also be used with similar results. 
b) If non-PEGylated protein is used additional ligand partitioning studies could be necessary to 
find appropriate conditions.  
c) If protein-based ligands are used. 
 
A schematic representation of the suggested process is presented in Fig. 5. 
However, as shown in this study, polymer – polymer ATPSs are preferable to 
polymer – salt systems for the first extraction system. In polymer-salt systems the 
partitioning of plasmid DNA and its contaminants could be very dependent on 
the PEG MW, TLL or salts used [8; 18; 19]. A system where all contaminants 
accumulated in the bottom phase would be much more difficult to predict as 
compared to PEG/dextran systems. 
 
Protein Ligands 
System 
Category Native 
protein 
PEGylated 
Protein 
Non-
Protein 
Ligand 
Advantages Drawbacks 
(A) 
 
PEG 600 – 
DEX 40 a) 
Not 
Suitable 
Good Good 
Elimination of all 
major contaminants 
in the first extraction 
Protein PEGylation 
needed 
 
Addition partition 
studies required b) 
(B) 
 
PEG 1000 – 
DEX 500 
Good 
Not 
Suitable 
Not 
Suitable 
No need for 
PEGylated ligand c) 
Total removal of the 
RNA 
 
High Protein 
impurities in the first 
extraction 
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Figure 5 - Schematic representation of the two suitable paths for utilisation of different DNA ligands.  
 * Alternatively PEG 3350 – DEX 100 could be used; 
 ** Polymer as second phase may be necessary if the salt precipitates the ligands or pDNA. 
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2.5 Conclusions 
We selected two suitable ATPSs for the affinity purification of plasmid DNA in 
downstream processing applications. Protein or non-protein based DNA affinity 
ligands might be easily used in the selected systems without the tedious process 
of finding an optimal system for the efficient removal of pDNA contaminants 
(gDNA, RNA and Proteins). Systems were selected where all the major pDNA 
contaminants accumulated in the bottom phase. A removal of more than 80 % 
of protein, 99 % of the RNA and ~100% genomic DNA can be achieved with 
only minimal loss of pDNA at the phase interface.  
We propose that the utilisation of affinity ligands that naturally accumulate in 
the top phase, or that can be modified with PEG molecules (PEGylation) to steer 
their partitioning to this phase, could be best used in category A systems. The 
category B system may be suitable for the utilisation of non-modified protein 
affinity ligands.  
We have also shown that polymer-polymer ATPSs confer a better choice for the 
first extraction systems when using pDNA affinity ligands compared to the PEG-
salt systems described in the literature since the partitioning of bacterial cell 
components varies less with different polymer MWs, or TLL of each system, 
despite the fact that salt might also impair the binding of the ligand to the 
pDNA. The utilisation of pDNA ligands in ATPSs might therefore improve upon 
the low selectivity usually observed in these systems compared to the 
chromatographic methods. Using these system compositions for pDNA 
purification may enable highly selective isolation of pDNA.  
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3.1.1 Abstract 
Protein-based ligands are commonly used for affinity extractions of 
biomolecules in aqueous two-phase systems (ATPSs). To increase the 
effectiveness of the purification process, the affinity ligand can be covalently 
conjugated to one of the phase forming polymers, usually poly (ethylene glycol) 
(PEG). This can assist the partitioning of the target biomolecule to a specific 
phase, which is usually the PEG phase. Here, a comparative PEG conjugation 
study of Glutathione-S-Transferase (GST) and a GST-zinc-finger fusion protein 
(GST-ZnF) is reported. GST is a common protein-tag used in recombinant 
applications. The GST-zinc finger fusion protein is designed to bind DNA, 
hence the purpose of its PEGylation is to increase the selectivity of DNA 
purification by ATPS.   
Four different functionalised PEGylation reagents were examined for GST 
modification. Two amine selective reagents, 20 kDa mPEG-butyraldehyde 
(mPEG-ALD) and 20 kDa mPEG-succinimidyl propionate (mPEG-SPA) were 
evaluated.  Two thiol selective reagents, 5 kDa mPEG-maleimide (mPEG-MAL) 
and the bis-alkylating 10 kDa mPEG-monosulfone (mPEG-MS).  
Thiol specific GST PEGylation was achieved in high conversion (approximately 
quantitative) with both of the thiol selective reagents in about 1h reaction time 
(20 PEG equivalents (equiv)). The amine specific PEGylation methods were less 
efficient. PEGylation reactions were then conducted with GST-ZnF and similar 
efficiencies were observed. All of the PEGylation products displayed increased 
protein partition coefficients to the PEG rich phase in ATPS comprised of PEG 
and dextran. The affinity partitioning of a DNA oligonucleotide containing the 
ZnF recognition site was evaluated for the differently PEGylated GST-ZnF 
protein and the results presented.   
Keywords: Glutathione-S-Transferase; zinc-finger protein; PEGylation; plasmid 
purification; aqueous two-phase systems.   
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3.1.2 Introduction  
The covalent conjugation of poly (ethylene glycol) (PEG) to proteins 
(PEGylation), first introduced in the 1970’s, has been shown to be applicable for 
a wide range of protein therapeutics.  PEGylation increases the pharmacokinetic 
profile of protein therapeutics by improving their circulation half-life and 
efficacy [1; 2; 3; 4].  
Applications of PEGylation in biopharmaceutical purification are also of 
interest. The purification of biomolecules using aqueous two-phase systems 
(ATPS) can be conducted using specific ligands for the target product, which 
can be covalently bound to one of the phase forming polymers, usually poly 
(ethylene glycol) (PEG). The utilization of a PEGylated protein ligand can 
enhance the partitioning of the target product into the PEG-rich phase. If ATPSs 
are selected in which major impurities accumulate in the opposite phase then 
this approach can potentially allow a significant improvement in the selectivity 
and effectiveness of the purification process, resulting in the higher yield and 
purity of the final product [5]. Several protein-based affinity ligands (Protein A 
[6], antibodies [7]), or small molecule-ligands (NADH [8], ATP [9], fatty acids 
[10] and reactive dyes [11]) have been grafted to PEG and used in this way.  
A common chromatographic strategy for protein purification is to fuse it to 
Glutathione - S - Transferase (GST) (EC 2.5.1.18) as an affinity tag. The fusion 
protein can be expressed in a suitable host strain and recovered by affinity 
chromatography using immobilized glutathione as ligand that binds specifically 
to the GST moiety of the fusion protein. Following elution, proteolytic cleavage 
of GST yields the target protein [12; 13]. 
Provided the functionality of the GST fusion protein is maintained [14], GST 
fused proteins ligands can be used for bioaffinity extractions by ATPS. This 
approach to has been used in this laboratory to isolate plasmid DNA (pDNA) by 
ATPS [15]. A GST - zinc-finger fusion protein (GST-ZnF) was PEGylated and 
used as an affinity ligand for the isolation of pDNA containing a zinc-finger 
recognition site.  During ATPS isolation pDNA localised in a dextran (DEX) rich 
3.1 Modified Fusion Proteins for Affinity Aqueous Extractions: PEGylation of Glutathione-S-
Transferase (GST)  
!""!
phase, and its extraction to a PEG rich phase by ATPS was achieved using the 
PEGylated GST-ZnF.  
Here, four PEGylation reagents are considered. Two of these reagents are 
selective for the PEGylation of free amine groups on proteins and the other two 
are specific for protein thiols. The aim of this comparative study was to optimize 
these four distinct reactions for PEG conjugation to GST and to evaluate 
whether the best reaction conditions could be translated to GST-ZnF.  
Since the ligand fused to the GST can also be PEGylated, it is important that the 
PEG conjugation sites are distinct from the ligand binding site. Furthermore, 
since most binding sites do not have free thiols it was hypothesised that thiol 
reactive PEG reagents would be least likely to interfere with. Four different 
PEGylation reagents were thus evaluated to determine their reaction yield, 
product heterogeneity and reaction time. The reagents used were: 1 20kDa 
mPEG-butyraldehyde (mPEG-ALD); 2 20kDa mPEG-succinimidyl propionate 
(mPEG-SPA); 3 5kDa mPEG-maleimide (mPEG-MAL); 4 10kDa mPEG-
monosulfone (mPEG-MS).  
There are 21 potential sites (!-amine groups of lysines (Lys)) for amine 
PEGylation in the recombinant GST protein plus the N-terminal amino acid 
residue ("- amino group of the methionine).  
The aldehyde reagent 1 achieves PEG conjugation by reductive amination.  This 
two-step reaction proceeds by the formation of an imine intermediate, which is 
then reduced with sodium cyanoborohydride (NaCNBH3) at acidic pH (~5) [3; 
16; 17]. The terminal amino group often has a slightly lower pKa compared to 
the !-amine groups of Lys and so can undergo the imine reaction more 
favourably.  However in practice since the imine reaction is not 
thermodynamically driven, an excess of PEG aldehyde reagent is often required 
and this can result in non-specific protein PEGylation.  
The active ester reagent 2 with the N-hydroxysuccinimide (NHS) leaving group 
is generally considered to be the most non-specific of the four reagents. While it 
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can undergo reaction with the N-terminal residue, it can also undergo acylation 
conjugation reactions with the !-amine groups of Lys of the GST. The active 
ester reagent 2 also undergoes competitive hydrolysis during conjugation 
(hydrolysis half-life – 16.5 min, pH 8 [17]), so excess is usually required in order 
to achieve a useful degree of PEGylation.   
Reagent 3 and 4 were used for site-specific PEGylation of the four cysteines 
(Cys) thiols within GST. Analysis of the three-dimensional structure of the GST 
protein (1GTA, PDB Protein Data Bank) reveals that the four Cys residues may 
not be cross-linked and thus available for PEGylation. However, the 
experimental data presented in this study shows that only 2 Cys on GST are 
easily accessible for PEGylation using non-reducing conditions.  
Reagent 3 undergoes alkylation reactions with the sulfhydryl groups to form one 
stable thioether bond to one sulfhydryl [17], whereas 4 is capable of bis-
alkylation by sequential addition-elimination reactions forming the 3-carbon 
bridge between two sulfhydryls with the PEG molecule attached [18; 19]. The 
bis-alkylation reagent 4 covalently binds to two thiols, hence it was used the 10 
kDa molecular weight instead of a 5 kDa reagent (as reagent 3) so that the 
relative mass of the PEG for the two thiols could potentially be compared.  
It is shown that optimized PEGylation conditions found for free GST could be 
applied to GST fused to the ZnF transcript factor protein (GST-ZnF). The zinc 
finger moiety contributes to more 6 Cys and 13 Lys for potential PEG-
conjugation. However, the Cys amino acids on the ZnF moiety are believed to 
be inaccessible for PEGylation in the non-reducing conditions, since together 
with histidine amino acids they form coordination site for binding a Zn2+ ion 
(the DNA binding site) [20]. The effect of each PEGylation chemistry on the ZnF 
DNA binding activity and its partitioning in PEG/dextran ATPS is considered. 
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3.1.3. Methods and Materials 
3.1.3.1 Reagents 
PEGylation reagents mPEG-butyraldehyde (mPEG-ALD, molecular weight (MW) 
20 kDa) 1, mPEG-succinimidyl propionate (mPEG-SPA, MW 20 kDa) 2, mPEG-
maleimide (mPEG-MAL, MW 5 kDa) 3 were purchased from Nektar (San Carlos, 
CA, USA) and mPEG-monosulfone reagent (mPEG-MS, MW 10 kDa) was obtain 
by synthesis [21]. Complementary synthetic oligonucleotides carrying the zinc 
finger recognition site 5’ - TTT-TTT-TTT-TGG-GGC-GGC-TTT-TTT-TTT-TT - 3’ 
and 5’ - AAA-AAA-AAA-AAG-CCG-CCC-CAA-AAA-AAA-AA - 3’ were 
purchased from Biomers (Ulm, Germany). They were annealed as described by 
[15]. PEG polymer, MW 10,000 Da was obtained from Sigma-Aldrich (St. Louis, 
MO, USA) and Dextran MW 500 kDa was purchase from GE Healthcare 
(Chalfont St Giles, UK).  
3.1.3.2 Expression and purification of GST protein 
GST protein was expressed from the pGEX-2TK vector (GE Healthcare) in E. coli 
BL21 cells and purified as described previously [22]. The resulting eluate 
containing GST protein was dialysed at 7 ºC against 50 mM Tris-HCl buffer, 130 
mM NaCl buffer pH 7.4 to remove reduced glutathione. The purified protein 
was stored at -20 ºC with 30 % glycerol. Protein concentration in solution was 
determined with the Bradford method (Pierce, Rockford, IL, USA) using BSA as 
standard. GST-ZnF fusion protein was expressed, purified and stored in the 
same conditions described above for GST protein.   
3.1.3.3 GST PEGylation  
3.1.3.3.1 Protein amine specific PEGylation of GST: reagent 1 mPEG-
ALD 
Reductive alkylation was performed by mixing purified GST protein (typically 
0.2-0.4 mg/mL) with the PEG aldehyde reagent 1 at varied GST molar 
equivalents (equiv) of the mPEG (ranging 1 to 50 equiv) in 50 mM sodium 
acetate buffer (1mL), pH 5.0 (unless otherwise stated). After adding the PEG 
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solution, sodium cyanoborohydride (50 µL of 60 mg/mL solution) was added to 
achieve the final concentration of 3 mg /mL of the reducing agent per sample 
(unless otherwise stated). The mixture was thoroughly mixed and was incubated 
at 7 ºC in 1.5 mL tubes for different reaction times (see figures legends for 
details). Reaction times were varied to optimise the extent of PEGylation. The 
reactions were quenched by adding 0.2 mL of 2.5M Tris-HCl buffer, pH 7.4 to 
the final concentration of 0.41M.  
A PD-10 desalting column (GE Healthcare) was used to remove low MW 
reaction end-products. The column was first pre-equilibrated with 50 mM Tris-
HCl buffer pH 7.4 and then the reaction mixture (1.0 mL) was loaded onto the 
PD-10 column. The third and fourth fractions (1.0 mL each) were collected. 
Typically the first two fractions did not contain any PEG modified protein and 
were discarded. The PD-10 eluate was then loaded into a cation exchange 
column (Hitrap SP FF 1 mL, GE Healthcare) previously equilibrated with 50 mM 
sodium acetate buffer pH 5.0. Ion exchange chromatography was used to 
remove unreacted PEG compounds. PEG-protein conjugate and unreacted 
protein were eluted with 50 mM sodium acetate buffer containing 1 M NaCl , 
pH 5.0. The first fraction (1.0 mL) was discarded and the second and third 
fractions were collected and combined for further analyses. It is anticipated that 
this step could be avoided since the excess of PEG would not be a major 
problem in the utilization of PEGylated ligands in ATPS applications due to the 
fact that systems are composed with PEG as phase-forming polymer. The 
separation of the unreacted GST protein from the PEGyated GST was performed 
by size exclusion chromatography (SEC) as described in section 2.4.2. GST-ZnF 
fusion protein was PEGylated using the reagent 1 in a similar way as used for 
GST using the optimal conjugation conditions found with GST, i.e. 25 mPEG-
ALD equiv was used in 48h reactions at pH 5 (unless otherwise stated).  
3.1.3.3.2 Protein amine specific PEGylation of GST- reagent 2 mPEG-
SPA 
Typically 0.2 mg/mL GST protein in phosphate buffer saline (50 mM PBS, pH 
7.8) in a 1 mL reaction volume was used. The reagent 2 mPEG-SPA was 
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previously dissolved in dimethylsulfoxide (DMSO) and added to the protein 
solution. The stoichiometry was varied with increased molar equiv (from 10 to 
100) to the GST solution (at room temperature) in an effort to optimise 
PEGylation. The reaction was then allowed to proceed at 7ºC by slow mixing in 
end-to-end rotor over 24 h periods. The removal of low molecular weight 
reaction end-products was performed as described for the reagent 1 reactions, 
i.e. PD-10 column. Cation exchange and size exclusion chromatography 
procedures were not employed because this PEGylation was not efficient 
enough to proceed with further studies. 
3.1.3.3.3 Thiol Specific Alkylation of GST – reagent 3 mPEG-MAL  
GST protein (typically 0.5 mg/mL, 1 mL) was reduced prior to PEGylation with 
100 mM dithiothreitol (DTT) (15.4 mg) at room temperature for 30 min. DTT 
was removed using a PD-10 desalting column that had been pre-equilibrated 
with 50 mM sodium phosphate buffer, pH 7.8. The total protein in the PD-10 
eluate was quantified (by UV280 nm) and 20 PEG equiv (5 molar excess per Cys) 
of the activated mPEG- MAL reagent (freshly prepared in the same buffer) was 
added to the 1 mL reaction volume. The reaction was performed for 1 h  at 7ºC. 
The removal of unreacted PEG was not performed by cation exchange column 
since the mPEG-MAL has low MW (5 KDa) and can be easily separated as an 
distinct peak in SEC (see Figure 4B). PEGylated protein products were isolated 
from the reaction mixture using SEC as described below in section 2.4.2. The 
sample peaks corresponding to the PEGylated protein were collected and 
protein was concentrated using a Vivaspin 6 concentrator column. The same 
reactions were performed in non-reducing conditions by removing the first 
reducing step with DTT and proceeding in a similar way. GST-ZnF was used as 
reduced and non-reduced form for PEGylated using this reagent in the same 
stoichiometry (20 PEG equiv, 1h) and in the same reaction conditions as 
described above.  
3.1.3.3.4 Thiol-specific Bis-Alkylation GST – reagent 4 mPEG-MS  
For the PEGylation reaction using the bis-alkylation reagent 4, the protein was 
first reduced in the same way as performed for PEG-MAL. After the removal of 
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DTT the reduced GST (0.5 mg/mL and 1mL) in 50 mM phosphate buffer pH 7.8 
was then mixed with an increased molar excess of freshly prepared PEG-MS and 
the reaction was allowed to proceed for 1h at 7ºC with occasional shaking. 
Unreacted PEG was removed by cation exchange chromatography) as 
performed above for PEG-ALD reactions. PEGylation without reducing the 
protein was also performed to determine the extent of non-thiol specific 
PEGylation and if there were free protein thiols present.  The purification steps 
were the same as described above. The GST-ZnF fusion protein was PEGylated 
using this reagent in similar conditions described for the GST (see Figure 6 for 
details).  
3.1.3.4 Physico-chemical Characterization of the Conjugates  
3.1.3.4.1 SDS-PAGE analysis 
Purity of each PEGylation reactions was assessed by SDS-PAGE analysis using 
NuPAGE 4-12 % Bis-Tris Gel and MOPS buffer (Invitrogen, Carlsbad, CA, USA). 
Samples were prepared under reducing conditions and protein samples were 
resolved in 1 h at 200V. SDS-PAGE gels were stained with colloidal blue stain.   
3.1.3.4.2 Size-exclusion HPLC 
Each reaction was further characterized using size exclusion chromatography 
with a Hi-Load Superdex 200TM prep grade column (GE Healthcare). SEC was 
also used for the separation of protein-PEG conjugates from unreacted protein 
or other low molecular weight contaminants present in the sample. Typically 
1.8 mL of sample solution was loaded into the column at a flow rate of 1 
mL/min using 50 mM Tris HCl containing 150 mM NaCl, pH 7.4 as the eluent 
buffer. Protein components were detected at UV 280 nm.  
3.1.3.4.3 MALDI-TOF-MS  
Mass spectra were acquired using an Applied Biosystems Voyager System DE 
PRO MALDI-TOF mass spectrometer using nitrogen laser. The matrix was a 
saturated solution of "-cyano-4-hydroxycinnamic acid in a 50:50 mixture of 
acetonitrile and water containing 0.1% trifluoroacetic acid. The spectrum was 
3.1 Modified Fusion Proteins for Affinity Aqueous Extractions: PEGylation of Glutathione-S-
Transferase (GST)  
!'#!
acquired in positive mode over the range 600-2500 Da using reflectron mode 
and 2-100 kDa using linear mode.  
3.1.3.4.4 SDS-PAGE bands densitometry  
PEGylation reaction efficiency (yield) and the percentage of each PEG-conjugate 
species obtained in each reaction were estimated by comparative bands 
densitometry analysis obtained from the colloidal blue stain stained SDS-PAGE 
gels using the ImageJ software [23; 24; 25]. Quantitative protein estimation by 
densitometry is not practical with silver stained gels since silver stain binds to 
protein non-stoichiometrically [26]. 
3.1.3.5 Affinity partitioning in aqueous two-phase systems 
Aqueous two-phase systems composed by 6 % (w/w) PEG 10,000 – 8 % (w/w) 
DEX 500 were prepared by weighing appropriate amounts of stock solutions of 
the phase forming polymers in 2 mL graduated tubes. Varied native and 
PEGylated GST-ZnF protein concentration (see figures for details) were allowed 
to interact with the double-stranded DNA Oligo containing the ZnF binding site 
(6 #g / 3.34 $mol) in 20 mM Tris-HCl buffer for at least 10 min at room 
temperature in 0.2 mL (final volume). The resulting complex was then added to 
the ATPS and pH was adjusted by adding 40 mL of 0.5 M Tris HCl buffer, pH 
7.4.  Finally, ultra pure water was added to make 1.5 g total system weight. The 
systems were then mixed by vortexing until all polymers were completely 
dissolved.  Phase separation was accomplished by centrifugation (2000 ! g, 2 
min) and each phase was collected for further analysis. Phase turbidity was 
avoided by equilibrating at 30 ºC prior to collection of each phase sample.  All 
further analyses were conducted at room temperature on the same day that the 
partitioning systems were prepared. 
3.1.3.6 Protein Partition coefficient determination 
The quantitative determination of the protein in each phase of these systems 
was performed by the Bradford assay using BSA as standard. The interference of 
PEG and DEX was overcomed by diluting the samples ten fold, and making a 
series of calibration curves using the diluted phase under analysis as solvent for 
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the BSA standards as described previously [27]. All concentrations were 
calculated using the average of at least 3 independent measurements. The 
partitioning of a protein in a two-phase system is described by the partition 
coefficient, Kc, and defined as Kc = CT/CB, where CT and CB are the 
concentrations of the protein in the top (PEG) and bottom (DEX) phases, 
respectively. Phase recovery (PR) of each protein, x, in each phase (i) was 
calculated as:  
  
where Vi is the volume of the phase.   
3.1.3.7 DNA partitioning analysis 
Native PAGE electrophoresis analysis of the bottom and top phases of each 
system was performed to evaluate the double-stranded DNA partitioning and its 
binding to the modified GST-ZnF affinity protein. SDS-free Tris-glycine buffers 
were used and the electrophoresis performed as previously described [15].  
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3.1.4 Results and Discussion  
The main goals of this study were to optimize four distinct PEGylation reactions 
on the GST-tag protein for later applications with a GST-fusion protein, to 
enhance the partitioning of a GST fusion ligand to the top phase of a PEG-
dextran ATPS system and to ensure efficient PEGylation without adversely 
affecting binding activity to the target biomolecule. Four PEG reagents were 
examined, two of which are selective for protein amines and the other two for 
protein thiols.  
3.1.4.1 Amine selective PEGylation of GST 
Two different conjugation chemistries were used for the amine selective 
PEGylation of the GST protein, but both of these reagents are widely used in 
PEGylation: reagent 1 20 kDa mPEG-ALD and 2 20 kDa mPEG-SPA (Figure 1).  
3.1.4.1.1 mPEG-ALD PEGylation of GST 
The reductive alkylation reaction conditions using reagent 1 were optimized in 
terms of the concentration of the reactants, reaction time, the concentration of 
reducing agent NaCNBH3 and reaction pH.  
At pH 5.0, the extent of GST PEGylation was increased from ~5 up to 95 % (as 
determined by densitometry) by increasing the molar ratio of PEG-ALD to 
protein (PEG equiv) from 1 to 50, (Figure 2A), albeit with the formation of multi-
PEGylated species. Mono-PEGylation was achieved using either 1 or 5 molar 
excess of reagent 1, though the maximum PEGylation yield was 12 % at this 
stoichiometry. Reaction with 50 PEG equiv resulted in a yield above 90 % with 
PEGylation at multiple sites of conjugation (see SDS-PAGE inset in Figure 2A).  
The reaction time used for PEG conjugation is also an important parameter 
(Table 1). PEGylation yield for the 25 equiv excess of PEG-ALD reactions, 
increased from 74 % to 98 % in the period of 7 to 72h but was accompanied by 
greater product heterogeneity. This reagent is more reactive at pH 7.8 compared 
to pH 5 (Figure 2B) and though the yield increased from 32 to 42 % using 5 
PEG-ALD equiv/24h reactions, at the higher pH di-PEGylated GST appeared.
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Figure 1 – GST PEGylation reaction schemes for the amine (A and B) and cysteine thiol (C and D) PEG conjugation. A) 1 mPEG-ALD reaction; B) 2 mPEG-SPA 
reaction; C) 3 mPEG-MAL reaction; D) 4 mPEG-MS reaction. In the centre is represented the 3D structure of GST protein (Protein data bank code: 1GTA). The 
four cysteines amino acids within GST are highlighted as black balls and the 21 lysines amino acids as orange balls. 
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Figure 2 - Characterisation of GST PEGylation using reagent 1, mPEG-ALD. A) GST PEGylation 
efficiency (square) and number of the PEGylation products (circle) with increased mPEG-ALD 
equivalents (3 mg/mL NaCNBH3, pH 5, 24h reaction) Inset: SDS-PAGE reaction 
characterization using 50 equivalents of reagent 1 showing a) free GST and b) GST PEGylated 
products. B) SDS-PAGE gel of the PEGylation reaction at different pH using 5 PEG equivalents 
over 24h reaction: 1) Molecular weight markers; 2) free GST; 3) PEGylation at pH 5; 4) 
PEGylation at pH 7.8. C) SDS-PAGE gel showing PEGylation reactions with increased 
NaCNBH3 concentration: 1) 1mg/mL; 2) 3 mg/mL; 3) 6mg/mL. 
 
Reagent 1 is known to react specifically with the N-terminal residue of some 
proteins in acidic pH (~5) because of the potential difference between the pKa 
of the terminal amine- (7.6 – 8.0) and the !-amines (10.0 – 10.2) [3]. 
Conjugation at the protein terminal residue would likely minimize any 
interference between PEG and important amino acid residues for biological 
activity but, as seen here, mono-PEGylation is commonly achieved at low 
reaction yield.  
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Table 1 - !"#$%&'!()*+$&'!,-./012$,03-45$60/7$/73$02893.53$1:$/73$93.8/012$/0%3$;502<$=>$
%&'!()*+$3?;0@$02$>A$%B$.83/./3$C;::39$DE$>$.24$F$%<G%*$H.IHJEKL$
 
Reaction time 
 (h) 
PEGylation products  
(nº) 
PEGylation yields 
 (%) 
0 0 0 
7 2 74.6 
24 3 85.4 
48 3 92.0 
72 4 98.3 
 
Barbosa et al. [15]have shown that the multi-PEGylation of a DNA binding 
protein did not disrupt DNA binding and similar binding constants were 
obtained compared to the unconjugated protein. Moreover, the authors have 
shown that the utilization of heterogeneous PEGylated species could be 
efficiently used in ATPS affinity applications [15]. This represents an advantage 
over the utilization of mono-PEGylated ligands since the separation of different 
PEGylated species is a complicated process and the cost of activated PEGs for 
efficient mono-PEGylation reactions is high [28]. Hence, the focus here is on 
the optimization of PEGylation yield rather than achieve homogenous 
PEGylation products.  
The effect of sodium cyanoborohydride (NaCNBH3) concentration as reducing 
agent is shown in Figure 2C.  A decrease in PEGylation yield was observed with 
increased concentration of reducing agent (from 1 to 6 mg/mL). The best 
reaction yields were obtained when 1mg/mL concentration (15.9 mM) was used 
per 0.4 mg/mL GST (13.9 "M). Excess reducing agent might make the solution 
alkaline, promoting GST aggregation.  
 
3.1.4.1.2 mPEG-SPA PEGylation of GST 
Figure 3A shows a SDS-PAGE analysis of reaction products obtained with 
increased PEG-SPA/GST stoichiometry at pH 7.8/ 24h. Compared to the 
reductive amination strategy with reagent 1, these reactions with the acylation 
reagent 2 were less efficient giving lower yields using similar PEG equiv. When 
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a 100 molar excess of reagent 2 was used only ca. 53 % of the protein was 
conjugated resulting in a population distribution of native (~47 %), mono- 
(~48 %) and di-PEGylated GST (~4 %).  
 
Figure 3 - Characterisation of the GST PEGylation reactions using reagent 2, mPEG-SPA. A) 
SDS-PAGE gel showing PEGylation reactions with increase in mPEG-SPA equivalents. B) 
MALDI-TOF mass spectrum of a typical 20 kDa mPEG-SPA reaction showing the presence of 
unreacted GST, mono-PEGylated GST and di-PEGylated GST. 
 
The reaction yield increased as the equiv of reactive PEG increased but mono-
PEGylation was only achieved with only 20 % yield. Since this reagent has a 
short hydrolytic half-life (16.5 min) in aqueous solutions no reactions were 
conducted with longer reaction times. Instead, reagent 2 was added as a 
powder directly to the stirred protein solution, but no significant improvements 
were observed compared to aqueous reaction (data not shown). MALDI-TOF 
analysis of a typical 20kDa PEG-SPA reaction (Figure 3B shows native GST 
(28.7 kDa) together with mono- and the di-PEGylated GST species with the 
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proportional increment of PEG-SPA mass (20,000 Da) for the sequential series of 
peaks in the spectrum. This result is in agreement with the SDS-PAGE gel.  
The difference in reactivity between the two activated PEGs 1 and 2 has been 
observed for other proteins [3; 29] and the distinction is due to the different 
synthetic routes for conjugation: alkylation (1) vs. acylation (2). The reductive 
alkylation conjugation occurs via formation of Schiff’s base, which requires 
reduction in situ with sodium cyanoborohydride to yield a stable amine linkage. 
PEGylation by acylation removes the charge of the #- amino group through the 
formation of an amide bond. In addition, whereas imine formation in water is 
favoured by the addition of increased amounts of reagent 1, competitive 
hydrolysis of reagent 2 removes this reagent from the reaction pathway. 
 
3.1.4.2 Thiol selective PEGylation of GST 
Two reagents were evaluated for thiol-specific PEGylation of the four cysteines 
on GST: Reagent 3, a 5 kDa mPEG-MAL, and 4 10 kDa mPEG-DB (Figure 1). 
Initial investigation focused on the specific reactivity of these two reagents 
without reducing the disulfides in the protein. Comparative reactions were then 
conducted using protein that was reduced using 100 mM DTT immediately 
prior to the PEG conjugation reactions. Prior to PEGylation the DTT was 
removed by buffer-exchange with PD-10 columns.  
 
3.1.4.2.1 mPEG-MAL PEGylation of GST 
SDS-PAGE characterisation of PEG-conjugation to native and reduced GST 
using reagent 3 is shown in Figure 4. These reactions achieved completion 
faster (~1 h) than those with the amino reactive PEGs (>24 h) under reducing 
conditions (lane 4, Figure 4a) compared with 85 % PEGylation for the non-
reducing conditions (lane 2). However, non-reducing conditions resulted in four 
different PEGylation products. This may correspond to proteins with a different 
number of PEGs attached to the four Cys amino acids residues. 
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Nonetheless, the protein band corresponding to tetra-PEGylated GST represents 
only 3 % of all reacted GST, whereas the di-PEGylated GST predominates with 
conversions of 72 % (c.f. mono-PEGylation 13 % and tri-PEGylated 12), 
suggesting that only two free thiols are easily accessible for PEGylation.  
 
Figure 4 – Characterisation and isolation of GST protein PEGylated with reagent 3, mPEG-
MAL. A) SDS-PAGE showing the PEGylation of non-reduced GST with 20 PEG equivalents of 
mPEG-MAL (lane2) pH 7.8 (1h), free GST protein (lane 3) and 20 equivalents mPEG-MAL 
using reduced GST pH 7.8 (1h). B) Size exclusion chromatogram of the GST PEGylation 
reaction shown in lane 4, showing the removal of excess of mPEG-MAL reagent (86´ peak) and 
non-reacted GST (~78´). Inset shows the MALDI-TOF analysis of the 86´ SEC peak showing an 
average Mn of 4,999 Da corresponding to the non-reacted mPEG-MAL. 
 
As for other PEGylated GST proteins, the SDS-PAGE gel shows that the PEG 
conjugated protein migrated at much higher apparent MW than expected by 
comparison with the protein marker. This feature of PEGylated proteins has 
been observed before by Kurfurst [30]. Although, the PEGylated proteins 
showed linear mobility with increase MW during migration on SDS PAGE gels, 
the comparison of the apparent molecular weights of conjugated species and 
the non-PEGylated protein standards resulted in incorrect molecular weight 
estimation due to the decrease of the electrophoresis mobility of PEGylation 
proteins.  
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The size exclusion chromatogram (SEC) of the reaction products obtained with 
20 molar excess of PEG per reduced GST (5 molar excess per Cys) is shown in 
Figure 4B.  When using low MW activated PEGs such as the 5 kDa reagent 3, a 
single chromatography step can be used to remove both the non-reactive GST 
and the excess of PEG using a size exclusion column. For higher MW PEGs (> 
10 kDa) their retention times are lower than that of GST and cation exchange 
chromatography has to be used to remove unreacted PEGs (data not shown). To 
confirm that the peak eluted after GST was the unconjugated PEG species 
MALDI-TOF analysis of this fraction was obtained which showed a mass at 5 
kDa corresponding to reagent 3 (Figure 4B inset).  
 
3.1.4.2.2 mPEG-MS PEGylation of GST 
The results of reactions using reagent 4 are shown in Figure 5. As with the 
maleimide PEGylation it was only observed almost complete conversions when 
the protein was fully reduced Figure 5 (A and B). Using 10 PEG equiv the 
reaction efficiency was around 34 % at pH 7.8 for non-reduced GST, whereas 
the reaction efficiency was above 90 % when reducing conditions were used.  
Again, only two Cys moieties were accessible for the PEGylation when non-
reduced conditions were used since only PEGylated protein product was 
observed. In this case the reaction yields mainly mono-PEGylated protein as this 
reagent is capable of forming a 3-carbon bridge between two sulfhydryls. 
Similarly to the other PEG reagents, as the PEG molar ratio was increased the 
number of different PEGylated species also increased. Mono-PEGylation 
resulted using 1PEG equiv but heterogeneous population of PEGylated species 
were obtained when 15 PEG equiv were used (Figure 5A, lane 5).  
The separation of the PEGylated conjugates using either 1 or 15 PEG equiv of 
reagent 4 was performed by size exclusion chromatography as shown in Figure 
5C. Peaks eluted with different retention times dependent upon the size of the 
PEG-conjugate, as shown. Similar to the SDS-PAGE gel in Figure 5A it was seen 
that the peak at 58 min, corresponding to the di- and tri-PEGylated species, 
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increased with the increase of PEG equiv used (Figure 5C-2). Non-reacted GST 
(78 min) was separated from the conjugates and the mono-PEGylation species 
(64 min), but the HPLC peak resolution inadequate to separate the other PEG-
conjugates.  
 
Figure 5 – Characterization and isolation of GST protein PEGylated with reagent 4, mPEG-MS 
A) SDS-PAGE Gel showing the mPEG-MS reaction with increased molar ratio of mPEG-MS 
using reduced and non-reduced protein. B) Reaction efficiency under reduced and non-
reduced conditions with increased PEG equivalents. The number of PEGylation products is 
shown for each reaction. C) Size-exclusion chromatograms of the PEGylation reactions with 
reduced GST using 1 PEG equivalent (1) or 15 PEG equivalents (2) in 50 mM phosphate buffer 
pH 7.8, 1h reaction time. 
 
 
3.1.4.3 PEGylation of GST-ZnF fusion protein  
The most efficient PEG conjugation conditions for GST were applied to GST-
ZnF (MW 38.3 kDa, [22]). The zinc finger protein increases the total protein 
size by 99 amino acids. The zinc-finger has an additional 6 cysteines and 13 Lys 
for PEGylation. Thus, the number of potential PEGylation sites increased from 
21 to 34 Lys (for amine PEGylation) and from 4 to 10 Cys (for thiol PEGylation) 
from GST to GST-ZnF. In consequence, it was anticipated that more complex 
mixtures of PEGylated products might result with the GST-ZnF fusion protein. A 
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further complication was that the free GST protein was co-expressed with GST-
ZnF although at much lower concentrations (see lower band around 28 kDa, 
Figure 6A). This has been observed previously [14] and attempts to remove the 
free GST protein in solution by either SEC or Ionic-exchange chromatography 
proved infeasible. Thus, GST had to be taken into account in considering the 
product heterogeneity.   
SDS-PAGE gels for PEG-conjugation reactions of GST-ZnF using reagents 1, 3 
and 4 are shown in Figure 6A. Reagent 2 mPEG-SPA was not evaluated in view 
of its low conjugation efficiency compared to the other activated PEGs.  
 
Figure 6 - Characterisation of the GST-ZnF fusion protein PEGylation with the mPEG-ALD, 
mPEG-MS, and mPEG-MAL reagents. A) SDS-PAGE gels showing the reaction products for 
each reagent: 1) Marker; 2) 1 mPEG-ALD equiv (pH, 24h); 3) 25 mPEG-ALD equiv (pH 5, 
48h); 4) free GST; 5) 1 mPEG-MS equiv (a); 6) 5 mPEG-MS equiv (a); 7) 10 mPEG-MS equiv 
(a); 8) free GST; 9) non-reduced GST- 20 mPEG-MAL equiv (a); 10) reduced GST- 20 mPEG-
MAL equiv. (a). B) Size exclusion chromatogram for the isolation of the GST-ZnF PEGylated 
products of lane 3 Fig. 6A reaction. Inset shows the SDS-PAGE gel with the collected peak 
limited within the dashed lines. * Reaction products from these reactions were used for the 
partitioning studies in ATPS. (a) Reactions were performed at pH 7.8 for 1h. 
 
The PEG-conjugation reactions with GST using 1 resulted in yields above 90 % 
when reaction time was increased to 48h (using 5 equiv) or by using 25 PEG 
equiv in 24 h at pH 5. For the GST-ZnF PEGylation, 25 PEG-ALD equiv were 
used and the reaction was allowed to proceed over a 48h reaction period at pH 
5 at a temperature of 7ºC. The reaction yield using these conditions was about 
80 % and resulted in multi-PEGylated species as shown in Figure 6A, lane 3.  
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The reaction conditions selected here involved a compromise between 
achieving a relatively low product heterogeneity and high reaction yield. It has 
been demonstrated already that almost complete conjugation reactions (95.3%) 
after 3 days of reaction time using this same protein and the reagent 1 [15]. 
However, more than 8 products of reaction were obtained.  
A typical SEC chromatogram for the separation of unreacted GST-ZnF from the 
reaction using 25 PEG equiv of reagent 1 mPEG-ALD is shown in Figure 6B. 
Peak fractions were collected and analysed using SDS-PAGE (Figure 6b inset). 
As it proved difficult to resolve the different PEGylated species, fractions were 
collected as shown and combined for further analysis. 
Thiol specific PEGylation of the 10 Cys sites on GST-ZnF was also evaluated 
using reagents 3 and 4. About half of the fusion protein (47 %) underwent 
reaction with reagent 3 PEG-MAL when mixed directly with the protein in non-
reducing conditions (lane 9, Figure 6). Almost ~100 % of the protein underwent 
reaction in 1h when it was first reduced with DTT and then allowed to react 
with a 20 molar excess of PEG-MAL 3 at pH 7.8 (lane 10, Figure 6). The 
PEGylated products using these conditions were separated and used for 
partitioning studies in PEG/dextran systems.  
Disulfide binding reagent 4 also underwent similar reactions with GST-ZnF. 
Using 1 molar equiv the mono-PEGylation could be achieved using reduced 
conditions (yield 39 %), but complete reactions were achieved when using only 
10 molar excess of PEG resulting in multi-PEG conjugates (lane 7, Figure 6). 
These later reactions were chosen to perform the following studies after 
purification by ion exchange and SEC.  
.  
3.1.4.4 Protein partition in ATPS 
An ATPS system comprised of PEG 10,000 and DEX 500 was selected to 
evaluate the GST-ZnF protein partition before and after PEGylation. Before 
PEGylation the fusion protein partitioned more than 90 % (k= 0.036) to the 
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bottom phase whereas after PEGylation it partitioned predominantly to the top 
phase of these same systems (Figure 7A and B). GST-ZnF PEGylated using 20 
kDa reagent 1 partitioned 96 % to the top phase (K= 8.1); 97.1 % for the 5 kDa 
reagent 3 (K=11.0); and 97.2 % for the 10 kDa reagent 4 (K=11.6).  
 
Figure 7 - Modified and non-modified GST partitioning in PEG 10,000 – DEX 500 pH 7.4. A) 
Protein phase recovery (%). B) Protein partition coefficient (Kprotein) in each system. 
 
In a previous study the partitioning of GST-ZnF PEGylated with reagent 1 (using 
less PEG equiv, 5) was examined in a PEG 600 – DEX 40 ATPS  and similar 
results to those presented here were obtained as the PEG-GST-ZnF partitioned 
97.5 % to the top phase [15]. 
Effective affinity partitioning using PEGylated ligands requires that the affinity 
ligand steers the partitioning of the target biomolecule to the PEG phase as 
shown in Figure 8. It is shown here the ligand accumulates in top phase of these 
ATPS in minimal loss to the bottom phase (less 3 %) after PEGylation and any of 
the activated PEGs used can be successfully used to this end. However, the 
highly heterogeneous population of PEG-GST-ZnF species makes it difficult to 
3.1 Modified Fusion Proteins for Affinity Aqueous Extractions: PEGylation of Glutathione-S-
Transferase (GST)  
!$%#!
compare the partitioning of the PEGylated proteins in terms of the effect of the 
mPEG molecular weight or reaction chemistry. Nevertheless, a linear 
relationship between the partition coefficient in ATPS and the degree of 
PEGylation has also been reported [31]. 
 
Figure 8 - Representation of the PEGylated GST-fused ligand for biomolecule affinity 
separation in aqueous two-phase systems. 
 
 
3.1.4.5 DNA affinity partition in ATPS 
While the ligand partitioning to the top phase is fundamental, the conjugated 
PEG might inhibit the binding activity of the ligand and thus make it ineffective 
for affinity extractions in ATPS. The affinity partitioning of the 29 base pairs (bp) 
double-stranded DNA oligonucleotide containing the zinc-finger binding site 
was evaluated using the PEGylated and non-PEGylated GST-ZnF protein ligand 
in aqueous two-phase systems composed by PEG 10,000 and DEX 500.  
Evaluation of the effect of the differently targeted PEG-conjugations on the DNA 
binding activity of the GST-ZnF protein and the top and bottom phase 
composition of these systems was conducted by native PAGE gels stained for 
DNA (Figure 9). When DNA binds to the GST-ZnF protein a shift of the free 
DNA band to a higher molecular weight is observed. A yet higher shift occurs 
(lower electrophoretic mobility) when PEGylated protein is used since the PEG 
increases the total mass of the binding complex.  
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As seen in Figure 9A the double-stranded DNA oligonucleotide partitioned to 
both phases when no protein was present in the system. When GST-ZnF was 
added the DNA bound to the ligand and partitioned to the bottom phase since 
the protein accumulates preferentially in this phase (Figure 9B).  On the other 
hand, it was expected that a DNA band shift would occur with samples of the 
top phase when PEGylated GST-ZnF was used since the PEGylated ligand 
accumulates in this phase. As seen in Figure 9 (2, 3 and 4), only systems with 
PEGylated GST-ZnF made using reagent 1 (amine PEGylation) resulted in a 
DNA band shift in samples from the top phase and no evident interaction in 
either top or bottom phases were observed when the fusion protein was 
PEGylated using the thiol-specific reagents 3 and 4.  
 
Figure 9 - Native PAGE electrophoresis of the top (TP) and bottom (BP) phases of PEG 10,000 
– DEX 500 systems composed of double stranded DNA oligonucleotide bearing binding site for 
GST-ZnF protein. A) Analysis of systems composed of different PEGylated GST-ZnF protein 
and the DNA oligonucleotide. Arrows denotes DNA/protein binding complex in the gel. B) 
Analysis of system composed of unmodified GST-ZnF fusion protein and the DNA 
oligonucleotide. Gels stained with ethidium bromide for DNA. 
 
 
 
In each aqueous two-phase system it was used 2.24 µM of the modified protein 
per 3.34 $mol of DNA, which is 2-fold molar protein excess as used on the 
positive control shown in lane 5, Figure 9. The control was prepared by mixing 
1.12 µM of unmodified GST-ZnF and 3.34 $mol of DNA oligonucleotide in 
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homogenous solution, without two-phase system. In the ATPS where thiol 
PEGylation proteins were used an even higher protein/DNA ratio was tested (5-
fold more) but no binding interaction was observed.  
The results from the present study for thiol-specific PEGylation are in agreement 
with earlier reported work, which described the DNA binding inhibition in 
buffer solutions after the fusion GST-ZnF has been PEGylated using reagent 3.   
Nonetheless, it has been shown that both reagents that undergo alkylation (3) or 
bis-alkylation (4) had been successfully applied for the PEG conjugation of 
therapeutic proteins, enzymes or antibody fragments [1; 18; 32; 33]. PEGylation 
did not disrupt either their tertiary structure or their biological activity of these 
proteins, although none have Cys amino acids on the active site.  
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3.1.5 Conclusions 
The results demonstrate that each of the three PEGylation reactions performed 
with the GST-ZnF fusion protein resulted in similar PEGylation yields to that 
obtained for the free GST-tag protein. Both thiol selective PEG reactions were 
completed after 1h under reducing conditions using either GST or GST-ZnF 
fusion protein. However, reaction yields dropped below 50 % when non-
reducing conditions were used. By contrast, amine selective reagents required 
much longer reaction times (24h) or high PEG equiv, in order to yield more then 
80 % conjugation, which could be prohibitive for large-scale affinity 
applications.  
All three PEGylated GST- ZnF fusion proteins partition almost completely 
(>96 %) to the top phase of PEG-based systems as opposed to non-PEGylated 
(only 10 %), which is desirable for the increased selectivity of an affinity 
extraction process in ATPS. Nevertheless, it is demonstrated that the selection of 
a suitable PEG regent has to be performed with caution to avoid interference of 
the conjugated PEG with the ligand-binding site. Both thiol PEGylation methods 
disrupted the GST-ZnF binding to the DNA bearing the ZnF recognition site due 
to PEGylation on the cysteine residues at the ZnF DNA binding site. However, 
amine PEGylation of GST-ZnF protein did not disrupt the DNA binding activity 
of the ZnF moiety resulting in the affinity partitioning of the DNA from the 
bottom to the top phase of these systems. Since most binding sites do not have 
free thiols, it is anticipated that the thiol reactive PEG reagents would be more 
appropriate for other affinity ligands. Amine selective reagents would be 
suitable for ligands with Cys at the ligand-binding site.  
It is hoped that our findings will aid in the development of affinity purification 
processes using PEGylated GST fusion ligands in ATPS and thus, improving the 
low selective of these systems.   
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a b s t r a c t
The affinity isolation of pre-purified plasmid DNA (pDNA) from model buffer solutions using native and
poly(ethylene glycol) (PEG) derivatized zinc finger–GST (Glutathione-S-Transferase) fusion protein was
examined inPEG–dextran (DEX) aqueous two-phase systems (ATPSs). In the absenceof pDNA, partitioning
of unbound PEGylated fusion protein into the PEG-rich phase was confirmed with 97.5% of the PEGylated
fusion protein being detected in the PEG phase of a PEG 600–DEX 40 ATPS. This represents a 1322-fold
increase in the protein partition coefficient in comparison to the non-PEGylated protein (Kc = 0.013). In the
presence of pDNA containing a specific oligonucleotide recognition sequence, the zinc fingermoiety of the
PEGylated fusion protein bound to the plasmid and steered the complex to the PEG-rich phase. An increase
in the proportion of pDNA that partitioned to the PEG-rich phase was observed as the concentration of
PEGylated fusion protein was increased. Partitioning of the bound complex occurred to such an extent
that no DNA was detected by the picogreen assay in the dextran phase. It was also possible to partition
pDNA using a non-PEGylated (native) zinc finger–GST fusion protein in a PEG 1000–DEX 500 ATPS. In this
case the native ligand accumulatedmainly in the PEG phase. These results indicate good prospects for the
design of new plasmid DNA purification methods using fusion proteins as affinity ligands.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
Molecular therapies and vaccines based on purified plasmid
DNA (pDNA) stimulate the need to develop scalable and cost-
effective purification processes that canmeet the stringent specifi-
cations on purity and quality [1,2]. Several chromatography-based
processes have been proposed [3–5], as have non-chromatography
processes [6–8]. Though promising results have been obtained,
there continues to be a need to increase pDNA selectivity and yields
while maintaining cost-effectiveness [9].
Traditional chromatographic methods based on porous beads
had been reported for pDNA purification [3,10–13], but they suf-
fer from low capacity, long separation times, small diffusion
coefficients, and difficulties with scalability. The introduction of
monoliths had overcome most of these drawbacks [14]. However
other methods like precipitation [15,16] and extraction offer addi-
tional advantages such as technical simplicity and the possibility
to use inexpensive equipment and chemicals. Extraction has been
performed using both reverse micellar two-phase systems and
aqueous two-phase systems (ATPSs). With the former systems it
∗ Corresponding author. Tel.: +351 253604054; fax: +351 253678983.
E-mail address: jcmarcos@quimica.uminho.pt (J.C. Marcos).
was possible to selectively extract RNA from a preconditioned bac-
terial lysate separating it from amodel plasmid that remains in the
aqueous phase [17]. Others experiments also show that this system
could also separate plasmid isoforms.
Both polymer–polymer and polymer–salt ATPSs had been
used for the downstream processing of plasmid DNA [18,19]. In
either case, in addition to the aforementioned advantages can be
added the mild conditions and non-toxicity of reagents offered
by this methodology. Better results are usually obtained using
a polymer–salt system with low-molecular weight poly(ethylene
glycol) (PEG). Potassium phosphate, ammonium sulphate and
sodium citrate had been used as salt with comparable results
[19–21]. High recovery of pDNA is obtained in the salt phase with
the elimination of most RNA, proteins and endotoxins to the poly-
mer phase. However the system composition must be carefully
chosen as significant differences between the top and bottom
phase compositions, corresponding to high tie-line values, result
in plasmid precipitation at the interface, with the concomitant
yield reduction [21]. A recent study reported thatwhile ammonium
sulphate systems give higher purity than citrate systems, a lower
recovery yield is obtained [22]. A compromise between these two
parameters could be found using a mixture of the two salts.
In polymer–polymer systems the removal of RNA is not so
efficient although 80% reduction of this contaminant has been
0021-9673/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
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achieved [18]. In addition, in these systems the lysate has to be
previously desalted in order to precisely control the salt composi-
tion of the systems, which determines the partitioning of nucleic
acids. In contrast, in salt–polymer systems the phase components
could be directly added to the lysate [20].
Despite all the enumerated advantages of ATPSs, they have
low selectivity when compared to chromatographic methods
[19–21,23]. As a consequence they are used mainly to concentrate
crude feedstocks and to remove major contaminants [18,21].
Increasing the specificity of ATPS purification processes is
attractive because they can be used immediately after cell dis-
ruption to avoid the need for centrifugation or removal of cell
debris. This could reduce downstream purification steps. Selec-
tivity of ATPSs might be increased by employing ligands that
bind specifically to the target biomolecules. Such approaches have
been extensively explored in protein purification [24,25] but in
the case of pDNA there is only one recent report of the utilisa-
tion of polyethylenimine to increase ATPS selectivity [6]. Potential
pDNA ligands include metal ions [26], polymers [27], amino acids
[28], proteins [29] and nucleic acids [15]. For proteins to act as
pDNA ligands, they need to bind specific sequences of DNA within
the plasmid. Zinc finger proteins are one of the best-known class
of DNA-binding proteins and bind to their target DNA sequences
with good sequence specificity via a well-understood molecular
mechanism [30,31]. In a recent model it is proposed that these
proteins bind initially non-specifically by electrostatic interaction
and then run along the DNA strand until they find the recog-
nition site where they strongly attached [32]. Indeed, the zinc
finger protein used here has been shown previously to act as
an effective affinity ligand for the isolation of pDNA [3,33]. The
DNA sequence specificity of this zinc finger protein has been
demonstrated previously [34,35] and is such that a plasmid that
contains the target sequence may be isolated, while another plas-
mid that shares 7 base pairs (bp) of the 9bp DNA recognition
sequence is not [3]. In this experiment the zinc finger protein was
fused to a glutathione-S-transferase (GST-ZnF) and immobilized on
Sepharose.
The utilisation of GST-ZnF in ATPSs might therefore improve
upon the selectivity observed when GST-ZnF is immobilised since
the affinity interaction would take place in a homogeneous phase
without the steric hindrance caused by the binding of GST-ZnF to a
resin. In addition, the loss of product due to non-specific adsorption
to the solid support could also be avoided.
The successful utilisation ofGST-ZnF inATPSs requires the selec-
tion of a two-phase systemwhere it can partitioned into the phase
with less contaminants. Polymer–polymer systems are preferred
over polymer–salt systems since a high salt concentration may
impair the interaction between the protein and pDNA. It has been
reported that in some of these systems the majority of pDNA con-
taminants can accumulate in one particular phase. ATPSs have been
described in which 97.5% of denaturated genomic DNA [36]; the
majority of the total proteins [37], nearly 100% RNA and ∼100%
pDNA from bacterial cell lysate accumulate in the bottom dextran-
rich phase [6].
It was hypothesised that partitioning of the DNA ligand to
the PEG-rich phase could be accomplished by either (1) tailoring
the two-phase PEG–dextran system such that the native GST-ZnF
protein preferentially accumulates in the PEG phase, or (2) PEGy-
lating the GST-ZnF protein to cause preferential partitioning into
the PEG phase. The latter approach was investigated with con-
jugation of PEG to the fusion protein by reaction with either an
amino or a thiol moiety on the protein. In this study the affin-
ity isolation of pre-purified pDNA from model buffer solutions
using native and PEGylated GST-ZnFwas examined in PEG–dextran
ATPSs.
2. Materials and methods
2.1. Reagents
PEGylation reagents mPEG-butyraldehyde (mPEG-ALD, molec-
ular weight 20kDa) and mPEG-maleimide (mPEG-MAL, molecular
weight 5kDa) were purchased from Nektar (San Carlos, CA, USA).
Complementary synthetic oligonucleotides carrying the zinc finger
recognition site 5′-TTT-TTT-TTT-TGG-GGC-GGC-TTT-TTT-TTT-TT-3′
and 5′-AAA-AAA-AAA-AAG-CCG-CCC-CAA-AAA-AAA-AA-3′ were
purchased from Biomers (Ulm, Germany). They were annealed
by combining 50pmol of each oligonucleotide in a final concen-
tration of 1pmol/!L in water, heating to 95 ◦C and allowing to
cool at room temperature. The resulting double strand synthetic
probe was stored at −20 ◦C until further use. Lysozyme (LYZ),
molecular weight 14.6 kDa; "-lactoglobulin ("-LAC), molecular
weight 18.4 kDa; bovine serum albumin (BSA), molecular weight
66.0 kDa and GST, molecular weight 28.0 kDawere purchased from
Sigma–Aldrich (St. Louis, MO, USA). PEG, molecular weight 600
and 1000Da were obtained from Sigma. Dextran (DEX), molecular
weigh 40kDa (DEX 40) and 500kDa (DEX 500) were both purchase
from GE Healthcare (Chalfont St. Giles, UK).
2.2. Expression and purification of GST-ZnF protein
GST-ZnF fusion protein was expressed from the pGEX-2TK (GE
Healthcare) vector in Escherichia coli BL21 cells and purified as
described previously [3]. The resulting eluate containing GST-ZnF
protein was dialysed at 7 ◦C against 50mM Tris–HCl, 150mM NaCl
buffer pH 7.4. The purified protein was stored at −20 ◦C with 30%
glycerol. When necessary, the protein was concentrated with a
Vivaspin 6 concentrator column (Sartorius, Göttingen, Germany)
and buffer exchanged using PD10 desalting columns (GE Health-
care). Protein concentration in solution was determined with the
Bradford method (Pierce, Rockford, IL, USA) using BSA as standard.
2.3. Purification of pTS plasmid
The plasmid containing the ZnF binding sequence (pTS) was
transformed into competent E. coli DH5# cells [38]. One single
colony was used to inoculate 5mL of LB (Luria-Bertani) medium
supplementedwith 50!g/mL ampicilin. After 8h culture, a 0.5-mL
aliquot was use to inoculate 500mL of similar media. The resulting
culturewasgrownovernightat37 ◦Candat250 rpm.Cellswerehar-
vested by centrifugation and stored at−20 ◦Cuntil needed. Plasmid
DNA was purified from this cells after alkaline lysis, using a Maxi
column (Qiagen, Hilden, Germany) according to themanufacturer’s
instructions.
2.4. PEGylation and isolation of GST-ZnF conjugates
2.4.1. Amino selective PEGylation
Purified GST-ZnF protein (typically 0.5mg/mL) was allowed to
react with mPEG-ALD reagent at different molar ratios of mPEG to
GST-ZnF (1:1, 5:1 and 25:1, i.e. 13, 65 and 325nM mPEG, respec-
tively) in 50mM acetate buffer, pH 5.0 in the presence of 3mg/mL
ofNaCNBH3 at 7 ◦C (Table 1). The reactionwas quenchedwith 0.5M
Tris–HCl, pH 7.4 (final concentration) after 24, 48 and 72h. The
protein-PEG products were analysed by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) in a NuPAGE 4–12%
Bis–Tris Gel (Invitrogen, Carlsbad, CA, USA) and stainedwith colloid
blue stain. Removal of low-molecularweight reactionend-products
and buffer exchange were performed using a PD10 desalting col-
umn (GE Healthcare) that had been pre-equilibrated with 50mM
Tris–HCl buffer pH 7.4. The PD10 eluate was then loaded into a
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Table 1
Preparation and characterization of GST-ZnF protein PEGylation using mPEG-ALD
(20kDa) and mPEG-MAL (5kDa) activated PEGs
Activated PEG PEG
equivalents
Reaction
time (days)
PEGylation
products (no.)
PEGylation
efficiency (%)
mPEG-ALD 1 1 1 11.2
mPEG-ALD 5 1 2 47.5
mPEG-ALD 5 2 2 83.3
mPEG-ALDa 5 3 3 91.8
mPEG-ALD 25 3 8 95.3
mPEG-MAL 20 0.041 (1h) n.d 100
a Reaction chosen for the DNA affinity studies.
cation-exchange column (Hitrap FF, GE Healthcare) that has been
pre-equilibrated with 50mM Tris–HCl buffer pH 7.4 to remove
any unconjugated PEG compounds. Size-exclusion chromatogra-
phy (SEC)with a Hi-load Superdex 200TM column (GEHealthcare),
elutedwith 50mMTris–HCl buffer, pH7.4with 0.15Msodiumchlo-
ride at a flow rate of 1mL/minwas used to separate the protein-PEG
conjugates from native protein. Protein components were detected
at 280nm. Reaction yield was estimated by comparative HPLC
peak area analysis using Azur software (Kromatek, Great Dunmow,
UK).
2.4.2. Sulfhydryl selective PEGylation
The GST-ZnF protein (typically 0.5mg/mL, 0.5mL) was first
reduced with 100mM DTT (dithiothreitol) (0.5h, room temper-
ature) and then the DTT was removed using a PD10 desalting
column. The PEGylation reagent (13!L), mPEG-maleimide (mPEG-
MAL, 5 kDa; 100mg/mL, 20 equivalents) in Tris–HCl buffer, pH
7.4 was then added to the reduced protein and the reaction mix-
ture was incubated for 1h at room temperature. PEGylated protein
products were isolated from the reaction mixture using the same
procedure described for the mPEG-ALD reaction. PEGylated peaks
were collected and protein was concentrated using a Vivaspin 6
concentrator column.
2.5. Band shift assays
The apparent dissociation constants (Kappd ) of native and PEGy-
lated GST-ZnF protein were determined by band shift assays using
native polyacrylamide gel electrophoresis. In the reaction mix-
tures the amount of double-stranded oligonucleotide bearing the
recognition sequence for the zinc finger protein was kept constant
(7.43pmol) while the protein concentration was varied from 0 to
2.28!M (see Fig. 3 for details). DNA-binding reactions involved
combining the zinc finger protein with the synthetic oligonu-
cleotide in a solution of Tris–HCl buffer, pH 7.4, with 0.15M sodium
chloride, 20% glycerol in a total volume of 12!L. The mixture was
incubated for 30min at room temperature and then resolved in a
native Tris-glycine 10% gel (Invitrogen) using 1X Tris-glycine run-
ning buffer at 100V for 80min. Prior to the run, the gel was allowed
to equilibrate in the same buffer for 2h at 100V. DNA was stained
using ethidiumbromide solution (0.5!g/mL) and visualized byUV.
After image acquisition a second stainingwas performed using col-
loid blue to detect protein.
To calculate the dissociation constants, the intensities of free
DNA and DNA–protein complex bands in each lane were deter-
mined using Image J software [39]. The complex band intensity
was taken as the sum of the intensities of all bands representing
the association of DNA with one or more proteins (multimers).
The apparent dissociation constant of the native and PEGylated
GST-ZnF protein was determined according toWieland [40]. It was
assumed that free protein (PF) binds to free DNA (DNAF) to form a
complex P/DNA according to:
PF +DNAF ↔ PDNA (1)
Total concentration of DNA ([DNA]T) and protein ([P]T) is given by:
[DNA]T = [DNA]F +
[ P
DNA
]
(2)
[P]T = [P]F +
[ P
DNA
]
(3)
The dissociation constant:
Kappd = [DNA]F
[P]F
[P/DNA]
(4)
Kappd can be expressed in terms of total concentration as:
Kappd =
(
[DNA]T −
[ P
DNA
]) ([P]T − [P/DNA])
[P/DNA]
(5)
For equal gel band intensities of free DNA andDNA complexedwith
protein we have:
[DNA]F =
[ P
DNA
]
(6)
Thus:[ P
DNA
]
= 0.5 [DNA]T (7)
For this protein concentration [P]50 we thus have:
Kappd = [P]50 − 0.5[DNA]T (8)
For known [DNA]T, [P]50 was determined at 50% binding from
the binding curve and used to calculate the apparent dissociation
constant for the native GST-ZnF and PEGylated GST-ZnF proteins
according to Eq. (8). The GST protein without the zinc finger fusion
was used as negative control in similar binding conditions.
2.6. Phase diagrams
Two different PEG–DEX systems were chosen for the parti-
tion experiments. Binodal curves of PEG 600–DEX 40 and PEG
1000–DEX 500 were determined at 20 ◦C by titration according to
Albertsson [37]. Briefly, small amounts of water were added to the
biphasic systems of defined composition until a single homoge-
nous phase was observed. At this point, the system composition
was calculated and plotted to form the binodal curve.
2.7. Affinity-based isolation of pDNA by aqueous two-phase
systems
Two systems composed of (A) 21.9% (w/w) PEG600–11.7% (w/w)
DEX 40 and (B) 15.7% (w/w) PEG 1000–8.9% (w/w) DEX 500 were
preparedbyweighing appropriate amounts of stock solutionsof the
phase forming polymers of different molecular weights in gradu-
ated tubes. Various concentrations of native or PEGylated GST-ZnF
proteins were allowed to interact with a constant amount of pre-
purified pTS plasmid (8.2!g/4.5pmol) in 20mM Tris–HCl buffer
for at least 10min at room temperature in 0.2mL (final volume).
The resulting complex was then added to one of the two partition-
ing systems and pHwas adjusted by adding 40!L of 0.5M Tris–HCl,
pH 7.4 buffer. Finally, ultra pure water was added to make 1g total
system weight. The partitioning systems were then mixed until all
polymers were dissolved. Phase separation was accomplished by
centrifugation (2000× g, 2min) and each phase was collected for
further analysis. Phase turbidity was avoided by equilibrating at
30 ◦C prior to collection of each phase sample. All analyses were
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conducted at room temperature on the same day that the parti-
tioning systems were prepared.
2.8. Partition coefficient measurements
Quantitative determination of the protein content in each phase
was performed by the Bradford assay using BSA as standard. The
interference of PEG and DEX was overcome by diluting the sam-
ples 10-fold, and making a series of calibration curves using the
diluted phase under analysis as solvent for the BSA standards.
All concentrations were calculated using the average of at least
three independentmeasurements. The partitioning of a protein in a
two-phase system is described by the partition coefficient, Kc, and
defined as Kc = CT/CB, where CT and CB are the concentrations of
the protein in the top (PEG) and bottom (DEX) phases, respectively.
DNA quantification was performed in a similar way using the
Picogreenassay (Invitrogen) ina96-plate reader. Blanksof each sys-
temwere prepared and a series of calibration curves using standard
concentrations of pTS plasmidweremade. Partition coefficients for
pTSplasmid in each systemwere calculatedusing the same formula
given above for proteins.
3. Results and discussion
3.1. PEGylation of GST-ZnF protein
The GST-ZnF protein has a molecular mass of 38.3 kDa with a
chain length of 331 amino acid residues [33] of which 34 residues
are lysine (Lys) and 10 are cysteine (Cys). Two different PEGylation
conjugation strategies were thus envisaged (Fig. 1). Amino selec-
tive PEGylation was achieved using mPEG-ALD (20kDa), which
has a terminal aldehyde moiety capable of undergoing reduc-
tive amination with primary amines in the presence of sodium
cyanoborohydride [41]. Often, a PEG-aldehyde reagent can be used
to predominantly PEGylate the terminal amine in a protein, espe-
ciallywhen the protein has anN-terminalmethionine as is the case
with GST-ZnF fusion protein used here [42].
Sulfydryl specific PEGylation was conducted using mPEG-MAL.
Since thiol conjugation canbemuchmore efficient than amine con-
jugation and there are 10 cysteines that are potentially available for
thiol alkylation, a smaller molecular weight PEG reagent of 5 kDa
was used. Four of the ten cysteines are located within the GSTmoi-
ety and the other six within the ZnF protein. Three-dimensional
structure analysis of the GST protein (1GTA, PDB Protein Data Bank)
reveal that they are not cross-linked. The six cysteines within the
zinc finger are coordinated to the zinc metal ion [34]. Therefore
a number of different PEGylated products can result representing
different sites and extent of conjugation. The relative amount of
each PEGylated form in the product mixture would be expected
to depend upon the rate of reaction at each site of conjugation. In
respect to the PEGylation of therapeutic proteins, product hetero-
geneity results in varied biological activities. Although PEGylation
heterogeneity with GST-ZnF may influence DNA binding, there
would be likely a lower influence on partitioning properties, spe-
cially for highly PEG modified proteins [43].
PEGylation by reductive aminationwas conducted in acidic con-
ditions (pH 5.0) with low (1) mPEG equivalents per protein in an
attempt to form stable conjugates with only one PEG molecule
per protein (mono-PEGylation). However, imine formation is inef-
ficient and a relatively low PEGylation yield (11.2%, Table 1) was
obtained when mono-PEGylation was desired. Analysis by SDS-
PAGE of the reaction conducted with 5 equivalents mPEG-ALD
(Fig. 2A, inset) indicated that multiple conjugations occurred (to
yield native, mono-, di-, and tri-PEGylated GST-ZnF) as the reaction
time was increased up to 72h. Conjugate heterogeneity was also
observed when the ratio of mPEG-ALD/GST-ZnF was increased to
25 equivalents (Table 1). The yield of different PEGylated formswas
dependent on both the reaction time and the relative PEG molar
ratio. As anticipated, attempts to increase PEGylation yield also
resulted in increased molecular weight in the product heterogene-
ity.We found that PEGylation efficiency of up to 95.3%was achieved
using 25mPEG equivalents over a 72h incubation period for reac-
tion (resulting in at least eight different PEG-protein conjugates).
For the reactions that were conducted with 5 equivalents of
mPEG-ALD per protein, at 24, 48 and 72h, the PEG–GST-ZnF
conjugateswere isolated by first removing unconjugated PEG com-
pounds by ion-exchange chromatography, and then fractionated
native GST-ZnF by SEC as shown in Fig. 2A. The first peak displayed
a retention time of 53min and corresponds to high molecu-
lar weight multi-PEGylated conjugates. A second peak at 58min,
which was not baseline resolved with the peak at 53min, was
also observed. Electrophoresis analysis showed that this later peak
contains mainly the mono-PEGylated conjugates (82.8%), although
small amounts of high molecular weight species are also observed
(datanot shown).As the reaction timewas increased from24 to72h
we observed a proportional increase of the 53min peak areawith a
concomitant decrease of the 58min peak area. The increase of the
high molecular weight species was accompanied by an increase
in PEGylation yield, as suggested by a decrease in the peak area
corresponding to the native GST-ZnF protein (75min).
To prepare the PEG–GST-ZnF conjugates for pDNA-affinity iso-
lation studies in the aqueous two-phase system we selected
PEGylation conditions of 72h incubationwith 5 equivalentsmPEG-
ALD/protein that gave an overall conversion of 92% of GST-ZnF. This
selection involved a compromise between achieving relatively low
product heterogeneity (the mono-, di- and tri-PEGylated popula-
tion represented 67.1, 28.7 and 4.1%, respectively) and high reaction
yield. The disadvantages of this compromise was that the different
PEGylated forms may display different affinities with pDNA due to
varying degrees of steric shielding of the pDNA binding site, as well
as the possibility that the different formsmay not partition equally
to the PEG phase. Since separation of mono- frommulti-PEGylated
Fig. 1. Schematic representation of GST-ZnF PEGylation reactions. Highlighted with bold are the PEGylation targets for each PEGylation chemistry used. (A) mPEG-ALD
(20kDa) reaction and (B) mPEG-MAL (5kDa) reaction. See Section 2 for complete reaction conditions.
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Fig. 2. Characterisation and isolation of PEG–GST-ZnF conjugates. (A) 5 equivalents mPEG-ALD per protein reactions. Size-exclusion chromatograms are shown after 24, 48
and 72h reaction time. Peaks retention time for PEG conjugates are at 53 and 58min and at 75min for native GST-ZnF/GST proteins. SDS-PAGE inset shows the (N) Native
GST-ZnF protein, (1) 24h reaction, (2) 48h reaction and (3) 72h reaction. (B) SDS-PAGE characterisation of mPEG-MAL reaction. Lane (M) marker, (1) 1h reaction.
species by SEC proved difficult the PEG–GST-ZnF conjugates from
peaks at 53 and 58min were collected and pooled as one sample
for use in the DNA-affinity partitioning studies.
PEGylation of free cysteine residues in GST-ZnF protein was
achieved using mPEG—5kDa (mPEG-MAL). As shown in Fig. 1
mPEG-MAL undergoes an alkylation reaction with sulfhydryl
groups to form a thioether bond. The GST-ZnF protein was incu-
bated with 100mM DTT prior to adding the mPEG-MAL to the
protein solution. After removal of the DTT, the protein was incu-
bated with PEG-MAL for 1h and quantitative conjugation was
observed (Table 1). Thiol alkylations are more efficient at mild pH
values than amine alkylations. Interestingly with GST-ZnF, incom-
plete PEGylation reactions were observed with mPEG-MAL (40
equivalents) if the protein was not first incubated with DTT.
SDS-PAGE characterisation of the completed PEGylation reac-
tions are shown in Fig. 2B. A narrow distribution of molecular
weights was observed. This might be circumvented using higher
molecular weight mPEG-MAL since we only used a 5-kDa reagent.
Also decreasing the molar ratio of PEG-MAL per protein could be
advantageous. Although we have seen that when using very low
mPEG molar ratio (1 equivalent) a decrease of about 60% in the
PEGylation efficiency was observed.
3.2. Apparent dissociation constant (Kappd ) determination
In order to evaluate the DNA binding affinity of the PEGy-
lated GST-ZnF protein, gel-shift assays were performed to compare
the apparent dissociation constants of native and PEGylated pro-
tein. Proteins at different concentrations were added to a constant
amountofdouble-strandedoligonucleotide (7.43pmol)bearing the
recognition sequence for the zinc finger protein. Typical results for
the mPEG-ALD modified GST-ZnF are shown in Fig. 3A and for the
native GST-ZnF protein in Fig. 3B. With increasing protein concen-
tration the intensities of bands representing free DNA decrease and
those bands showing the bound complex increase. Quantitative
analyses of the gels bands (fromA and B, Fig. 3) are shown in Fig. 3C.
Apparent dissociation constants were estimated from the protein
concentration at which 50% DNA was bound using Eq. (8) (Section
2). Apparent dissociation constants of Kappd = 0.11!M for native
GST-ZnF and Kappd = 0.24!M for aldehyde PEGylated GST-ZnF pro-
tein were obtained. In view of the known structural heterogeneity
of themPEG-ALDmodifiedPEGconjugates the estimatedvalue rep-
resents the average of the interaction of the three species with
the pDNA molecule. Others have reported that in PEGylated pro-
teins potential non-covalent interactions between PEG and other
groups within the protein might lead to a region rich in this poly-
mer [44,45]. If this region is near the active site then it may mask
the pDNA binding site of the protein. The observed increase of
Kappd upon PEGylation corresponds to a change of 2 kJ/mol in the
Gibbs free energy of binding, which is approximately the same
energy as a single dipole–dipole interaction. This suggests that
although a relatively high molecular weight mPEG-ALD (20kDa)
was used for the conjugation it does not significantly impair the
binding of the protein with the oligonucleotide, possibly because
PEG was attached to the protein in a region far from the binding
site.
While the amino PEGylation approach resulted in only a slightly
reduced DNA binding affinity as compared to that for the native
protein, cysteine PEGylated GST-ZnF protein displayed no bind-
ing affinity with the double-stranded oligonucleotide. As shown
in Fig. 3D (lanes 1–2), GST-ZnF that has been PEGylated using this
approach did not bind to the oligonucleotide for any protein con-
centration tested (up to 3.8!M). The ZnF protein is a consensus
sequence zinc finger protein that binds to the sequence 5′-GGG-
GCG-GCT-3′ belonging to the family Cys2His2 zinc fingermotif [34].
Since in this case the PEG is bound to GST-ZnF by its cysteines
residues it is possible that the PEGylation chemistry disrupted
the coordination of the zinc ion to these amino acids, so modi-
fying the binding site and impairing the interaction between the
protein and the oligonucleotide. It is known that the structure of
the zinc finger determines nucleotide sequence binding specificity
[46].
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Fig. 3. Binding analysis of PEGylated and native GST-ZnF protein. (A) Binding of PEGylated (ALD) GST-ZnF (5 equivalents mPEG-ALD/protein reaction, 72h reaction time).
Lanes 1–7 increasing PEG–GST-ZnF concentrations: lane 1, 0.0!M; lane 2, 0.20!M; lane 3, 0.45!M; lane 4, 0.67!M; lane 5, 1.12!M, lane 6, 1.68!M; lane 7, 2.28!M. Below
the gel the DNA binding sequence for the zinc finger protein is shown. (B) Binding of native GST-ZnF. Lanes 1–7 increasing PEG–GST-ZnF concentrations: same concentrations
as in the gel A. (C) Chart representation of the data of the gels shown in (A) and (B). Circles, binding values for GST-ZnF. Squares, binding values for PEG–GST-ZnF (ALD).
Dashed arrows, [Protein]50, protein concentration for 50% binding. (D) Lanes 1–2 binding of PEG–GST-ZnF, 3.8!M (20 equivalents mPEG-MAL/protein reaction). (1) Ethidium
bromide stain; (2) colloid blue stain. Lanes 3–4 binding of GST, 5.7!M (negative control). (3) Ethidium bromide stain; (4) colloid blue stain.
Fig. 4. Phase diagrams with binodals for PEG 600–DEX 40 (circles) and PEG
1000–DEX 500 (triangles), at room temperature. Two systems were selected from
the two-phase region of each binodal: (A) 21.9% (w/w) PEG 600–11.7% (w/w) DEX
40 and (B) 15.7% (w/w) PEG 1000–8.9% (w/w) DEX 500.
3.3. Protein partitioning in aqueous two-phase systems
Successful affinity partitioning requires that the affinity ligand
directs the partition of the target biomolecule to the phase where
less contaminants accumulate. Adequate systems will be the ones
wheremost contaminants and the target biomolecule accumulates
in one phase and the affinity ligand in the other. In this way the
affinity ligandwill promote the extractionof the target biomolecule
to the phase with less contaminants increasing its purity. With this
goal in mind two different ATPSs were chosen (Fig. 4) that differ
mainly with respect to the molecular weight of the phase forming
polymers used. In system A, PEG 600 and DEX 40 were used while
in system B, PEG 1000–DEX 500were used. The phase composition
(% w/w of each phase forming polymers) is also different in both
systems.
The protein partition coefficients (Kc) in both systems A and
B are summarised in Table 2. In system A GST-ZnF protein accu-
mulated in the bottom phase (Kc = 0.013) while in system B it
accumulated in the PEG-rich top phase (Kc = 37.89). Addition-
ally, in system A PEG–GST-ZnF partitioned mainly to the PEG
phase with an enhanced partition coefficient of Kc = 17.19. This
corresponds to 97.5% of the PEG–GST-ZnF protein accumulating
in the top phase of system A, while 96.5% of native GST-ZnF
accumulated in the bottom phase. Harris et al. [47] claimed
similar partitioning behaviour for an antibody against alkaline
phosphatase that had been chemically modified (38%) withmPEG-
ALD, with 99% partitioning of the antibody conjugate to the
top PEG phase while unmodified antibody partitioned mainly
(90%) to the bottom phase (in a system consisting of 6% PEG
8000–8% DEX 40, 150mM NaCl, 10mM sodium phosphate, pH
7.2).
Table 2
Comparison of different proteins partition coefficient (Kc) on the systems (A) 21.9% (w/w) PEG 600–11.7% (w/w) DEX 40 and (B) 15.7% (w/w) PEG 1000–8.9% (w/w) DEX500
in Tris–HCl buffer, pH 7.4
System PEG–GST-ZnFa BSA (66.0 kDa) GST-ZnF (39.1 kDa) "-LAC (18.4 kDa) LYZ (14.6 kDa)
A PEG 600–DEX 40 17.19 0.012 0.013 0.21 2.55
B PEG 1000–DEX 500 n.d. 46.16 37.89 6.91 4.81
Total volume, 1mL.
a 72h aldehyde PEGylation reaction (5 equivalents mPEG/protein).
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Fig. 5. Partition coefficients of pTS plasmid DNA versus GST-ZnF concentration in
the top phase of the system B, 15.7% (w/w) PEG 1000–8.9% (w/w) DEX 500 at pH 7.4.
Table 3
Analysis of pTS partition with increase PEG–GST-ZnF concentration (!g/mL) in the
top phase of the system A, 21.9% (w/w) PEG 600–11.7% (w/w) DEX 40 at pH 7.4
Systems Top phase pTS partition
coefficient (Kc)
[PEG–GST-ZnF]± S.D. % pTS± S.D.
A1 0 0.10 ± 0.04 0.0003
A2 38.5±2.8 62.1 ± 4.6 0.883
A3 52.8±7.8 72.9 ± 3.5 1.282
A4 244.2±4.3 82.1 ± 2.5 2.435
A5 293.4±5.6 100.0 ± 1.3 TPa
a TP—top phase.
There is an approximately linear relationship between the log-
arithm of the partition coefficient in ATPS and the degree (n) of
PEGylation (number of mPEG molecules per protein). However,
this relationship, predicted on the assumption that each grafted
PEG contributed equally to Kc, did not hold over the larger range
of n [43]. The PEG-protein partition behaviour is governed by the
phase systems used, surface density, topographical and conforma-
tion distribution of their grafted PEGs and PEGylation chemistry
used [43,48].
In order to assess the feasibility of using these systems in purifi-
cation protocols it was studied the partition behaviour of three
model proteins; BSA (MW 66.0 kDa, pI (isoelectric point) = 4.8); "-
LAC (MW 18.4 kDa, pI=5.1) and LYZ (MW=14.6 kDa, pI=11). From
Table 2 it can be seen that as the molecular weight of the protein
was increased itspartition coefficient also increased in systemAbut
decreased in systemB. It seems that in these systems conditions the
protein molecular weight is an important determinant of its parti-
tioning behaviour rather then the protein charge. From system A
to B the dextran molecular weight was changed from 40,000Da
to 500,000Da (12.5 times higher) whereas similar PEG molecular
weights (600 and 1000Da, respectively)were used in both systems.
This behaviour is usually attributed to an excluded volume effect
and has been observed for several other proteins [49,50]. Increas-
ing the molecular weight of one polymer steers the protein to the
other phase, an effect that increases with the molecular weight of
the protein.
With systems in which highmolecular weight dextran is used it
is likely that similar proteins from E. coli will accumulate in the
same phase system as the ligand. It is known that the average
molecular weight of proteins from E. coli is around 40kDa [51],
a very close molecular weight to the affinity protein used here
(38.3 kDa). Though, other factors such as hydrophobicity, salt com-
position, polymers molecular weight, temperature and pH might
influence the partitioning of biomolecules in PEG–dextran systems
[37,52]. Thus, it is essential to study the behaviour of the total pro-
tein partitioning from a complex mixture of a bacterial cell lysate
in these polymer–polymer systems to precisely select an appropri-
atedATPS for the use of affinity ligands. The utilization of PEGylated
GST-ZnF conjugates rather than native protein in systemswith low-
molecular weight dextran would confer an advantage since the
majority of the proteins from a bacterial lysate would likely accu-
mulate in the bottom phase and the PEG–GST-ZnF in the top.
3.4. Affinity partition of pDNA by native and PEGylated GST-ZnF
protein
The partitioning of pTS plasmid as a function of added native
GST-ZnF ligand in system B, pH 7.4 is shown in Fig. 5. In this sys-
tem native protein accumulatedmainly in the top phase, Kc = 37.89,
while in the absence of ligand pTS plasmid DNA accumulated in the
bottom phase, Kc = 0.005. A notable shift of pTS partition (∼5900-
fold) was observed upon increasing the GST-ZnF concentration
in the top phase, demonstrating that the protein interacts with
pDNA in ATPSs and changes its partitioning to the top phase (up
to Kc (pDNA) =29.42, Fig. 5). As the concentration of the ligand was
increased a shift of the true partition coefficient of pTS towards that
of the ligand, Kc = 37.89 was observed.
We similarly examined the system PEG 600–DEX 40 (A) to eval-
uate the pTS affinity partition using the PEG–GST-ZnF conjugates
(Table 3). In these systems pTS accumulated almost totally in the
bottomphase, Kc = 0.0003while the PEGylated ligand accumulated
97.5% in the top phase (96.5% native GST-ZnF protein accumulates
on the bottom). For PEG-ligand concentrations in the top phase
up to 293!g/mL pTS accumulated completely (100%) in this phase
(the detection limit of the Picogreen assay is 0.2ng dsDNA (double-
stranded DNA) and 4.5pmol (8.2!g) of pTS DNAwas added to each
system, from which it is estimated that less than 0.002% pTS DNA
might be in the bottom phase). Fig. 6 shows a comparison of pTS
and GST-ZnF protein partitioning with and without PEGylation.
Fig. 6. Schematic representation of the pTSDNAandGST-ZnF partition before and after the protein ligand be PEGylatedwithmPEG-ALD. SystemA, 21.9% (w/w) PEG600–11.7%
(w/w) DEX 40 at pH 7.4.
112 H. Barbosa et al. / J. Chromatogr. A 1206 (2008) 105–112
Using either native or PEGylated GST-ZnF ligand a shift on the
pTS DNA partition was observed in each system. However, in sys-
tem A when the PEG-ligand concentration in the top phase was
244.2!g/mL it hada lowerpTSpartition coefficient (Kc = 2.43) com-
pared to the pTS partition coefficient of Kc of 29.42 obtained when
179.42!g/mL of native protein was used in system B (Fig. 5). This
may be due to different composition of the systems that influ-
ence the partition of the GST-ZnF/pTS complex. It could also be
that although the dissociation constant is similar for the PEGylated
and native protein in buffer solution, as determined by the gel-shift
assays (Fig. 3), it may be different in the PEG phase. One reason
for this is that the protein bound PEG could interact strongly with
the free PEG in solution making a PEG-rich region around the pro-
tein that impairs the interaction with the DNA molecule. In either
case it seems that adding more ligand overcame these problems
as total accumulation of pTS in the top phase was achieved using
293.4!g/mL of ligand.
4. Conclusions
It has been shown that both PEGylated and native GST-ZnF
protein were able to significantly enhance pDNA partition to the
PEG-rich phase, though in ATPSs of different composition. The util-
isation of PEGylated ligands rather than native protein in affinity
purification of pDNA confers advantages since the ligand might be
easily recovered following elution by a second extraction of the pTS
partitioned from the PEG phase to a new salt phase. The PEGylated
ligand would accumulate in the PEG phase and both could be re-
used. Additionally, ligands bearing affinity tags to specific supports
such as GST orHis tagswill facilitate its recovery. Polymer–polymer
ATPSs would be preferential as the primary system as this would
circumvent the utilization of a salt as themain phase forming com-
ponent, thus avoiding possible interferences of the salts in the
protein ligand–DNA interactions.
ATPSs have been recognized as a good process alternative for
the separation and purification of pDNA. Affinity partitioning can
enhance thepreviously lowselectivityof these systemsas thepDNA
has a high and selective affinity for the protein ligand. Additionally,
the pDNA/ligand complex accumulates in a low contaminant con-
tent phase (top phase) rather than the bottom. A simple and fast
method for the isolation pDNA from the dextran-rich phase to the
PEG-rich phase with no pDNA loss in the bottom phase has been
demonstratedhere by exploiting PEGylatedGST-ZnF. This approach
for pDNA purification opens good perspectives to the design of a
procedure for a high selectivity isolation of pDNA.
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4.1 Abstract  
 
The DNA binding fusion protein, LacI-His6-GFP, together with the conjugate 
PEG-IDA-Cu(II) (10 kDa) was evaluated as a dual affinity system for the pUC19 
plasmid extraction from an alkaline bacterial cell lysate in poly(ethylene glycol) 
(PEG) /dextran (DEX) Aqueous Two-Phase Systems (ATPS).  In a PEG 600 – DEX 
40 ATPS containing 0.273 nmol of LacI fusion protein and 0.14 % (w/w) of the 
functionalised PEG-IDA-Cu(II), more than 72 % of the plasmid DNA partitioned 
to the PEG phase, without RNA or genomic DNA contamination as evaluated 
by agarose gel electrophoresis. In a second extraction stage, the elution of 
pDNA from the LacI binding complex proved difficult using either dextran or 
phosphate buffer as second phase, though more than 75 % of the overall protein 
was removed in both systems. A maximum recovery of approximately 27 % of 
the pCU19 plasmid was achieved using the PEG-dextran system as a second 
extraction system, with 80-90 % of pDNA partitioning to the bottom phase. This 
represents about 7.4 µg of pDNA extracted per 1 mL of pUC19 desalted lysate.  
 
 
 
 
 
 
 
Keywords: Aqueous Two-Phase Systems; Plasmid Purification; Affinity ligand; 
Immobilized Metal-ion Affinity Partitioning; Lac repressor; bacterial cell lysate 
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4.2 Introduction 
Non-viral vectors, such as plasmid DNA, have been shown to be adequate to 
mediate both gene therapy and DNA vaccination. Expression of therapeutic 
proteins has been attained both in vitro and in vivo using these vectors [1].  
Also, they are able to stimulate humoral and cellular immune responses to a 
specific antigen [1; 2]. The increased number of clinical trials using 
naked/plasmid DNA (there are currently 281 ongoing trials) have brought a 
focus on the large-scale manufacturing of pDNA as high demand for these 
vectors is soon expected [3]. 
The most common methods for large-scale purification of plasmids are  
chromatographic [4]. However, other methods such as liquid-phase extraction 
in Aqueous Two-Phase Systems (ATPSs) may be interesting alternatives since the 
problem of access and mass transfer within solid-phase chromatography 
matrices for large plasmids is avoided. Several studies show that ATPS 
extraction has several other advantages, such as; operational simplicity, easy 
scale-up and the possibility to combine several process steps in a single 
operation [5; 6; 7]. However, one of the main drawbacks of this technique is its 
low selectivity, which may be overcome by the use of affinity ligands [8; 9]. The 
specificity and bio-recognition properties of affinity ligands for pDNA capture 
from a crude feedstock with large and structurally related impurities (such as, 
high molecular weight RNA, endotoxin and shear genomic DNA) may facilitate 
the preparation of pDNA products that fulfil the stringent specifications for 
market approval. 
Although affinity based separations have been extensively applied for protein 
extraction in ATPS’s [10; 11; 12], only two recent reports refer to the utilisation 
of pDNA ligands [8; 9]. Duarte et al. [8] have used the cationic polymer 
poly(ethyleimine) (PEI) as non-specific ligand for the purification of pDNA from 
crude cell lysates in a two-step ATPS process. Although the authors report up to 
100 % pDNA recovery in the form of DNA/PEI polyplexes, with only minor 
protein impurities, they did not elute the pDNA from the polyplexes. Although it 
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is not yet clear if the pDNA could be eluted and used in pure form, concerns 
remain about the use of PEI based vectors for gene therapy applications since 
the cationic polymers might present some toxicity issues [13]. In addition, the 
PEI/DNA interactions are mainly electrostatic, thus there is a potential risk for 
non-specific binding of the cationic polymer to other negative charged 
molecules, such as endotoxins, RNA and genomic DNA, which would also 
raise potential safety concerns.   
Alternatively, Barbosa et al. [9] have described a protein-based ligand 
composed of Glutathione-S-Transferase protein (GST) fused to a  Zinc Finger 
transcription factor (ZnF) designed as GST-ZnF.  The GST-ZnF affinity protein 
was able to isolate pDNA bearing a ZnF recognition site from the bottom to the 
top phase of a PEG-dextran ATPS in either the native or a PEGylated form. GST-
ZnF binds to a specific base sequence at the DNA recognition site, from which 
it is not easily eluted. Thus, no attempts were made to extract pure pDNA from 
a complex mixture of a crude cell lysate.  
In both approaches the ligand has to be covalently bound to poly(ethylene 
glycol) (PEG); through PEGylation [14; 15]. In the PEG-dextran systems used, 
this PEGylation drives the ligand to the PEG phase where less contaminants 
usually accumulate. The presence of the ligand in the PEG phase may draw the 
pDNA to this phase by affinity binding, so separating it from the contaminants. 
Though effective, this approach is limited by the need for PEGylation. This can 
be a complex and inefficient procedure and several products are often obtained 
with different degrees of PEGylation [9]. Such inhomogeneity in the PEGylated 
ligands may require further purification of the final DNA sample to obtain a 
homogeneous product and this in turn may lead to high production costs and to 
the increase in batch operation times. Additionally, because many PEGylations 
are inefficient, a stoichiometric excess of the reagent is needed, which can 
potentially make the entire process uneconomic for some ATPS purifications. 
To circumvent these problems a modified PEG might be used that binds site 
specifically and in situ with the ligand. This approach has been already explored 
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for the affinity purification of proteins bearing a His-tag in aqueous two-phase 
systems [16; 17]. Thus, Immobilized Metal-ion Affinity Partitioning (IMAP) has 
been used as an alternative to Immobilized Metal-ion Affinity Chromatography 
(IMAC)[18].  IMAP exploits the grafting of a chelator, such as iminodiacetic acid 
(IDA), onto one the phase forming polymers, usually the PEG polymer. The IDA 
ligand chelates a transition metal ion (e.g. Cu2+ or Ni2+), which binds 
preferentially to electron-rich amino acid residues such as histidines and 
cysteines that are accessible on the surface of proteins [19]. This enables the 
extraction of specific his-tagged proteins into the PEG phase while the bulk of 
contaminant proteins without a his-tag remain in the other phase [17].  
The strategy set out above does not require the previous PEGylation of the 
protein and the binding to the His-tag occurs almost instantly. Here, the use of 
this highly selective method to enhance the partitioning of a DNA affinity 
protein to the PEG-rich phase of a PEG-dextran ATPS is exploited in order to 
steer the target pDNA to the same phase.  
One of the ligands that is being investigated for the affinity chromatographic 
purification of plasmid DNA is the LacI repressor protein fused to both a His6 
tag and a Green Fluorescent Protein (GFP) moiety [20; 21]. As shown in Figure 
1, the LacI-His6-GFP fusion protein is a tetramer protein (two dimer units) 
composed of three different domains: 1) A LacI domain that binds sequence 
specifically the LacO3/LacO1 operator on the pUC19 plasmids; 2) The GFP 
domain that enables the specific detection of the protein in a mixture of other 
proteins; 3) The His6 tag that bridges the two domains and enables the 
purification of the protein by IMAC. This protein has been immobilised onto an 
IMAC column for the purification of pDNA directly from crude bacterial cell 
lysates, yielding highly pure supercoiled pDNA with no RNA, genomic DNA or 
denatured pDNA [20; 21]. 
Here, we report a dual affinity ATPS approach for the purification of plasmid 
DNA in which the heterofunctional DNA binding ligand LacI-His6-GFP is 
combined with an Immobilized Metal–Ion Affinity PEG. The functionalised PEG 
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binds to the His-tag of this protein, resulting in the Immobilized Metal-Ion 
Affinity Partitioning (IMAP) of the LacI-His6-GFP / pDNA complex to the PEG-
rich top phase. The advantages of using this approach are that the covalent 
PEGylation of the DNA ligand is not necessary. The high pDNA sequence 
specificity of the DNA binding protein is effectively exploited and the binding of 
the functionalised PEG to the DNA binding protein can be performed in a crude 
cell extract that is then mixed with the pDNA lysate, thus potentially reducing 
operating costs and processing complexity.  
 
 
Figure 1 - Schematic representation of the dual affinity method developed for pDNA 
purification using PEG/dextran aqueous two-phase systems.   
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4.3 Material and Methods 
4.3.1 Reagents 
PEG polymers, MW 10,000 and 600 Da were obtained from Sigma-Aldrich (St. 
Louis, MO, USA) and dextran MW 40 kDa was purchased from GE Healthcare 
(Chalfont St Giles, UK).  LB broth media, β-lactoglobulin protein, boron 
trifluoride ethyletherate (BF3) and epichlorohydrin were purchased from Sigma-
Aldrich. 
4.3.2 Preparation of PEG-IDA-Cu(II)  
PEG-IDA-Cu(II) was synthesised using the epichlorohydrin method, as similarly 
described in [22]. Briefly, 30 g of PEG 10,000 Da was dissolved in 100 mL 
toluene and 0.3 mL BF3 (50 % w/w) and 0.4 mL epichlorohydrin were added 
dropwise. The reaction mixture was stored for 48h and 2ml NaOH (45 %) was 
then added to the mixture, which was slowly stirred for 4h at 37 ºC. PEG was 
precipitated and the powder was then dissolved in 100 mL carbonate buffer pH 
12.1 containing 0.35 M iminodiacetic acid (IDA) and the mixture was stirred at 
70 ºC overnight. After three extractions with chloroform, the product was 
crystallised twice in ice-cold diethyl ether (yielding 85-90 % of total PEG). The 
Cu(II) complex with PEG-IDA was obtained by dissolving the PEG-IDA product 
in 50 mL sodium acetate buffer pH 4 containing 5g of CuSO4. The extraction 
was repeated yielding proximally 75 % of the original PEG. The 0.88 µmoles of 
Cu(II) per µmol PEG was determined by atomic absorption spectrometry using 
appropriate standards. 
4.3.3 Expression and purification of LacI-His6-GFP protein 
LacI-His6-GFP DNA construct [20] was transformed into E. coli BL21-gold cells 
(Stratagene, La Jolla, CA) and a single fresh colony was inoculated into 200 mL 
of LB media containing 50 µg/mL ampicillin and incubated overnight at 30 ºC 
and 200 rpm. 1:1000 dilution of this culture was then prepared in 0.5 L of 
similar media and the LacI-His6-GFP was expressed constitutively overnight at 
200 rpm and 30 ºC.  Cells were then harvested by centrifugation and the pellet 
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was stored at -80 ºC until needed. Protein was purified using a 1 mL Histrap HP 
column (GE Healthcare). Briefly, a cell pellet from 0.5 L cell culture was re-
suspended in 20 mL of 20 mM phosphate, 500 mM Nacl and 40 mM Imidazole 
buffer pH 7.4 and lysed by 3!3 second pulse sonication at maximum power 
inside an ice bucket. The resulting lysate was clarified by centrifugation at 
19,000 rpm for 15 min at 4 ºC and loaded into a Histrap column using a syringe 
pump. The column was extensively washed after the loading step with the re-
suspended buffer until no absorbance was detected by UV 280 nm.  Protein was 
eluted using 20 mM phosphate, 500 mM NaCl, 500 mM imidazole buffer pH 
7.4. The resulting eluate containing LacI-His6-GFP was dialysed at 7 ºC against 
PBS buffer pH 7.4 to remove imidazole. The buffer was exchanged when 
necessary by using a PD10 desalting column (GE Healthcare). Protein 
concentration in solution was determined with the Bradford method (Pierce, 
Rockford, IL, USA) using BSA as standard.  
4.3.4 Preparation of pure pUC19 plasmid and pUC19 alkaline lysate.  
Escherichia coli DH5-! strain, harbouring the pUC19 plasmid was cultivated 
and the pUC19 plasmid was purified as previously described [9]. Preparation of 
the alkaline cell lysate was performed according to Duarte et al. [8]. The 
resulted clarified lysate was filtered using a 0.22 µm syringe filter and stored at -
20 ºC until needed. On the day of the experiment the buffer was exchanged to 
20 mM phosphate buffer pH 7.4 using a PD10 column. 
4.3.5 Affinity partitioning in aqueous two-phase systems 
Aqueous two-phase systems composed of PEG 600 – DEX 40 were prepared by 
weighing appropriate amounts of stock solutions (30 - 40 % w/w) of the phase 
forming polymers in 2 mL graduated tube. Immobilized metal-ion affinity 
partitioning experiments were performed by replacing part of the PEG with the 
modified PEG-IDA-Cu(II) (the amount of PEG derivative is given hereafter as a 
percentage of the total mass of PEG present in the systems). The two proteins 
under study (LacI-His6-GFP and β-Lactoglobulin) were then added into the 
systems and mixed by vortex shaking. The crude cell lysate containing pUC19 
or the pure pUC19 solution was added and pH was adjusted to the desired pH 
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using concentrate stock buffers. Finally, ultra pure water was added to make 1.5 
g total system weight. The systems were well mixed by vortex shaking until all 
polymers were completely dissolved. Phase separation was accomplished by 
placing the tubes in a water bath at 30 ºC for ~2 hours to avoid phase turbidity.  
Each phase was collected and all further analyses were conducted at room 
temperature on the same day that the partitioning systems were prepared.  
The second extraction stage was performed by collecting the desired top phase 
of a system (0.5mL) and adding a fresh lower phase (DEX 40, 14 % w/w) or 0.4 
mL potassium phosphate solution, K2HPO4-KH2PO4 (40 %). IPTG or NaCl was 
added to the final concentrations described in Table 4.  
4.3.6 Analytical Methods 
4.3.6.1 LacI-His6-GFP and total protein Partition analysis 
The quantitative determination of the total protein in each phase was performed 
by the Bradford assay using BSA as standard. The specific concentration of LacI-
His6-GFP fusion protein in each phase was estimated by measuring the GFP 
fluorescence in a 96 well plate reader calibrated against pre-purified LacI-His6-
GFP as described previously [23]. All concentrations were calculated using the 
average of at least 3 independent measurements.  
4.3.6.2 DNA partitioning analysis 
Total DNA quantification was performed using a Picogreen assay (Invitrogen, 
Carlsbad, CA, USA) in a 96 well plate reader. Blanks for each system were 
prepared and a series of calibration curves using standard concentrations of 
purified pUC19 plasmid in the blank top or bottom phase of each system was 
used. To diminish any quenching effects of LacI-His6-GFP bound to pUC19 
plasmid all samples were treated with 1µg/µl DNase-free proteinase K (Sigma) 
for 1.5h prior to readings.  
The partitioning of a component, x, in a two-phase system is described by the 
partition coefficient, Kx, and calculated as Kx = CTP/CBP, where CTP and CBP are 
the concentrations of the protein in the top and bottom phases, respectively.  
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The partition percentage (PP) of each component, in each phase (i) from the 
total recovered component was calculated as:  
   
and the final pDNA yield as 
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4.4 Results and Discussion  
4.4.1 LacI-His6-GFP protein affinity partitioning  
Whether the modified PEG-IDA-Cu(II) would increase the free LacI-His6-GFP 
partitioning to the top phase of the 18 % (w/w) PEG 600 – 14 % (w/w) DEX 40 
system was first examined. Several ATPSs were made with increasing 
concentration of functionalised PEG, but keeping the LacI-His6-GFP protein 
concentration constant (Fig. 2A).   
 
Figure 2 - Effect of modified PEG-IDA-Cu(II) and imidazole on the LacI-His6-GFP partition 
coefficient (KLacI) in systems composed by 18 % (w/w) PEG 600 – 14 % (w/w) DEX 40 in 50 
mM Tris-HCl pH 7.4. A) Variation of KLacI with the addition of PEG-IDA-Cu(II). B) Variation of  
KLacI with the addition of imidazole in the presence of 10 % PEG-IDA-Cu(II). 
 
 
In the absence of PEG-IDA-Cu(II) the LacI-His6-GFP protein partitioned to the 
dextran-rich bottom phase (KlacI= 0.037, 92.5 %). The partitioning behaviour of 
LacI-His6-GFP was significantly enhanced by increasing the concentration of 
PEG-IDA-Cu(II)  and it accumulated to 99.5 % in the PEG-rich top phase (KlacI= 
131) when 12 % of total PEG was replaced by the functionalised PEG.  
To confirm that the binding between protein/PEG was due to the coordination 
between the transition metal ion (Cu(II)) chelated by PEG-IDA and the imidazole 
rings of the histidines on the LacI-His6-GFP surface, we added increased 
concentrations of exogeneous imidazole in solution. As seen in Fig. 2B, in 
systems where 10 % of the PEG was replaced by PEG-IDA-Cu(II), increased 
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concentration of exogeneous imidazole steered the LacI-His6-GFP protein to the 
bottom phase. For 3 mM imidazole the protein partitioning coefficient was KlacI= 
0.073, which is close to that observed when no functionalised PEG was added 
(KlacI= 0.037).  This confirms that IMAP of the LacI fusion protein was achieved.   
 
4.4.2 pUC19 plasmid affinity partition   
Fig. 3 shows the effect of increased LacI fusion protein concentration on systems 
with constant amount of pUC19 (7.9 pmol) and PEG-IDA-Cu(II) ( 12 % (w/w)).  
In systems with no LacI fusion protein present, the pre-purified pUC19 plasmid 
partitioned to the bottom phase (96.9 %) whereas the his-tagged LacI fusion 
protein partitioned almost totally to the top phase in systems without the pDNA 
(see Fig. 2). When the LacI-His6-GFP protein (0.062 nmol) was combined with 
pUC19 DNA in the same system there was a slight increase in pUC19 
partitioning to the top phase (KpUC19 increased from 0.027 to 0.129). When the 
LacI-His6-GFP concentration was increased further, a decrease in pUC19 
partition coefficient was observed, eventually to such an extent that no DNA 
was detected in the top phase of these systems. 
 
Figure 3 - pUC19 (circles) and LacI-His6-GFP (squares) partition coefficient (K) in systems 
composed with increased LacI concentration and constant amount of PEG-IDA-Cu(II). Systems 
composed by 18.0 % (w/w) PEG 600 – 13.4 % (w/w) DEX 40 with 12 % of the PEG replaced 
by PEG-IDA-Cu(II) in 50 mM Tris-HCl pH 7.4. Each system contained constant amount of 
pUC19 (7.9 x10-12 mol, 14.36 µg). pUC19 accumulates on bottom phase only for systems with 
7.4x10-10 mol of LacI-His6-GFP.  Inset shows the DNA yield on the top phase. 
4. Dual Affinity Method for Plasmid DNA Purification in Aqueous Two-Phase Systems 
138 
The top phase recovery of pUC19 in all these systems was around 4-6 % as 
shown in the inset to Fig. 3.  Agarose gel electrophoresis analysis of the bottom 
and top phases of the systems was performed to determine if the pDNA was 
present in its free form or bound to the LacI fusion protein (Fig. 4). The pDNA 
was found to be bound to the affinity protein as an increase in the pDNA 
molecular weight was observed in the bottom phase of these systems, 
particularly for systems with higher protein concentration as 0.24 or 0.74 nmol 
(lane 8 and 9 respectively). This initially suggested that the affinity between the 
DNA-protein was higher than that between protein and PEG-IDA-Cu(II), so 
compromising the use of the PEG-IDA-Cu(II) to enhance the partitioning of 
pDNA/protein complex to the top phase. 
 
Figure 4 - DNA electrophoresis analysis of the top and bottom phase of systems composed 
with increased LacI-His6-GFP concentration with constant amount of pUC19 plasmid (7.9 x10
-
12 mol, 14.36 µg) and PEG-IDA-Cu(II) (12 % of the total PEG). Systems composed by 18 % 
(w/w) PEG 600 – 13.4 % (w/w) DEX 40, 50 mM Tris-HCl pH 7.4. 1) DNA marker; 2) pUC19 
plasmid; 3) Top phase (TP) and bottom phase (BP) analysis of system with only pUC19 
plasmid; 4) System with pUC19 plasmid and 12 % PEG-IDA-Cu(II); 5-9 systems with pUC19 
plasmid and 12 % PEG-IDA-Cu(II) and 0.3, 0.6, 1.2, 2.4, 7.4 x10-10 mol of LacI-His6-GFP 
protein, respectively. 
 
To further determine why the pDNA/LacI complex had partitioned to the bottom 
phase of these systems we also measured the decrease of the PEG-IDA-Cu(II) 
ligand in these systems, as shown in Fig. 5 and Table 1. Employing lower PEG-
IDA-Cu(II) concentrations, while keeping pUC19 (2ρmol, 3.6 µg) and LacI (190 
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ρmol, 54.2µg) concentrations constant, enhanced the partitioning of both to the 
top phase (Fig. 5A). The percentage of LacI-His6-GFP and pUC19 partitioned to 
the top phase in systems without PEG-IDA-Cu(II) were 27.2 % and 11.4 % 
respectively (Table 1). By contrast, with similar conditions but with 0.15 % 
(w/w) of the total PEG replaced with the functionalised PEG, the LacI fusion 
protein partitioned to the top phase.  
Under these conditions, the LacI protein accumulated 85 % in the top phase 
(KlacI= 5.09) while pUC19 partitioned 89.4 % (KpUC19= 7.29) into the same phase. 
However, as the concentration of PEG-IDA-Cu(II) was increased, the partition 
coefficients of both protein and pDNA fell. Agarose gel analysis of the top and 
bottom phases of these systems (Fig. 5B) now showed that the pDNA was 
complexed with LacI protein in the top phase as a shift in the molecular weight 
of the supercoiled and open-circular bands of pDNA was observed (see for 
reference Fig. 5B, lane 1).  
 
Figure 5 – Effect of PEG-IDA-Cu(II) on the pUC19 plasmid and LacI-His6-GFP protein partition 
in systems composed by 16.0 % (w/w) PEG 600 – 14.3 % (w/w) DEX 40 in 15 mM phosphate 
buffer pH 7.4. A) Partition coefficient of pUC19 (circles) and LacI-His6-GFP (squares) in each 
system contained constant amount of pUC19 (2 x 10-12 mol, 3.6 µg) and LacI-His6-GFP (1.9 x 
10-10, 54.2 µg). B) DNA gel electrophoresis of top and bottom phase  of systems described in 
A; 1) pUC19 plasmid (control); 2) DNA marker (see Fig. 4); 3) Top phase (TP) and bottom 
phase (BP) of system composed with pUC19 and PEG-IDA-Cu(II) (12 % total PEG); 4-7) 0.15, 
0.71, 1.5, 12 % of modified PEG added, respectively. 
 
It is speculated that the retention of the pDNA in the bottom phase for higher 
PEG-IDA-Cu(II) concentrations may have arisen because the functionalised PEG 
significantly changed the physical properties of the top phase, possibly due to 
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the formation of dimers or multimeric PEG-IDA-Cu(II) chains. Since a 10 kDa 
PEG-IDA-Cu(II) was used, it is possible that a very high MW chain was formed, 
particularly at high concentrations of the functionalised polymer. Thus, 
excluding from that PEG-rich phase the pDNA/protein complex. This behaviour, 
an excluded volume effect, has been observed for several other proteins in ATPS 
with increase of the molecular weight of one of the phase forming polymers [24; 
25].  
Table 1 - Top phase partition percentage of pUC19 plasmid and LacI-His6-GFP protein with 
increased PEG-IDA-Cu(II) concentration in systems composed by 16.0 % (w/w) PEG 600 – 14.3 
% (w/w) DEX 40, 15 mM phosphate buffer pH 7.4. Each system contained constant amount of 
pUC19 (2 x 10-12 mol, 3.6µg) and LacI-His6-GFP (1.9 x 10-10 mol, 54.2 !g). 
 
 
 
 
 
 
 
The selective partitioning of the his-tagged LacI protein was confirmed by 
replacing it by β-lactoglobulin (Table 2). In the same polymer- polymer systems 
in phosphate buffer pH 7.4 the β-lactoglobulin protein partitioned to the top 
phase, Kβ-lacto= 1.5, and a slight increase of its partition value Kβ-lacto= 1.8 was 
observed when 0.148 % of the modified PEG-IDA-Cu(II) was added. When both 
β-lactoglobolin and pUC19 were added in the same systems there was no 
significant shift of pDNA partitioning to the top phase (KpUC19= 0.015) similar to 
systems where no protein was added (KpUC19= 0.024).  
4.4.3 Extraction of pUC19 plasmid from crude cell lysate  
Affinity capture of pUC19 directly from crude cell lysate was performed by 
adding the desalted lysate (14 % load, w/w) into systems with 0.148 % of the 
Partition percentage, % mass PEG-IDA-Cu(II) 
% (w/w) LacI-His6-GFP pUC19 
0 27.2 ± 2.5 11.4 ± 3.5 
0.15 85.4 ± 0.7 89.4 ± 5.3 
0.71 75.9 ± 0.5 75.3 ± 6.1 
1.48 59.5 ± 0.6 49.9 ± 1.6 
12.00 31.9 ± 0.9 21.6 ± 2.7 
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modified PEG. Preliminary experiments with the original pUC19 alkaline lysates 
had shown that no pDNA/LacI interaction was observed (data not shown).  
However, it was observed that exchanging the buffer prior to extraction the 
binding between the pDNA/LacI occurred. Therefore, in all further experiments, 
the lysate was desalted (i.e., buffer exchanged to phosphate buffer pH 7.4) prior 
to extraction. This observation may have been due to the possible excess of 
sodium dodecyl sulfate (SDS) detergent used in the cell lysis and to the low pH 
" 5.6 of the lysate.  SDS is a known protein denaturant and the optimal pH for 
LacI/pDNA binding occurs at pH 7.4 [20; 21].  
 
Table 2 - Partition coefficient of pUC19 plasmid in the presence of "-lactoglobulin protein 
(negative control) in systems composed by 18.0 % (w/w) PEG 600 – 13.4 % (w/w) DEX 40 in 
15 mM phosphate buffer pH 7.4. 
 
Partition Coefficient 
ATPS 
!–
Lactoglobulin 
mol x 10-9/µg 
pUC19 
mol x 
10-12/µg 
PEG-IDA-Cu2+ 
% (w/w) !-
lactoglobulin 
pUC19 
DNA Partition 
percentage 
(%)a) 
1 
 
- 3.62 / 6.3 - - 0.024 3.954 ± 0.95 
2 - 3.62 / 6.3 0.148 - 0.007 0.984 ± 0.05 
3 3.5 / 65.3 3.62 / 6.3 0.148 2.0 0.015 2.46 ± 0.05 
4 3.5 / 65.3 - 0.148 1.8 - - 
5 3.5 / 65.3 - - 1.5 - - 
a) DNA partition percentage to the top phase of each system  
 
Although no genomic DNA (gDNA) is thought to be present on the lysates (see 
lane 3, Fig. 6A or B), we will report to total DNA partition (KDNA) instead of 
pUC19 partitioning when lysates are used since the quantification method used 
here (Picogreen) does not differentiate from both forms of DNA.  
As shown in Table 3, without LacI-His6-GFP or PEG-IDA-Cu(II) ligands total 
protein (Kprotein= 0.78) and DNA (KDNA=0.022) from the desalted lysate partition 
to the bottom phase of these systems in phosphate buffer pH= 7.4.  When 0.148 
% (w/w) of immobilized metal-PEG was added to the system an increase of total 
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protein partitioning from the pUC19 lysate (to Kprotein = 0.96) was observed, 
showing that some non-specific binding might occur. The competitive binding 
of the modified PEG to other proteins is expected to be low in ATPSs that have 
low concentrations of a binding competitor added, such as imidazole.  
Increase of the his-tagged LacI concentration in these systems resulted in a 
concomitant enhancement of the DNA partitioning to the top phase. For 
example, in systems with 0.27 nmol of LacI-His6-GFP, the DNA partition 
coefficient increased to KDNA=1.54 representing 72.8 % top phase partition 
percentage whereas, in systems without LacI protein and PEG-IDA-Cu(II) the 
DNA partitioned only 3.6 % to this phase (KDNA= 0.022).  
 
Figure 6 - Agarose gel analysis of the interaction between LacI-His6-GFP protein and bacterial 
lysate in ATPS (A) and in solution (B). A) Top phase (TP) and bottom phase (BP) of systems 
composed with bacterial lysate and LacI fusion protein. Systems composed by 16 % (w/w) 
PEG 600 – 13.3 % (w/w) DEX 40 (0.148 % of the PEG was replaced with PEG-IDA-Cu(II)); 1) 
pUC19 plasmid; 2) Marker; 3) bacterial lysate containing pUC19; 4) top and bottom phase 
system with only bacterial lysate; 5) system with bacterial lysate and PEG-IDA-Cu(II); 6) 
Systems with pUC19 and LacI-His6-GFP protein (without modified PEG); 7)  system with 
bacterial lysate, 2.73x10-10 mol LacI fusion protein and 0.14 % of PEG-IDA-Cu(II); 8) back 
extraction of system shown in lane 7 to a new DEX 40, 2.5 mM IPTG. B) Analysis of pUC19 
lysate with LacI protein and BSA in solution. 1) pUC19; 2) marker; 3) bacterial lysate; 4) 
bacterial lysate and LacI-His6-GFP; 5) bacterial lysate and BSA. 
 
The top phase recovery (yield) achieved with the above system composition was 
about 49.2 % of total DNA added.  Given the crude nature of cell lysates it is 
significant that neither RNA nor genomic DNA is co-extracted to the top phase 
of these systems (lane 7-TB, Fig. 6A). Fig. 6B shows the binding of the LacI 
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protein to the pUC19 plasmid in solution. As shown for ATPS, the LacI fusion 
protein binds preferentially to the pDNA instead of RNA and no interaction is 
observed with BSA. Although no genomic DNA is present in this pUC19 lysates, 
as no high MW bands in the gels are present, it is also known that the LacI 
fusion protein binds almost 4 x 106 fold more strongly to its operator compared 
to other non-specific sites within the DNA sequence [20]. Although the his-
tagged LacI might bind to one operator it requires two operators, 
LacO3/LacO1in the pUC19 plasmid, in order for the protein/DNA complex for 
optimal binding.  
Here it was accomplished one step elimination of RNA and genomic DNA, two 
major pDNA contaminants. For the therapeutically use of plasmid DNA a lack 
of contamination by RNA, genomic DNA, host proteins, and endotoxin is 
necessary to meat the stringent specifications of regulatory agencies [26].  
 
4.4.4 Second extraction / pUC19 elution 
To elute the pUC19 plasmid from its LacI-His6-GFP affinity protein and remove 
excess of the co-purified host proteins, a second extraction stage was performed 
with either DEX 40 polymer or a potassium phosphate salt buffer as the second 
phase. The top phase of ATPS with composition shown on system 6 (Table 3) 
was collected and, additionally to the phase forming polymer/salt, IPTG or NaCl 
were also added.  IPTG is known to induce an allosteric change in the LacI 
protein, allowing the release of the plasmid, whereas NaCl addition increases 
the ionic strength of the solution and weakens the electrostatic interactions that 
mediate the binding of the protein to the DNA [20]. 
As seen in Table 4, the use of dextran as the second phase resulted in the 
accumulation of the pDNA in the bottom phase, KDNA= 0.09, for systems with 
2.5 mM IPTG / 0.3M NaCl, and KDNA=0.04 when only IPTG was added.  Total 
protein partitioned to the opposite PEG phase with Kprotein= 2.91 and Kprotein = 
2.63, respectively for each system, whereas in both systems LacI partitioned to 
the bottom with the DNA.  
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Table 3 - Effect of LacI-His6-GFP increase concentration on the pUC19 plasmid partition from a desalted bacterial cell lysate. System composed by 18 % (w/w) 
PEG 600 – 13.3 % (w/w) DEX 40 in 15mM phosphate buffer pH 7.8. 
Partition coefficient (K) ATPS 
 
PEG-IDA-Cu(II) 
% (w/w) 
LacI 
x10-10 mol Total protein LacI pUC19 
DNA PP topa) 
(%) 
DNA Yield 
(%) 
1 - - 0.78 - 0.022 3.6 ± 0.2 1.7 ± 0.1 
2 0.14 - 0.96 - BPb) BP b) BP b) 
3 - 1.36 0.99 0.77 0.14 17.4 ± 1.2 8.0 ± 0.4 
4 0.14 0.82 1.32 0.72 0.13 16.5 ± 1.8 12.2 ± 0.6 
5 0.14 1.36 3.45 1.24 1.00 59.8 ± 1.6 36.7 ± 1.2 
6 0.14 2.73 4.17 2.35 1.54 72.8 ± 4.3 49.2 ± 3.1 
a) PP Top – Partition Percentage on Top Phase  
b) BP – Bottom Phase only 
pUC19 lysate: 109.6 µg/mL protein and 11.9 µg/mL DNA 
 
 
Table 4 - Second extractions of pUC19 plasmid using the top phase of the system 16 % (w/w) PEG 600 – 13.3 % (w/w) DEX 40 composed with 
bacterial cell lysate, 2.73 x10-10 mol LacI-His6-GFP protein and 0.14 % of PEG-IDA-Cu(II) in,15mM phosphate buffer pH 7.8. 
 
Partition coefficient 
Second 
phase 
IPTG 
(mM) 
NaCl 
(M) Total 
protein 
LacI DNA 
Protein removal 
(%) 
DNA PP a)  
(%) 
DNA yield 
(%) 
2.5 0.3 2.91 0.71 0.09 
76.3 ± 0.79 
(bottom)  
81.8 ± 3.9 
(bottom)  
27.3 ± 1.3 
(bottom)  DEX40 
(pH 7.4) 
2.5 - 2.63 0.51 0.04 
85.9 ± 1.6 
(bottom)  
89.2 ± 8.4 
(bottom)  
25.5 ± 2.7 
(bottom)  
1.2 - 0.31 TBb) 12.86 
74.4 ± 2.6 
(top)  
94.7 ± 5.9 
(top)  
23.8 ± 1.5 
(top)  
K2HPO4 – 
KH2PO4 
(pH 7.4) - - 0.33 TB b) 2.90 
76.7 ± 0.8 
(top)  
81.3 ± 2.2 
(top)  
9.0 ± 0.3 
(top)  
a) DNA PP – DNA Partition Percentage on Top Phase 
b) TB- Top phase only 
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Agarose gel analysis of the bottom phase of the second extraction system 
showed that the pDNA remained in the bound form (Fig. 6A, lane 8-BP) and 
thus elution had not been properly achieved.  Further attempts to elute the DNA 
were made by adding PEG-IDA-Cu(II) to the systems or by increasing the IPTG 
concentration but no improvement to the pDNA elution was observed. In both 
cases more than 75 % of total protein was removed (85 % for back-extraction 
systems without NaCl). Much greater protein removal would have been 
achieved if the pUC19 plasmid had been eluted from the LacI protein since 
under these conditions the LacI protein would partition to the PEG-IDA-Cu(II) 
rich phase, as shown in Fig. 2A. 
We speculated that polymer–salt systems might improve upon the pDNA 
elution since a high salt concentration may impair the pDNA / protein 
interaction. As shown in Table 4, however, similar results were obtained and no 
elution was achieved with K2HPO4 - KH2PO4 solution. With salt as the second 
phase, the DNA and LacI partitioned to the PEG-rich phase rather than to the 
salt phase where total protein accumulated (Kprotein! 0.3). A slightly improvement 
on the final pDNA yield from 9.0 % to 23.8 % was attained when 1.2 mM IPTG 
was added but in both cases the pDNA was still in the bound form.  
The lack of DNA elution by IPTG is confusing and requires further study.  It is 
conceivable that steric hindrance by PEG may impede the access of IPTG to the 
binding site on LacI and thus not induce the conformational change in the 3D 
structure of LacI.  A similar effect would result if IPTG partitioned to the 
opposite phase to the LacI/pDNA complex or if the protein/pDNA complex 
aggregated during the extraction process, hindering access to the site for IPTG 
binding. These hypotheses are being investigated and the protocol is being 
optimised for pUC19 elution.  
Nonetheless with this current protocol, 75 % of total protein was removed 
without either genomic DNA nor RNA contamination. Although an overall yield 
of ~25 % was obtained, this represents about 1.4 mg of pDNA per 200 mL 
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desalted lysate which is about a 9-fold improvement compared to that reported 
for LacI-His6-GFP immobilized into an IMAC column [21].  
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4.5 Conclusions 
A dual affinity partitioning strategy is presented for the purification of pUC19 in 
PEG-dextran ATPS.  A system composed of PEG-IDA-Cu(II)/ LacI-His6-GFP has 
been shown to be effective for the affinity purification of pDNA from bacterial 
alkaline lysates without the need for covalent PEGylation of the ligand. This 
represents an advantage over this process since there is no need to perform the 
expensive and time consuming PEGylation reactions or the subsequent PEG-
ligand purification steps. Although pDNA elution from the complex proves to be 
difficult we believe that with further improvements this method may be 
appropriate for the development of large-scale manufacturing of pDNA for gene 
therapy applications or DNA vaccines. 
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5.1 Summary of the Central Results 
5.1.1 Affinity purification heuristics   
The work presented in this thesis constitutes the first experimental study on the 
affinity partitioning of plasmids in aqueous two-phase systems using protein-
based affinity ligands. The results presented provide useful information for the 
future development and designing of affinity pDNA extraction process using 
aqueous two-phase systems. In this chapter the major practical implications of 
the studies discussed in the previous chapters are synthesised. Areas for future 
research identified in this thesis are also summarised in this section. 
On the analysis of the results one has to bear in mind that an ideal system for 
the affinity extraction of pDNA in aqueous two-phase systems has to comply 
with a number of rules of thumb or heuristics:  
• Remove the most plentiful impurities first 
• Specificity of the ligand to the target pDNA without co-purification of 
impurities 
• Simple elution strategy that gives high elution yields 
• Stability and robustness of the ligand 
• Affinity ligand that can be produce cheaply. 
 
5.1.2 Selection of a suitable ATPS system 
ATPS can be divided mainly into two types: polymer–salt, polymer–polymer 
systems. Polymer-salt systems are not recommended for affinity extraction 
systems since the salts may interfere on the binding of the affinity ligand to 
target DNA [1] and thus polymer-polymer systems, such the model PEG/dextran 
systems, are preferred. For the first time, it was systematically evaluated the 
partitioning of bacterial cell lysate components in different PEG-dextran systems 
in order to select systems which accumulates most of the pDNA impurities in 
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the dextran-rich phase. From the results of presented in Chapter 2, we divided 
the ATPSs into two main categories, A and B, which differ mainly in the 
partitioning of total protein from the bacterial cell lysate. In Category A systems, 
protein accumulated mainly in the bottom dextran phase together with the 
pDNA and RNA. By contrast, in category B systems protein accumulated in the 
PEG rich phase, whilst pDNA and RNA accumulated in the bottom phase. The 
utilisation of affinity ligands that naturally accumulate in the top phase, or that 
can be modified with PEG molecules (PEGylation) to steer their partitioning to 
this phase, could be best used in category A systems. The category B system 
may be suitable for the utilisation of non-modified protein affinity ligands.  
 
Advantages of PEG-dextran systems   
The PEG-dextran systems has the following advantages for the utilization of 
affinity ligands in pDNA production:  
• Most of pDNA impurities accumulated in the bottom phase in category A 
systems (e.g. PEG 600 – DEX 40).  A removal of more than 80 % of protein, 
99 % of the RNA and ~100% genomic DNA can be achieved. 
• In systems composed with PEG 1000 – DEX 500 (category B systems) 
protein-affinity ligands, such as GST-ZnF and LacI-His6-GFP fusion proteins, 
partitioning to the top phase without the need for PEGylation. However, 
protein based impurities also partition to this phase.  
• Unlike polymer-salt systems the partition of bacterial cell lysates 
components in these polymer-polymer systems varies less from system-to-
system composed with different molecular weight polymers. 
 
Disadvantages of PEG- dextran systems  
The main disadvantages of PEG-dextran system are:  
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• Dextran polymer is relative expensive and may limit its application at large-
scale. 
• Viscosity of some systems may be high (particularly for high molecular 
weight polymers) that would difficult the operation at bigger scales.  
• Proteins impurities, unlike nucleic acids, partitioning more equally between 
phases in most of the systems. 
 
5.1.3 Affinity Purification of pDNA in ATPS 
Two affinity systems were investigated in this thesis for their suitability to purify 
therapeutic grade plasmid DNA in ATPS:  
1) GST-ZnF/pTS: a fusion protein, comprised of Glutathione-S-Transferase 
(GST) and a zinc finger transcription factor (ZnF) that binds to 5´-
GGGGCGGCT-3´ sequence within pTS plasmid was utilized to isolate it 
in ATPS; and 
2) LacI-His6-GFP/pUC19: a lac repressor protein (LacI) fused to a His6 tag 
and to Green Fluorescence Protein (GFP) that displays affinity for the lac 
operator sequences (lacO1/lacO3) within pUC19 plasmid.  
The tailoring of the affinity protein into the PEG phase was accomplished using 
two different approaches.  
The first method investigated was performed by covalent attachment of the PEG 
phase-forming polymer to the GST-ZnF affinity protein. In Subchapter 3.1 this 
approach was initially investigated using the free GST-tag using four different 
functionalised PEGylation reagents for modification. Two amine selective 
reagents, 20 kDa mPEG-butyraldehyde (mPEG-ALD) and 20 kDa mPEG-
succinimidyl propionate (mPEG-SPA) were evaluated, as were two thiol 
selective reagents, 5 kDa mPEG-maleimide (mPEG-MAL) and the bis-alkylating 
10 kDa mPEG-monosulfone (mPEG-MS). In the same subchapter it was 
demonstrated that the optimized PEGylation reactions performed with GST 
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could be translated to the GST fused to a Zinc Finger protein (GST-ZnF) 
resulting in similar reactions efficiencies and products of PEGylation. In 
Subchapter 3.2 the affinity partitioning of the plasmid DNA containing the 
specific recognition sequence for the PEGylated GST-ZnF was studied in more 
detail.  
In Chapter 4 it was tested a second type of PEGylation composed of 
immobilized metal–ion affinity PEG (PEG-IDA-Cu(II), 10 kDa) which binds to 
the poly(histidines) tag that is accessible on the surface of LacI-His6-GFP protein 
as shown in Figure 1. In both PEGylation methods developed, it was achieved 
the enhancement on the partitioning of the affinity protein bounded to the target 
pDNA to the PEG-rich top phase, allowing the extraction of the pDNA from the 
dextran-rich phase.  
 
Figure 1 - Scheme of the affinity partition of pUC19 plasmid in ATPS using the LacI-His6-GFP 
protein. Sizes of the biomolecules correspond to the relative concentrations in each phase and 
the arrows indicate the directions of partitioning. 
 
Advantages of using the GST-ZnF/pTS affinity mechanism 
The main advantages of using the GST-ZnF ligand approach are: 
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• Four different PEGylation reactions are now optimized for the PEG 
conjugation to the free GST-tag which could be translated to other GST 
fusion proteins  
• N-terminal amino acid PEGylation of the GST-ZnF protein could be 
obtained in the GST-tag domain, which is far from the protein active site 
within ZnF domain, decreasing the probably of inhibiting binding to the 
target pDNA.  
• Heterogeneous PEGylation products (more than one PEG chains per 
GST-ZnF) can be used without inhibiting the DNA binding properties. 
Complicated separations of the different PEGylated species, as result of a 
PEG-conjugation reaction, are not necessary.  
• A 1322-fold increase in the protein partition coefficient (97.5%) after 
PEGylation is obtained in comparison to the non-PEGylated protein (Kc = 
0.013). 
• Plasmid DNA partition totally to the top phase in the presence of PEG-
GST-ZnF ligand whereas without the ligand partitions 99.9 % to the 
bottom phase.  
 
Disadvantages of using the GST-ZnF/pTS affinity mechanism 
The main disadvantages of the GST-ZnF/pTS affinity approach are as follow:  
• The pre-purification of the affinity ligand followed by the PEG 
conjugation and separation of the non-reacted protein may not be cost 
effective and relative expensive to produce.  
• Thiol reactive PEGylation disrupted the ZnF binding to the target pDNA. 
The thiol conjugation reactions were much faster (~1h) comparatively to 
the amine selective mPEG reagents (days). However, the PEG 
conjugation on the cys site (probably the cys coordinating with zinc ion) 
disrupted the binding.  
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• Protein-based affinity ligands, as the GST-ZnF protein, are unstable and 
easily degraded (GST-ZnF data not shown).  
• In practice, a part from the proof-of-concept presented in this thesis, the 
GST-ZnF would not be a suitable ligand for a commercial pDNA 
purification process since the pDNA elution from the ligand is 
impractical. The presence of the ligand may denote a potential safety 
hazard. 
• In addition, a Blast (Basic Local Alignment Search Tool) has shown that 
both the GST and ZnF moiety of the fusion protein are similar to protein 
expressed in humans. It has yet to be shown that native protein do not 
bind to the therapeutic plasmid containing the GST-ZnF recognition 
sequence. 
 
Advantages of using the PEG-IDA-Cu(II) / LacI-His6-GFP / pUC19 
mechanism 
The principal advantages of the aforementioned mechanism are:  
• Simple mechanism. All the affinity components are added into the 
bacterial cell lysate and the pDNA is extracted to the top phase.  
• Covalent PEGylation of the affinity protein and sequent purifications 
steps are not necessary. This will decrease the operation costs and 
processing time as compared to the GST-ZnF affinity approach.   
• Very low amounts of the PEG-IDA-Cu(II) ligand (0.14% w/w) is necessary 
for the partitioning of the affinity protein to the top phase of PEG-dextran 
systems.  
• More than 72% of the plasmid DNA partition to the top phase, without 
RNA or genomic DNA contamination. 
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• The pDNA yields obtained in this thesis represents a 9 fold improvement 
from the chromatographic methods reported previously in literature. 
• The ligand can be lyophilized and stored at room temperature and re-
hydrated for use when required. 
• A Blast search for nearly exact match of LacI domain showed that no 
protein produced by human genome matches the ligand.  
Disadvantages of using the PEG-IDA-Cu(II)/LacI-His6-GFP /pUC19 
mechanism 
The main limitations of the PEG-IDA-Cu(II)/LacI-His6-GFP /pTS mechanism are: 
• Bacterial cell lysate requires to be desalted prior to plasmid extraction. 
The addition of a chromatographic step for the desalting it will increase 
the operational costs.  
• Relative low pDNA yields (~27%). The dissociation of pDNA from the 
protein ligand proved to be a challenging task in aqueous two-phase 
systems.  
• Maximum removal of proteins was only about 76 % from the original 
feed. This is partially due to the protein ligand that stills tightly bounded 
to the pDNA.   
• It maybe possible that the protein ligand binds to other LacO regions in 
bacterial gDNA. Although, in this work no co-purification of gDNA was 
observed. This may not be an issue as bacterial strain could be selected 
or genetically modified in order to produce a genome that contains no 
lacO sequences.  
• pUC19 plasmids employs antibiotic resistance gene. This disadvantage 
was discussed in Section 1.2.1 
• The use of pure protein-based ligands may be relative expensive to 
produce. 
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5.1.4 Affinity Purification Summary 
Two affinity approaches were developed for the affinity extractions of plasmid 
DNA in ATPS. The PEG-IDA-Cu(II)/LacI-His6-GFP/pUC19 mechanism is the one 
that offers higher potential for use in a commercial pDNA purification process. 
The mechanism is much simpler and faster compared to the GST-ZnF/pTS 
mechanism and does not require the covalent binding of the PEG phase forming 
polymer to the affinity ligand previous to the extraction of pDNA. In addition, 
very small amounts of PEG-IDA-Cu(II) are needed in order to enhance the 
partition of the ligand bounded to the target pDNA for the phase where less 
contaminants accumulate.  
Nonetheless, for the process to be commercially viable and to comply with the 
safety guidelines, the elution of pDNA from the ligand has to be improved in the 
future. It is hypothesized that the elution difficulties are likely to be attributed to 
a combination of several effects such as the system composition, elution buffer 
strength or the opposite phase-partitioning of the eluting agent, IPTG, to the 
LacI/pDNA complex.  
When IPTG binds to the affinity protein, the LacI conformation is altered [2; 3] 
resulting in the release of the pDNA plasmid from the protein. In this study up to 
2.5 mM IPTG was unsuccessfully used for pDNA release whereas 1mM 
concentration in 5 min incubations, was found to be enough for the release of 
pDNA when the affinity ligand was immobilized into a chromatographic 
column [3; 4]. When ATPSs are used the first hypothesis to consider in order to 
explain this phenomenon, is the partition of the IPTG to the opposite phase 
where the binding complex accumulates, and thus the elution buffer has limited 
contact with the affinity protein. However, this hypothesis requires further 
investigation to determine the IPTG partition in these systems. 
Alternatively, it is possible that the IPTG-binding site in the LacI fusion protein 
may not be easily accessible if protein-DNA complex tend to form molecular 
aggregates originated by the phase forming polymers.  
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Nonetheless, as the affinity binding is a complex combination of hydrophobic, 
electrostatic forces and hydrogen binding, the maximum elution yield may only 
be achieved with the process optimization of several factors at the same time. 
Further studies have to be planned with this in mind in order to determine 
which are the optimal conditions for the efficient pDNA dissociation.  
Although pDNA elution from LacI binding complex proved to be difficult, the 
non-optimized method described here, removed more than 75% of the protein 
yielding proximally 27 % of pUC19 plasmid DNA. This represents about 7.4 µg 
of pDNA extracted per 1 mL of pUC19 desalted lysate which is about a 9 fold 
improvement compared to what was previously obtained using LacI-His6-GFP 
immobilized into a chromatographic support column [4].  
The results demonstrate that a high capacity affinity purification process was 
developed with specificity to target plasmid DNA, without co-purification of 
structural similar impurities such as RNA or gDNA. The development of such 
plasmid recovery processes in ATPS will have an impact on the number of unit 
operations currently in use in the downstream processing of pDNA.  
With this dual affinity method, most of other chromatographic unit operations 
could be removed, except for a buffer exchange stage, in order to removed 
phase forming components and elution buffers (IPTG/NaCl). This ultimately, will 
promote the ATPS process from a mainly primary recovery step to a more global 
operation step, combining the primary and intermediate recovery stages. 
Boehringer Ingelheim has determined that more than 50 % of total production 
costs for pDNA are incurred during the downstream processing [5]. The 
elimination of some purification steps (e.g. concentration, Ionic-exchange or 
hydrophobic chromatography) could reduce the downstream purification costs 
by over 50% and the current total costs for the production of pDNA could be 
reduced by over 25 % [6]. The affinity aqueous two-phase systems processes 
are thus foreseeable to have a huge impact on the industrial and economical 
manufacturing of pharmaceutical grade plasmid DNA in the future.  
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5.2 Recommendations for Future Work  
In order to further elucidate the economical viability and process effectiveness 
of the affinity approaches developed in this thesis, there are several aspects that 
require to be addressed before large-scale implementation. In Table 1, the 
several unanswered questions and areas that deserve further investigation are 
summarised. 
The utilisation of the affinity ligands in polymer-polymer has proved to be 
suitable, since systems can be selected where all major pDNA impurities 
accumulates in the bottom phase. However, the industrial application of the 
model systems used in this study, the PEG-dextran systems, maybe limited due 
to the high cost of the dextran phase forming polymer (~$400/kg). The use of 
dextran is only possible when the cost of the product of interest is considerable 
and therefore compensates the cost of the forming phase polymers. However, 
inexpensive substitutes of dextran can be considered in future applications, like 
cellulose, polyvinyl alcohol. Currently, the utilization of a starch derivative 
Reppal PES, as less expensive bottom phase-forming polymer, is being 
investigated in our lab [7]. 
In addition, the use of protein-based affinity ligands in large-scale processes 
may be a concern owing to the expense of producing the pure protein ligand. A 
potential less expensive approach will be the utilisation of crude cell lysates of 
the protein ligands rather than the pure ligand, as used in this work. The 
economical benefit will be significant since the operation costs associated to the 
chromatographic purification of the ligand will be removed. The price of PEG-
IDA-Cu(II) is believed not to be very significant, as the PEG and the copper 
metal are low-cost and the immobilized metal-ion ligand is used in very low 
amounts. Nonetheless, a more detailed economical analysis of the real costs has 
to be assessed enclosing the overall stages of ligand production.  
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Table 1 - Summary of topics for further research  
Chapter Limitation / Problem Topics for further research 
Chapter 2 
Selection of ATPS 
for Affinity 
Purification of 
plasmid DNA 
expensive dextran 
 
Explore cheaper substitutes of dextran, like 
derivatives of starch, cellulose, polyvinyl alcohol 
thiol-PEGylation 
disrupt binding 
activity 
Engineer ligands with additional cysteine residues 
for preferential PEG conjugation 
 
Subchapter 3.1 
Modified Fusion 
Proteins for ATPS 
Affinity 
Applications: 
PEGylation of 
GST 
only one fusion GST-
protein tested 
Examine the optimized PEGylation reactions with 
other GST fusion proteins 
Design alternative ZnF ligands with less affinity 
for pDNA pDNA elution 
Test chaotropic agents 
Eliminate chromatographic separation steps for 
the separation of non-reacted protein from 
PEGylated protein by using ATPS  expensive covalent 
PEGylation process 
Access the re-utilization/recycling of the ligand 
Subchapter 3.2 
Affinity 
Partitioning of 
Plasmid DNA 
with a Zn Protein 
 
antibiotic resistance 
gene 
Design vector using antibiotic-free selection such 
as such as mention in Section 1.2.1 
Study alternative second extraction systems with 
different phase forming-salts such as citrate, 
ammonium sulfate, etc. 
Design plasmid DNA vector with lower binding 
constants to LacI affinity protein pDNA elution 
Test natural alternative eluting agents such as 
such as allolactose 
co-purification of host 
proteins 
Add imidazole (in minimal amounts) to extraction 
systems  
desalted lysates  
Study alternative bacterial cell lysis process 
without SDS detergent, such as sonication; 
autolysis bacterial strains, freeze-thaw. 
ligand Stability / re-
usability 
Synthetic ligands mimicking natural biological 
recognition 
Utilization of bacterial lysates of LacI-His6-GFP 
ligand rather than pure affinity ligands;  
Chapter 4 
Dual Affinity 
Method for 
Plasmid DNA 
Purification in 
Aqueous two-
phase systems 
 
overall process Cost  
Continuous mode-operations using ligand 
recycling 
 
Another aspect that needs to be considered for future research is the evaluation 
of a continuous-mode extractions processes in ATPS. As the production of such 
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ligands are expensive, the economical impact for such process will be 
significantly lower as compared to batch mode process, where a fresh ligand is 
used in every new extraction. In the continuous-mode operation the cost-
effectiveness will be also variable dependent on the number of times the ligands 
can be re-used. Thus, process optimizations for increase stability and durability 
of these ligands are also desirable.   
Alternatively, the use of synthetic ligands, mimicking natural biological 
recognition) may result in ligands that are cheaper to produce, more stable and 
reusable while being exceptional selective to the plasmid DNA. Molecular 
modelling studies may aid to find an ideal affinity mechanism with optimal 
binding and elution conditions. This will offer solutions to the above-mentioned 
shortcomings of affinity extraction of pDNA in ATPS. 
Further work must be also focused on the improvement of the elution yields as 
mentioned above and on the increase of the final pDNA recovery in ATPS. This 
may require the optimization of the ligand and/or the pDNA sequence in order 
to maintain specificity but enable easier elution of the bounded pDNA from the 
affinity ligand. The utilization of other polymer-salt systems (such as PEG-
ammonium sulfate or PEG-citrate) as second extraction may be an alternative 
approach. Testing other elution buffers or systems conditions may also provide 
high elutions yields. As the IPTG eluting agent have some toxicity issues, pDNA 
dissociation should be developed with the absence of IPTG, or by replacing it 
with allolactose, a non-toxic, but more expensive, natural alternative.  
To conclude, the ability to combine the process goals of purification, 
concentration and clarification into one unit operation would revolutionize the 
production of pharmaceutical grade pDNA. Aqueous two-phase systems meet 
all the characteristics of an ideal extraction technology since it has the potential 
to combine all three operations in one single step. However, these systems lack 
for high selectivity to the target plasmids and consequently are not yet widely 
adopted at industrial scale. 
It is envisaged in this thesis that the knowledge obtained using pDNA affinity 
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ligands would contribute to development of high selectivity ATPS process, with 
higher capacity compared to the traditional chromatographic processes. The 
specificity and biorecognition properties of these ligands for the pDNA capture 
from a crude feedstock with large and structurally related impurities, such as, 
high molecular weight RNA, endotoxin and shear genomic DNA, will facilitate 
the preparation of a pDNA product fulfilling the stringent specifications for 
market approval. 
In addition, as the affinity mechanism relies on the specific recognition 
sequence, the technology developed here should be ready transferable to any 
plasmid DNA containing the recognition site, and, potentially, to other forms of 
nuclei acid such as RNA and oligonucleotides. It is believed that all the 
improvement features developed in this thesis, will lead to an increase adoption 
of ATPS for the downstream processing of pharmaceutical-grade plasmid DNA.  
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“Science never solves a problem without creating ten more” 
George Bernard Shaw 
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a b s t r a c t
Some experimental methodologies require the quantification of protein in the presence of polymers like
poly(ethylene glycol) (PEG) and dextran (DEX). In the aqueous two-phase system (ATPS) extraction of
biomolecules, the interference of these phase-forming polymers on the Bradford quantification assay is
commonly recognized. However, how these polymers interfere has not been reported hitherto. In this
study we show that while dextran concentrations of 20% (w/w) can be used without error, loss of accu-
racy occurs for solutions with PEG concentrations >10% (w/w). Above this value a substantial decrease on
the assay sensitivity is observed.
! 2009 Elsevier Inc. All rights reserved.
Protein determination in the presence of poly(ethylene glycol)
(PEG)1 or dextran (DEX) polymers is commonly required in several
applications, namely protein precipitation studies [1], protein graft-
ing (e.g., PEGylation) [2], and in the aqueous two-phase systems
(ATPS) extraction of biomolecules [3].
In ATPS there are several methods for protein determination
currently in use. The method of Bradford [4] is the most commonly
used but the utilization of bicinchoninic acid (BCA) [5] and absor-
bance at 280 nm (A280) methods have also been reported [3,6,7].
The Bradford method is popular because it uses a single addi-
tion of the dye reagent to the sample, it is rapid (!10 min), and
it is done at room temperature (RT). In contrast, the BCA assay
takes !30 min to complete and must be performed at 37–60 "C.
The A280 assay is the only direct and nondestructive method but
it requires that no other compounds present in solution absorb
at 280 nm.
Polymer–polymer systems have been studied as two-phase sys-
tems for the downstream processing of bioproducts such as cells
[8], proteins [7], viruses [9], and plasmid DNA [3]. No specific infor-
mation has been given regarding the interference of polymers in
the protein quantitative assay, though interference is generally
recognized. To circumvent this problem a series of samples dilu-
tions are usually performed prior to analysis (to diminish the inter-
ference of the polymers) and the standards curves are prepared
with the same polymer composition as the samples. This could
lead to assay errors.
In this study we evaluated the effect of the concentration of the
poly(ethylene glycol) and dextran polymers, and their molecular
weights, on the Bradford assay sensitivity using the dye commer-
cially available as Coomassie Plus from Pierce (Rockford, IL, USA).
The reagent compatibility with temperature, salt type, salt concen-
tration, and pH is usually given in the manufacturer’s manual, but
no information is given regarding the recommended working con-
centrations of PEG and DEX polymers.
PEG polymers (St. Louis, MO, USA) of the molecular weight
ranging from 600 to 10,000 Da and DEX (GE Healthcare, Chalfont
St. Giles) ranging from 40 to 2000 kDa were used with various con-
centrations in samples containing the protein bovine serum albu-
min (BSA) (Pierce) as standards. All the quantitative assays were
carried out according to the manufacturer’s instructions. Briefly,
BSA protein samples were prepared in 5 mM Tris-HCl buffer, pH
7.5. Concentrated polymer solutions were added to each sample
to attain the required final concentration prior to standardizing
the 0.5 mL final volume with water. The Bradford reagent
(0.5 mL) was then added and the sample mixed thoroughly. After
10 min incubation at RT the absorbance of each sample was read
at 595 nm wavelength (A595). For each concentration three inde-
pendent measurements were made and the best estimate taken
as their mean.
The standards curves of BSA prepared in the presence of
increasing concentrations of PEG 600 (%, w/w) are shown in
Fig. 1A. For higher PEG concentrations a substantial decrease of
the A595 was observed for the same protein concentration. For
example, for PEG concentrations of 40% (w/w) a decrease of about
80% of the A595 values for BSA concentrations of 25 lg/mL was ob-
served. This reduction was only 15% if 10% (w/w) PEG is used. It
was also observed that for the higher PEG concentrations a plateau
on A595 values was reached at lower BSA protein concentrations
0003-2697/$ - see front matter ! 2009 Elsevier Inc. All rights reserved.
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compared to the low PEG concentration samples. This could lead to
the underestimation of real protein concentration in the samples
even when calibrations curves are prepared with the same poly-
mer concentrations.
As the inset of Fig. 1A shows, a similar effect was also observed
for PEG 3350, indicating that the decrease of A595 values for a con-
stant BSA concentration in the samples (15 lg/mL) is dependent on
the concentration of the PEG polymers.
Another parameter that is commonly screened when optimiz-
ing ATPS for the separation of biological products is the MW of
the phase-forming polymers. Differences in size of the polymers
can influence the partition behavior of target biomolecules. To
evaluate the influence of polymer MW on the protein determina-
tion assay we studied PEG solutions at 10% (w/w) and 20% (w/w)
as shown in Fig. 1B. For the 10% (w/w) PEG samples, all the stan-
dard curves were very similar among the different PEGMWs tested
(600; 1000; 3350; 10,000). Therefore the PEG MW at this concen-
tration had no interference with the assay. However, for higher
PEG concentrations (20%, w/w) the PEG MW had significant effects
on the protein quantification since differences on the A595 readings
Fig. 2. BSA calibration curves in the presence of DEX using the Bradford reagent. The BSA standard curves with DEX with 40-, 110-, 500-, and 2000-kDa molecular weight and
20% (w/w) concentrations are shown. SD bars are within points.
Fig. 1. BSA calibration curves in the presence of PEG using the Bradford reagent. (A) BSA standard curves with increased PEG concentrations (%, w/w) with the MW 600 Da
(PEG600). Inset shows the effect of PEG3350 concentration on the A595 readings using samples with constant BSA concentration (15 lg/mL). (B) BSA standard curves in the
presence of different MW PEG (600; 1000; 3350; 10,000 Da) at 10 and 20% w/w concentrations. Standard deviation (SD) bars are within points.
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were easily observed for each sample. At this concentration, the
PEG 3350 had a higher interference in the assay compared to the
other PEG MWs tested (with PEG 1000 interference the lesser).
Nevertheless, all samples at 20% had considerably lower A595 val-
ues compared to the 10% PEG samples in agreement with Fig. 1A.
In Fig. 2 the effect of dextran concentration and dextran MW in
the BSA standard curve preparation was evaluated. In contrast to
PEG, dextran concentrations up to 20% (w/w) had the same stan-
dard curves as those prepared with 0% dextran. Moreover, it seems
that the molecular weights of the dextran tested at 20% (40; 110;
500; 2000 kDa) had no diminishing effects on the A595 values com-
pared to the blank standards. Neither the concentration nor the
MW of the dextran polymer interfere with the Bradford reagent
and much better tolerance is observed compared to the PEG
polymer.
Curvature of the protein standard curve can be due to the deple-
tion of free dye at high protein concentrations as well as to protein
aggregation for higher protein concentrations [10]. The effect is
more apparent when the assay is performed in the presence of
PEG, which could be attributed to the fact that PEG can precipitate
proteins out of solution. Although no precipitation was observed
under the conditions tested a similar mechanism should be present
here. This is usually explained on the basis of an excluded volume
effect according to which proteins are sterically excluded from the
regions of the solvent that are occupied by PEG linear chains [11].
Proteins are thus concentrated and the Coomassie dye has much
less volume to bind to the protein with a consequent decrease on
the A595 readings being observed. It is also well known that differ-
ent PEG MWs and/or concentrations may cause protein precipita-
tion and this might have an impact on the quantitative
determination of protein in solution. These differences are specifi-
cally dependent on the protein structure, size, or isoelectric point
[11,12]. Since the Coomassie dye may also exhibit some degree
of variation response toward different proteins (see manufacturer’s
manual) it is recommended that for greater assay accuracy the
standard curves should be prepared using a pure sample of the tar-
get protein to be measured. If that is not possible, then appropriate
controls must be made in order to further investigate the influence
of PEG on the target protein.
In conclusion, protein determination in PEG/dextran ATPS using
Bradford reagent can be greatly influenced by the concentration
and molecular weight of PEG. It is recommended that a maximum
of 10% (w/w) PEG concentration be used in the samples to give a
minimum error in protein quantification in the presence of differ-
ent PEG MWs. Calibration curves should be made using the same
polymer concentration since a decrease of the A595 is observed
compared to blanks without the polymer and sample dilution. Con-
centrations of 20% (w/w) of dextran with various MWs can be used
for results similar to those of the control blanks.
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Phase diagrams of each PEG-dextran systems used in this thesis. Binodals using tie-line points. A) The DEX 40 and PEG (600, 1000, 3350, 10,000) phase 
diagrams. B) DEX 100 and PEG (600, 1000, 3350, 10,000) phase diagrams; C) – DEX 500 and PEG (600, 1000, 3350, 10,000) phase diagrams. 
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Appendix C  
Synthesis of PEG-IDA-Cu(II) 
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Synthesis route of PEG-IDA-Cu(II) 
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Fourier Transform Infrared (FTIR) spectra of PEG and PEG-IDA-Cu(II) 
 
 
Infrared spectra were recorded on a BOMED MB 104 spectrophotometer. 
IR(KBr): ! (cm-1) 3473 (OH), 1967, 1635 (C=O) 1467. 
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Atomic Absorption Spectrometry analysis 
 
Standard solutions 
Stock solutions of copper metal with a concentration of 1000 ppm (1000 mg/L) 
were prepared using copper (II) nitrate hexahidrated (Merck, p.a., 99,9 %). An 
intermediate standard solution of 100 ppm concentration was prepared by 
dilution of 10.00±0,04 mL of 1000 ppm stock solution in a 100.00 mL 
volumetric flask and the final volume was set by using diluted nitric acid 
solution (1:499 mL). Standard solutions used in the calibration procedures have 
a concentration range from 0.05 to 5.0 ppm and were prepared by dilution of 
adequate volumes of 100 ppm solution on 100.00±0,04 mL volumetric flask 
using diluted nitric acid solution (0.02 % v/v) to adjust the final volume. 
Samples were prepared by dissolving appropriate amounts of PEG-IDA-Cu(II) in 
adequate volumes of diluted nitric acid solution (0.02 % v/v). 
 
Flame atomic absoption spectroscopy measurements 
The direct aspiration flame atomic absorption (FAA) spectrometry measurements 
were performed using a Philips-Pye Unicam  spectrometer (model SP)  using a 
air/acetylene gas mixture. The wavelength 324.7 nm was used for the 
determination of metal concentration in the samples. 
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